Clinical Study Protocol

SPARTAN
(Selective Prostate AR Targeting with ARN-509)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Protocol Number: ARN-509-003
Amendment 8

Investigational Product: JNJ-56021927 (apalutamide)

IND Number: 104676

EudraCT Number: 2012-004322-24

Development Phase: 3

Sponsor: Aragon Pharmaceuticals, Inc*

*Aragon Pharmaceuticals, Inc. is a wholly-owned subsidiary of Johnson & Johnson. Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson and provides various services to its affiliated company, Aragon Pharmaceuticals, Inc.

This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312).

Status: Approved
Date: 15 March 2017
Prepared by: Janssen Research & Development, LLC
Document No.: EDMS-ERI-70784696; 10

GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements.

The confidential information in the following document is provided to you as an investigator, potential investigator, or consultant, for review by you, your staff, and appropriate ethical review committee. By accepting this document, you agree that the information contained herein will not be disclosed to others without written authority from Aragon Pharmaceuticals, Inc., except to the extent necessary to obtain approval of this protocol by an ethical review committee.
SPONSOR APPROVALS

Protocol: ARN-509-003 Amendment 8

Protocol Title: SPARTAN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

Margaret Yu, MD
Clinical Leader

3/5/2017
PROTOCOL AGREEMENT

I confirm that I have read this protocol. I will comply with the protocol and the principles of Good Clinical Practice (GCP), as described in the United States Code of Federal Regulation (CFR) 21 Parts 11, 50, 54, 56, and 312 and the appropriate International Conference on Harmonisation guidance documents.

Protocol: ARN-509-003 Amendment 8

Protocol Title: SPARTAN: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

________________________________________________________________________________

Investigator Signature       Date

________________________________________________________________________________

Print Name and Title

Site # __________

Site Name ________________________________________________
**PROTOCOL SYNOPSIS**

<table>
<thead>
<tr>
<th>Title</th>
<th>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>Aragon Pharmaceuticals, Inc</td>
</tr>
<tr>
<td>Development Phase</td>
<td>3</td>
</tr>
<tr>
<td>Rationale</td>
<td>Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males, accounting for 14% (903,500) of the total new cancer cases and 6% (258,400) of the total cancer deaths in males worldwide. The course of prostate cancer from diagnosis to death is best categorized as a series of clinical stages based on the extent of disease, hormonal status, and absence or presence of detectable metastases: localized disease, rising levels of prostate-specific antigen (PSA) after radiation therapy or surgery with no detectable metastases, and clinical metastases in the non-castrate or castrate stage. Although surgery, radiation, or a combination of both can be curative for patients with localized disease, a significant proportion of these patients have recurrent disease as evidenced by a rising level of PSA, which can lead to the development of metastases, especially in the high risk group – a transition to the lethal stage of the disease. Androgen depletion is the standard treatment with a generally predictable outcome: decline in PSA, a period of stability in which the tumor does not proliferate, followed by rising PSA and regrowth as castration-resistant disease. Molecular profiling studies of castration-resistance prostate cancers commonly show increased androgen receptor (AR) expression, which can occur through AR gene amplification or other mechanisms. ARN-509 (JNJ-56021927; apalutamide, hereafter referred to as apalutamide) is a next-generation anti-androgen that binds directly to the ligand-binding domain of AR, impairing nuclear translocation and DNA binding. Apalutamide binds AR with 5-fold greater affinity than bicalutamide, and induces partial or complete tumor regression in both castration-sensitive and castration-resistant human prostate cancer xenograft models. A Phase I/II study (Protocol ARN-509-001) was designed to assess the safety, pharmacokinetics, and anti-tumor activity of apalutamide in men with castration-resistant prostate cancer (CRPC). The Phase I portion of the study has been completed and the Phase II is currently ongoing. In the Phase II, 97 patients were enrolled across 3 different patient population subsets: high risk NM-CRPC, treatment-naive metastatic CRPC (no prior treatment with abiraterone acetate or chemotherapy), and metastatic CRPC after</td>
</tr>
</tbody>
</table>
failure with abiraterone acetate.

In the NM-CRPC subset (n = 51), the most frequent treatment-related adverse events reported in >10% of subjects as of 30 November 2013 are fatigue (43%), diarrhea (31%), nausea (20%), increased thyroid stimulating hormone (12%), dysgeusia (12%), and hot flush 12%. Eight (16%) patients have discontinued the study due to adverse events. Seven (14%) patients have discontinued due to disease progression. No deaths were reported in this subgroup as of the safety cutoff. The 12-week PSA response (≥ 50% decline from baseline) is 91%.

### Study Design

This is a randomized (2:1), multicenter, double-blind, placebo-controlled, Phase III clinical trial evaluating the efficacy and safety of apalutamide versus placebo in men with high risk (M0) NM-CRPC, defined as PSA Doubling Time (PSADT) ≤ 10 months.

Patients will be stratified based on:

- PSADT: > 6 months vs. ≤ 6 months
- Bone-sparing agent use: Yes vs. No
- Loco-regional disease: N0 vs. N1

Patients will be followed for safety and efficacy as per the schedule of activities and will remain on study treatment until documented radiographic progression (development of distant metastases as assessed by blinded independent central review) or the development of unacceptable toxicity.

Patients discontinuing treatment due to documented radiographic progression will enter the Long-term Follow-up Phase, where they will be followed for the development of symptomatic progression and initiation of subsequent anti-cancer therapies (in particular, cytotoxic chemotherapy) every 4 months until death, loss of follow-up, or withdrawal of consent, whichever comes first.

Patients discontinuing treatment prior to documented radiographic progression will also enter the Long-term Follow-up Phase where they will continue to have scheduled disease assessments every 16 weeks until documented radiographic progression, and will be followed for the development of symptomatic progression and initiation of subsequent anti-cancer therapies (in particular, cytotoxic chemotherapy) every 4 months until death, loss of follow-up, or withdrawal of consent, whichever comes first.

At the time of study unblinding and in the event of a positive study result, all subjects currently receiving placebo will have the opportunity to receive active therapy with apalutamide.
Primary Objective
To demonstrate superiority in the metastasis-free survival (MFS) of men with high risk NM-CRPC treated with apalutamide versus placebo

Secondary Objectives
- To compare the overall survival (OS) of men with high risk NM-CRPC treated with apalutamide versus placebo
- To compare the time to symptomatic progression in men with high risk NM-CRPC treated with apalutamide versus placebo
- To compare the time to initiation of cytotoxic chemotherapy in men with high risk NM-CRPC treated with apalutamide versus placebo
- To compare the progression-free survival (PFS) of men with high risk NM-CRPC treated with apalutamide versus placebo
- To compare the time to metastasis (TTM) in men with high risk NM-CRPC treated with apalutamide versus placebo
- To evaluate the safety and tolerability of apalutamide

Other Objectives
- To compare patient reported outcomes (PROs) of health-related quality of life and prostate cancer-specific symptoms in men with high risk NM-CRPC treated with apalutamide versus placebo
- To evaluate the population pharmacokinetics (PK) of apalutamide
- To evaluate the effect of apalutamide on ventricular repolarization in a subset of patients from selected clinical sites
- To evaluate exploratory biomarkers predictive of response and resistance to apalutamide treatment

Number of Patients
1,200 (apalutamide: 800; placebo: 400)

Enrollment Criteria
The study population includes men 18 years of age or older with NM-CRPC at high-risk for metastases defined as a prostate-specific antigen doubling time (PSADT) of 10 months or less. Patients are excluded if blinded independent central review (BICR) confirms the presence of distant metastases including CNS and vertebral or meningeal involvement or a history of distant metastases. Patients who present at Screening with lymph nodes less than 2 cm in the short axis (N1) located below the iliac bifurcation, are eligible. Any patient who received first generation anti-androgens must show continuing disease (PSA) progression after discontinuation of the anti-androgen for at least 4 weeks prior to randomization. Bone sparing therapies for the treatment of osteoporosis are allowed if the patient were on stable doses for at least 4 weeks before randomization. Patients with symptomatic loco-regional disease are excluded.
requiring medical intervention are excluded. An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) grade of 0 or 1 is required

| Dose, and Route of Administration | Apalutamide/matched placebo tablets will be administered orally on a continuous daily dosing regimen, at a starting dose for apalutamide of 240 mg once daily (4 x 60-mg tablets). The only difference between apalutamide tablet and its matched placebo tablet is the absence of the active ingredient in the matched placebo tablet. |

| Safety Assessments | Patients will be assessed for adverse events (AEs) at each monthly clinic visit while on the study. Adverse events will be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Type, incidence, severity, timing, seriousness, and relatedness of AEs, and laboratory abnormalities will be reported. |

| Data Monitoring Committee | An Independent Data Monitoring Committee (IDMC) will be established to monitor data on an ongoing basis to ensure the safety of the subjects enrolled in this study. The committee will meet periodically to review interim safety data. After the review, the IDMC will make recommendations regarding the conduct of the study. The IDMC will serve as the primary reviewers of the efficacy analysis. Details are provided in a separate IDMC charter. |

| Efficacy Assessments | Disease assessments will be performed as scheduled according to the calendar, regardless of treatment delays resulting from toxicity. Disease assessments (CT scans of the chest, abdomen, and pelvis, plus bone scan) will be performed at baseline and at 16-week intervals from Cycle 1 Day 1 until documented progression. All scans will be submitted for BICR by a third-party core imaging laboratory to confirm patient eligibility (i.e., no presence of distant metastases) and disease progression during the study. |

| Primary Endpoint | - Metastasis-free survival (MFS) |

| Secondary Endpoints | - Time to Metastasis (TTM)  
- PFS  
- Time to symptomatic progression  
- Overall survival (OS)  
- Time to initiation of cytotoxic chemotherapy |

<p>| Other Evaluations | - Health-related quality of life and prostate cancer-specific symptoms |</p>
<table>
<thead>
<tr>
<th>Statistical Analysis Plan and Rationale for Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>The primary efficacy analysis will be event-driven. Based on results from a large Phase III study of denosumab versus placebo in high risk NM-CRPC patients, the expected median MFS in the control arm is 25 months. Applying a 2:1 randomization, a planned accrual period of 24 months and a minimum follow-up period of 9 months, it is estimated that approximately 1,200 patients will need to be enrolled in order to observe 372 MFS events. This sample size has 90% power to detect a 30% reduction in the risk of developing metastases (HR = 0.70) for patients receiving apalutamide, with a 2-sided α of 0.05. This treatment effect corresponds to an increase in median MFS of approximately 11 months (from 25 to 36 months), which would be considered clinically relevant. The study was also designed to provide 85% power to detect a 25% reduction (HR = 0.75) in the risk of death for patients receiving apalutamide, based on an assumed median OS of 49 months in the placebo arm. This treatment effect represents an increase in median OS of approximately 16 months (from 49 to 65 months).</td>
</tr>
</tbody>
</table>
### Duration of Patient Participation and Duration of Study

 Patients will remain on study treatment until BICR-confirmed radiographic disease progression (ie, distant metastasis), development of unacceptable toxicity, or withdrawal of consent. Patients discontinuing study treatment will enter the Long-term Follow-up Phase and remain on study until death, loss of follow-up, or withdrawal of consent, whichever comes first.

With an estimated accrual duration of 24 months, it is assumed that patients are expected to be followed for a minimum of approximately 9 months beyond Last Patient In (LPI) for the primary endpoint of MFS, to approximately 41 months beyond LPI for the key secondary endpoint of OS. This corresponds to a projected study duration of approximately 65 months.

If the study is not terminated beforehand per the recommendation of the IDMC, the end of trial in all participating countries will be defined as the time at which the secondary endpoint of OS has been met.
LIST OF ABBREVIATIONS

ADT    androgen deprivation therapy
AE     adverse event
ALT    alanine aminotransferase
ANC    absolute neutrophil count
AR     androgen receptor
AST    aspartate aminotransferase
BICR   blinded independent central review
BSE    bovine spongiform encephalopathy
BUN    blood urea nitrogen
CFR    Code of Federal Regulations
CNS    central nervous system
CRF    case report form
CRPC   castration-resistant prostate cancer
CTCAE  Common Terminology Criteria for Adverse Events
DLT    dose-limiting toxicity
ECG    electrocardiogram
FFPE   formalin-fixed paraffin-embedded
EDC    electronic data capture
EWB    emotional well-being
FACT-P Functional Assessment of Cancer Therapy-Prostate
FDA    Food and Drug Administration
FDHT   16β-[18F] fluoro-α-dihydrotestosterone
FWB    functional well-being
GCP    Good Clinical Practice
GnRHa  gonadotropin releasing hormone analog
HIPAA  Health Insurance Portability and Accountability Act of 1996
HIV    human immunodeficiency virus
ICF    informed consent form
ICH    International Conference on Harmonisation
IDMC  Independent Data Monitoring Committee
IEC    Independent Ethics Committee
IRB    Institutional Review Board
MFS    metastasis-free survival
NCI    National Cancer Institute
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>NM-CRPC</td>
<td>non metastatic castration-resistant prostate cancer</td>
</tr>
<tr>
<td>NOAEL</td>
<td>no observed adverse effect level</td>
</tr>
<tr>
<td>OS</td>
<td>overall survival</td>
</tr>
<tr>
<td>PCWG2</td>
<td>Prostate Cancer Clinical Trials Working Group 2</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PFS</td>
<td>progression-free survival</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetics</td>
</tr>
<tr>
<td>PQC</td>
<td>product quality complaint</td>
</tr>
<tr>
<td>PSA</td>
<td>prostate-specific antigen</td>
</tr>
<tr>
<td>PSADT</td>
<td>prostate-specific antigen doubling time</td>
</tr>
<tr>
<td>PWB</td>
<td>physical well-being</td>
</tr>
<tr>
<td>QTc</td>
<td>corrected QT interval</td>
</tr>
<tr>
<td>QTcB</td>
<td>corrected QT interval according to the Bazett correction</td>
</tr>
<tr>
<td>QTcF</td>
<td>corrected QT interval according to the Fridericia correction</td>
</tr>
<tr>
<td>RECIST</td>
<td>Response Evaluation Criteria in Solid Tumors</td>
</tr>
<tr>
<td>SAE</td>
<td>serious adverse event</td>
</tr>
<tr>
<td>SGOT</td>
<td>serum glutamic oxaloacetic transaminase</td>
</tr>
<tr>
<td>SGPT</td>
<td>serum glutamate pyruvate transaminase</td>
</tr>
<tr>
<td>SOC</td>
<td>system organ class</td>
</tr>
<tr>
<td>SWB</td>
<td>social well-being</td>
</tr>
<tr>
<td>TPGS</td>
<td>d-α-tocopheryl polyethylene glycol 1000 succinate</td>
</tr>
<tr>
<td>TTM</td>
<td>time to metastasis</td>
</tr>
<tr>
<td>ULN</td>
<td>upper limit of normal</td>
</tr>
</tbody>
</table>
TABLE OF CONTENTS

PROTOCOL AMENDMENTS .................................................................................................................. 16

1. BACKGROUND ............................................................................................................................. 38
   1.1 APALUTAMIDE .......................................................................................................................... 38
      1.1.1 Molecular Formula and Chemical Class .............................................................................. 39
      1.1.2 Pre-Clinical Development Overview .................................................................................. 39
      1.1.3 Overview of Clinical Studies .............................................................................................. 42

2. STUDY OBJECTIVES ................................................................................................................... 44
   2.1 PRIMARY OBJECTIVE .............................................................................................................. 44
   2.2 SECONDARY OBJECTIVES ..................................................................................................... 44
   2.3 OTHER OBJECTIVES .............................................................................................................. 44

3. STUDY DESIGN ............................................................................................................................ 45
   3.1 STUDY OVERVIEW AND RATIONALE .................................................................................... 45
      3.1.1 Crossover Option in the Event of Unblinding .................................................................... 46
      3.1.2 Selection of the Primary Endpoint ...................................................................................... 46
   3.2 STUDY OUTCOMES .................................................................................................................. 47
      3.2.1 Primary Endpoint .............................................................................................................. 47
      3.2.2 Secondary Endpoints ......................................................................................................... 47
      3.2.3 Other Evaluations .............................................................................................................. 47

4. PATIENT SELECTION .................................................................................................................. 47
   4.1 INCLUSION CRITERIA .............................................................................................................. 48
   4.2 EXCLUSION CRITERIA ............................................................................................................. 50

5. STUDY TREATMENTS ................................................................................................................... 52
   5.1 RANDOMIZATION CRITERIA ................................................................................................... 52
   5.2 BLINDING ................................................................................................................................ 52
   5.3 FORMULATION ....................................................................................................................... 53
      5.3.1 Apalutamide/Matched Placebo ............................................................................................ 53
      5.3.2 Packaging, Storage, and Labeling ...................................................................................... 53
      5.3.3 Drug Administration .......................................................................................................... 53
      5.3.4 Cycle Management ............................................................................................................ 53
      5.3.5 Dose Modifications ............................................................................................................ 53
   5.4 STUDY DRUG ACCOUNTABILITY .......................................................................................... 54
   5.5 MEASURES OF TREATMENT COMPLIANCE ........................................................................ 55

6. CONCURRENT MEDICATIONS ..................................................................................................... 55
   6.1 PROHIBITED MEDICATIONS AND TREATMENTS ............................................................... 55
   6.2 RESTRICTED THERAPIES ...................................................................................................... 55
   6.3 LIFE STYLE GUIDELINES ....................................................................................................... 56

7. STUDY PROCEDURES AND GUIDELINES ................................................................................. 58
   7.1 CLINICAL ASSESSMENTS ...................................................................................................... 58
      7.1.1 Demographics .................................................................................................................... 58
      7.1.2 Medical History ................................................................................................................ 58
7.1.3 Physical Examination................................................................. 58
7.1.4 Vital Signs.................................................................
7.1.5 Performance Status ................................................................. 59
7.1.6 Adverse Events ................................................................. 59
7.1.7 Concomitant Medications/Therapies ................................................................. 59
7.1.8 Tumor Assessments ................................................................. 59
7.1.8.1 Blinded Independent Central Review (BICR)................................. 59
7.2 CLINICAL LABORATORY MEASUREMENTS ................................................................. 60
7.2.1 PSA ................................................................. 60
7.2.2 Electrocardiogram (ECG) ................................................................. 60
7.3 PHARMACOKINETIC MEASUREMENTS ................................................................. 60
7.4 PATIENT-REPORTED OUTCOMES ................................................................. 61
7.5 EXPLORATORY BIOMARKERS ................................................................. 61
8. STUDY ASSESSMENTS BY VISIT (APPENDIX 1) ................................................................. 62
8.1 PRESCREENING ................................................................. 62
8.2 SCREENING (WITHIN 35 DAYS OF RANDOMIZATION) ................................................................. 62
8.3 CYCLE 1 DAY 1 ................................................................. 62
8.4 DAY 1 OF CYCLES 1-6, THEN DAY 1 OF EVERY 2 CYCLES STARTING FROM CYCLE 7 UP TO C13 THEN DAY 1 OF EVERY 4 CYCLES (±2 DAYS) ................................................................. 63
8.5 EVERY 16 WEEKS STARTING FROM CYCLE 1 DAY 1 (±2 DAYS) ................................................................. 63
8.6 EVERY 16 WEEKS STARTING FROM CYCLE 1 DAY 1 (±7 DAYS) ................................................................. 63
8.7 END-OF-TREATMENT VISIT ................................................................. 63
8.8 SAFETY FOLLOW-UP (28 DAYS FOLLOWING THE LAST DOSE OF STUDY DRUG) ................................................................. 64
8.9 LONG-TERM FOLLOW-UP ................................................................. 64
8.10 SUBSEQUENT THERAPY WITH ABIRATERONE ACETATE ................................................................. 64
9. ADVERSE EVENT REPORTING REQUIREMENTS ................................................................. 66
9.1 DEFINITIONS ................................................................. 66
9.1.1 Adverse Events (AE) ................................................................. 66
9.1.2 Serious Adverse Events (SAE) ................................................................. 67
9.1.3 Expectedness ................................................................. 67
9.1.4 Attribution ................................................................. 68
9.1.5 Severity ................................................................. 68
9.1.6 Pregnancy ................................................................. 69
9.2 REPORTING REQUIREMENTS ................................................................. 69
9.2.1 SAE Reporting ................................................................. 69
9.2.2 Non-Serious AE Reporting ................................................................. 70
9.2.3 Sponsor Reporting Requirements to Regulatory Authorities ................................................................. 70
9.2.4 Product Quality Complaint Handling ................................................................. 71
9.2.4.1 Procedures ................................................................. 71
9.2.4.2 Contacting Sponsor Regarding Product Quality ................................................................. 71
10. END OF TREATMENT ................................................................. 71
11. PROTOCOL VIOLATIONS ................................................................. 72
12. DATA MONITORING COMMITTEE .................................................................. 73
13. STATISTICAL METHODS AND CONSIDERATIONS ............................. 73
  13.1 ANALYSIS POPULATIONS .................................................................. 73
  13.2 EFFICACY ANALYSES ..................................................................... 73
  13.2.1 Analysis of Primary Endpoint ....................................................... 74
  13.2.2 Analyses of Secondary Endpoints .................................................. 75
    13.2.2.1 OS ......................................................................................... 76
    13.2.2.2 Time to Symptomatic Progression ......................................... 76
    13.2.2.3 Time to Initiation of Cytotoxic Chemotherapy ...................... 76
    13.2.2.4 Progression-Free Survival ...................................................... 77
    13.2.2.5 Time to Metastasis ................................................................. 78
  13.3 SAFETY EVALUATIONS .................................................................... 78
  13.3.1 Analysis of Adverse Events .......................................................... 78
  13.3.2 Analysis of Clinical Laboratory Results ....................................... 79
  13.3.3 Analysis of Vital Signs ................................................................. 79
  13.3.4 Concomitant Medications/Treatments ........................................ 79
  13.4 OTHER EVALUATIONS ..................................................................... 80
    13.4.1 Second Progression-free Survival (PFS2) ................................. 80
    13.4.2 PSA ......................................................................................... 80
    13.4.3 Health-Related Quality of Life and Prostate Cancer-Specific Symptoms Analysis .... 80
    13.4.4 Population Pharmacokinetics (Pop PK) Analysis ....................... 80
    13.4.5 Exploratory Biomarkers Analysis .............................................. 81
    13.4.6 Assessment of Ventricular Repolarization .................................. 81
    13.4.7 Medical Resource Utilization Analysis ....................................... 81
  13.5 INTERIM ANALYSIS ......................................................................... 82
  13.6 DETERMINATION OF SAMPLE SIZE ............................................. 82
14. DATA COLLECTION, RETENTION AND MONITORING ...................... 82
  14.1 DATA COLLECTION INSTRUMENTS .................................................. 82
  14.2 DATA MANAGEMENT PROCEDURES .............................................. 82
  14.3 DATA QUALITY CONTROL AND REPORTING ............................... 83
  14.4 ARCHIVAL OF DATA ...................................................................... 83
  14.5 AVAILABILITY AND RETENTION OF INVESTIGATIONAL RECORDS 83
  14.6 PATIENT CONFIDENTIALITY ............................................................ 84
15. ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS ...... 84
  15.1 INVESTIGATOR RESPONSIBILITIES .................................................... 84
  15.2 PROTOCOL AMENDMENTS ............................................................... 84
  15.3 INSTITUTIONAL REVIEW BOARDS AND INDEPENDENT ETHICS COMMITTEES 85
  15.4 INFORMED CONSENT FORM ............................................................ 85
  15.5 REPORTING OF SAFETY ISSUES AND SERIOUS BREACHES OF THE PROTOCOL OR ICH GCP ....................................................... 86
  15.6 END OF TRIAL IN ALL PARTICIPATING COUNTRIES ..................... 86
  15.7 SPONSOR DISCONTINUATION CRITERIA ......................................... 86
  15.8 PUBLICATIONS ................................................................................ 87

Aragon Pharmaceuticals, Inc - Confidential
16. REFERENCES ............................................................................................................... 87
17. APPENDICES ............................................................................................................. 89
**PROTOCOL AMENDMENTS**

<table>
<thead>
<tr>
<th>Protocol Version</th>
<th>Issue Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original Protocol</td>
<td>5 November 2012</td>
</tr>
<tr>
<td>Amendment INT-1*</td>
<td>11 January 2013</td>
</tr>
<tr>
<td>Amendment INT-2*</td>
<td>8 May 2013</td>
</tr>
<tr>
<td>Amendment INT-3</td>
<td>11 March 2014</td>
</tr>
<tr>
<td>Amendment INT-4</td>
<td>16 June 2014</td>
</tr>
<tr>
<td>Amendment INT-5</td>
<td>1 July 2014</td>
</tr>
<tr>
<td>Amendment INT-6</td>
<td>18 May 2015</td>
</tr>
<tr>
<td>Amendment 7</td>
<td>1 June 2016</td>
</tr>
<tr>
<td>Amendment 8</td>
<td>15 March 2017</td>
</tr>
</tbody>
</table>

*These amendment changes are provided in a separate document (EDMS-ERI-71567787)
Amendments are listed beginning with the most recent amendment.

---

**Amendment 8 (13 March 2017)**

This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union.

The overall reason for this amendment is to revise the statistical sections of the protocol. The current statistical analysis plan for analysis of secondary endpoints lacks power given the projected low event rates; therefore, the Sponsor is revising the multiple testing procedure for the secondary endpoints. In addition, text was added to allow, in the event of a positive study result and unblinding, for subjects receiving placebo to begin receiving active therapy with apalutamide. The rationale for and description of the changes are listed below, when revisions are provided verbatim, bold font denotes new text, and strikethrough denotes deleted text.

---

<table>
<thead>
<tr>
<th>Applicable Section(s)</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rationale:</strong></td>
<td>The current statistical analysis plan for analysis of secondary endpoints lacks power given the projected low event rates; therefore, the Sponsor is revising the multiple testing procedure for the secondary endpoints.</td>
</tr>
</tbody>
</table>

**Section 13.2.2, Analyses of Secondary Endpoints**

Deleted:

Following the primary analysis of MFS, the analyses of the secondary endpoints will be performed at the time of the expected total number of MFS events (372 events). The secondary endpoints will be subdivided into the following 2 groups:

- **Group 1:**
  - Time to symptomatic progression
  - Time to initiation of cytotoxic chemotherapy
  - PFS
  - TTM

- **Group 2:**
  - OS

The statistical testing of the 2 groups of secondary endpoints will be performed by allocating 0.01 to Group 1 and 0.04 for the OS endpoint in Group 2 with an overall familywise type I error rate of 0.05. Details of the testing procedure will be provided in the statistical analysis plan.
<table>
<thead>
<tr>
<th>Applicable Section(s)</th>
<th>Description of Change(s)</th>
</tr>
</thead>
</table>
| Section 13.2.2, Analyses of Secondary Endpoints (cont’s) | Replaced with: For the secondary endpoints, a hierarchical testing will be performed in the following order:  
- TTM  
- PFS  
- Time to symptomatic progression  
- OS  
- Time to initiation of cytotoxic chemotherapy each at alpha=0.05 (2-sided). Each secondary endpoint will have a final analysis but there will be no interim analysis for TTM and PFS. There will be 1 interim time to symptomatic progression, and up to 2 interim analyses for OS and time to initiation of cytotoxic chemotherapy. The testing of time to symptomatic progression, OS and time to initiation of cytotoxic chemotherapy endpoints will utilize an adaptive group sequential method, according to the pre-specified O’Brien-Fleming-type alpha spending function with possible re-estimation of the required number of events necessary for the next analysis to maintain the desired conditional power. If time to symptomatic progression is significant at the IA, then there will be only 1 interim analysis for OS and time to initiation of cytotoxic chemotherapy; otherwise there will be 2 interim analyses for OS and time to initiation of cytotoxic chemotherapy. The final analysis of TTM and PFS, interim analysis of time to symptomatic progression, and the first interim analysis of OS and time to initiation of cytotoxic chemotherapy will all be performed at the same time as the primary analysis of MFS (approximately 372 events). Full details about the adaptive group sequential testing procedure will be provided in the statistical analysis plan.  
Time-to-event-based secondary endpoint analyses (TTM, PFS, time to symptomatic progression, OS, and time to initiation of cytotoxic chemotherapy) will be performed using a two-sided log-rank test, stratified by PSADT (>6 months vs. ≤ 6 months), the use of a bone-sparing agent (Yes vs. No), and the presence of loco-regional disease (N0 vs. N1). |
<p>| Rationale: | The next 3 changes were made in the sections identified as a result of changes made to the analysis of secondary endpoints (covered in Section 13.2.2). |
| Section 13.2.2.1, OS | Deleted (text that was following table in this section): The final analysis of OS will occur after approximately 526 deaths have occurred. Two interim analyses are also planned (see Section 13.5). Additional analyses may be conducted as appropriate. |
| Section 13.4.2, PSA | PSA kinetics (e.g., 12-week PSA response and time to PSA progression) will be assessed at the time of the primary analysis of MFS according to the Prostate Cancer Clinical Trials Working Group (PCWG2) recommendations. |</p>
<table>
<thead>
<tr>
<th>Applicable Section(s)</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 13.5, Interim Analysis</td>
<td>Deleted: Two interim analyses and 1 final analysis are planned for the OS endpoint. The testing of the OS endpoint will be performed according to the O’Brien Fleming boundary as implemented by the Lan DeMets alpha spending function with a planned alpha of 0.04. For the OS endpoint, the maximum expected total number of death events is 526 (final analysis). At the time of the first interim analysis, approximately 46% (243/526) of the death events will be observed with an alpha spend of 0.0012. The second interim analysis will be performed after observing approximately 70% (369/526) of the death events with a cumulative alpha spend of 0.0109. The actual alpha spent for the 2 interim analyses will be based on the number of death events observed at the time of the analyses. Replaced with: There will be 1 interim analysis for time to symptomatic progression, and up to 2 interim analyses for OS and time to initiation of cytotoxic chemotherapy; see Section 13.2.2 for an outline of analysis methods.</td>
</tr>
</tbody>
</table>

**Rationale:** Added details for placebo subjects to begin receiving active treatment with apalutamide, in the event of a positive study result and the study is unblinded.

| Synopsis, Study Design; Section 3.1.1, Crossover Option in the Event of Unblinding; Section 4, Patient Selection; and Appendix 10, Crossover to Open Label Apalutamide After Study Unblinding | Synopsis and Section 3.1.1: At the time of study unblinding and in the event of a positive study result, all subjects currently receiving placebo will have the opportunity to receive active therapy with apalutamide (refer to Appendix 10). Section 4: Treatment criteria for placebo subjects who crossover to active treatment with apalutamide (in the event of a positive study result and unblinding) are described in Appendix 10. New Appendix 10 added (not included here in summary of changes due to size). |

**Rationale:** Changed ‘is’ to ‘was’ to clarify that the text in this section reflects thinking at the time the original protocol was written; deleted text that is no longer applicable.

| Section 13.6, Determination of Sample Size | The study is was also sized to provide 85% power to detect a 25% reduction (HR = 0.75) in the risk of death for patients receiving apalutamide, based on an assumed median OS of 49 months in the placebo arm. This treatment effect represents an increase in the median OS of approximately 16 months (from 49 to 65 months). The final analysis of OS will occur after approximately 526 deaths have occurred. The total study duration (including the time it takes to reach the secondary endpoint of OS) will be approximately 65 months. |

<p>| Synopsis, Statistical Analysis Plan and Rationale for Number of Patients | The study is was also designed to provide 85% power to detect a 25% reduction (HR = 0.75) in the risk of death for patients receiving apalutamide, based on an assumed median OS of 49 months in the placebo arm. This treatment effect represents an increase in median OS of approximately 16 months (from 49 to 65 months). Two interim analyses and 1 final analysis will be performed for the OS endpoint. The final analysis for OS will occur after approximately 526 deaths have been observed. The first interim analysis of OS (approximately 46% of total death events) will occur at the time of the final analysis of the primary endpoint, MFS, and the second interim analysis will occur when approximately 70% of total death events are observed. |</p>
<table>
<thead>
<tr>
<th>Applicable Section(s)</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rationale:</strong> Correction of the median OS time in the study population.</td>
<td>Section 3.1.2, Selection of the Primary Endpoint In consideration of the relatively long median OS (~45 months) in this population and the opportunity to assess for the development of distant metastasis as a clinically important milestone, metastasis-free survival (MFS) was chosen as the primary objective of this study.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Correction was made to note that email can be used for reporting of SAEs in addition to fax.</td>
<td>Section 9.2.1, SAE Reporting The initial and follow-up reports of an SAE should be made by facsimile (fax) or email.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Clarification for criteria of disease progression for administration of subsequent therapy with abiraterone acetate, if the study is unblinded.</td>
<td>Section 8.10, Subsequent therapy with Abiraterone Acetate (second bullet) • documented disease progression (i.e., meet criteria for the primary endpoint [distant metastasis], see Section 13.2.1). <strong>If the study is unblinded, the requirement for meeting disease progression by BICR in Section 13.2.1 will not be required.</strong></td>
</tr>
<tr>
<td><strong>Rationale:</strong> Minor errors were corrected, minor revisions were made.</td>
<td>Throughout the protocol Minor grammatical, formatting, or spelling changes were made. Minor organizational changes were made.</td>
</tr>
</tbody>
</table>

**Amendment 7 (1 June 2016)**

This amendment is considered to be non-substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union, in that it does not significantly impact the safety or physical/mental integrity of subjects, nor the scientific value of the study.

The overall reason for this amendment is to reduce the frequency of visits after Cycle 7 per request of the investigators and patients. The revised visit schedule is consistent with other apalutamide Phase 3 protocols. The tablet formulation with improved shelf-life allows for fewer visits. Collection of medical resource utilization (MRU) should continue during the Long-term Follow-up Phase.

The rationale for and description of the changes are listed below, when revisions are provided verbatim, bold font denotes new text, and strikethrough denotes deleted text.

<table>
<thead>
<tr>
<th>Applicable Section(s)</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rationale:</strong> A reduction in the clinic visits will reduce burden to patients and the improved shelf-life of the tablets also allows for fewer clinic visits.</td>
<td>Section 8.4 Day 1 of Cycles N (+2 Days); Appendix 1, Schedule of Activities Visit frequency revised to the following: Every cycle up to Cycle 6, starting at Cycle 7 reduce to every 2 cycles (e.g., C9, C11, etc), starting at Cycle 13 reduce to every 4 cycles (e.g., C17, C21, etc).</td>
</tr>
<tr>
<td>Applicable Section(s)</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Rationale:</strong> The PK and biomarker sample collection timings were revised to align with the revised visit schedule.</td>
<td></td>
</tr>
<tr>
<td>Section 7.3 Pharmacokinetic Measurements; Section 8.4 Day 1 of Cycles N (±2 Days); Section 13.4.5 Exploratory Biomarker Analysis; Appendix 1, Schedule of Activities</td>
<td>To align the PK sample collection with the revised visit schedule, the visits for PK collection were changed from Cycle 12 to Cycle 11, Cycle 18 to Cycle 17, and Cycle 24 to Cycle 25. To align the biomarker sample collection with the revised visit schedule, the visits for biomarker sample collection were changed from Cycle 12 to Cycle 11, Cycle 18 to Cycle 17, from Cycle 24 to Cycle 25, and from Cycle 36 to Cycle 37.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> The frequency for completion of the FACT-P and EQ-5D questionnaires will coincide with the revised clinic visit schedule during the Treatment Phase.</td>
<td></td>
</tr>
<tr>
<td>Appendix 1 Schedule of Activities</td>
<td>The collection timing of the questionnaires was aligned with the reduced number of clinic visits.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Collection of MRU should continue during the Long-term Follow-up Phase.</td>
<td></td>
</tr>
<tr>
<td>Section 8.9 Long-term Follow-up; Appendix 1, Schedule of Activities</td>
<td>Added collection of MRU to the Long-term Follow-up Phase.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> The Survival Follow-up includes collection of other information and referring to this phase as Survival Follow-up was not accurate.</td>
<td></td>
</tr>
<tr>
<td>Synopsis Study Design, Duration of Patient Participation and Duration of Study; Section 4.1 Inclusion Criteria; Section 8.9 Long-term Follow-up; Section 10 End of Treatment; Section 15.6 End of Trial in all Participating Countries; Appendix 1, Schedule of Activities</td>
<td>Revised the name of this phase of the study to “Long-term Follow-up Phase.” Inclusion Criterion #13.2 was revised to the following: Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures, including ability to swallow study drug tablets, the completion of patient reported outcomes questionnaires and survival long-term follow-up visits.</td>
</tr>
<tr>
<td>Applicable Section(s)</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>Rationale</strong>: If thyroid stimulating hormone (TSH) levels are abnormal, additional reflex testing must be performed.</td>
<td></td>
</tr>
<tr>
<td>Section 8.5 Every 16 weeks...; Appendix 1 Schedule of Activities: Footnote 11; Appendix 2</td>
<td>Added the following statement to Appendix 2: <strong>If TSH is abnormal; total T3, free T4 (direct), and total T4 are required.</strong> Added reference to Appendix 2 in Footnote 11 of Appendix 1</td>
</tr>
<tr>
<td><strong>Rationale</strong>: SAE reporting requirements were not aligned with the current Janssen protocol template.</td>
<td></td>
</tr>
<tr>
<td>Section 9.2.1 SAE Reporting</td>
<td>Made the following revision: Information regarding SAEs will be transmitted to the Sponsor using the Serious Adverse Event Form, which must be completed and signed by a physician from the study site, and transmitted to the Sponsor within 24 hours. <strong>The initial and follow-up reports of an SAE should be made by facsimile (fax).</strong> This timeframe also applies to additional new information (follow-up). SAEs should be reported by facsimile or email.</td>
</tr>
<tr>
<td><strong>Rationale</strong>: All patients will have switched from softgel capsules to tablets at the time of implementation of this amendment therefore guidance for the switching, is no longer necessary.</td>
<td></td>
</tr>
<tr>
<td>Section 5.3.3 Drug Administration</td>
<td>Removed guidance for the switch from softgel capsules to tablets.</td>
</tr>
<tr>
<td><strong>Rationale</strong>: A generic name for ARN-509 is now available.</td>
<td></td>
</tr>
<tr>
<td>Throughout the protocol, where appropriate</td>
<td>The designation of ARN-509 is changed to the generic name, apalutamide.</td>
</tr>
<tr>
<td><strong>Rationale</strong>: Updated drug-drug interaction information is available</td>
<td></td>
</tr>
<tr>
<td>Section 6.2 Restricted Therapies; Attachment 5</td>
<td>Updated drug-drug interaction information.</td>
</tr>
<tr>
<td><strong>Rationale</strong>: All Janssen Phase 3 protocols must now include a list of anticipated events.</td>
<td></td>
</tr>
<tr>
<td>Section 9.2 Reporting Requirements; Section 9.2.3 Sponsor Reporting Requirements to Regulatory Authorities; Appendix 9</td>
<td>Added details for reporting and a list of anticipated events in Appendix 9. A statement to reference the Appendix was added to Section 9.2 of the protocol. Additional information in cases of serious anticipated events was added to Section 9.2.3 as follows: <strong>For anticipated events reported as individual serious adverse events the Sponsor will make a determination of relatedness in addition to and independent of the investigator’s assessment. The Sponsor will periodically evaluate the accumulating data and, when there is sufficient evidence and the sponsor has determined there is a reasonable possibility that the drug caused a serious anticipated event, they will submit a safety report in narrative format to the investigators (and the head of the institute).</strong></td>
</tr>
</tbody>
</table>
**Applicable Section(s)** | **Description of Change(s)**  
---|---  
**Rationale:** Minor errors or clarifications were noted  
Synopsis, Duration of Patient Participation...; Section 8.10 Subsequent Therapy with Abiraterone Acetate; Section 8.6 Every 16 Weeks...  
Protocol Synopsis Study Design; Section 3.1 Study Overview and Rationale; Section 8.9 Long-term Follow-up Appendix 1 Schedule of Activities, Footnotes 4 and 13  
Section 8.9 Long-term Follow-up; Appendix 1 Schedule of Activities, Footnotes 4 and 21  
Section 4.1 Inclusion Criteria; Section 4.2 Exclusion Criteria  
Throughout the protocol  

**Amendment INT-6** (18 May 2015)

This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union.

The overall reason for this amendment is to switch softgel capsules to tablets (commercial formulation) for patients currently receiving the softgel capsules and to administer tablets to newly enrolled patients. Added the restriction that Section 8.10 does not apply in Japan. Additional minor changes were made as outlined below.

**Applicable Section(s)** | **Description of Change(s)**  
---|---  
**Rationale:** Switch of softgel capsules to tablets is incorporated. (b)(4) is not included in the tablet formulation.
### Applicable Section(s) Description of Change(s)

<table>
<thead>
<tr>
<th>Throughout</th>
<th>Changed “softgel capsules” or “capsules” to “tablets.”</th>
</tr>
</thead>
<tbody>
<tr>
<td>Section 5.3.1 ARN-509/Matched Placebo; Section 5.3.2 Packaging, Storage, and Labeling</td>
<td>Removed information on formulation, packaging, and storage of the softgel capsules. Replaced with appropriate wording for the tablets.</td>
</tr>
<tr>
<td>Section 5.3.1 ARN-509/Matched Placebo; Section 6.2, Restricted Therapies; Appendix 5</td>
<td>Removed information, no longer applicable with the tablet formulation.</td>
</tr>
<tr>
<td>Section 5.3.3 Study Drug Administration</td>
<td>Added a new table showing the conversion from capsule to tablet and clarifying that the conversion is 2:1. Provided timing for the switch from the softgel capsules to tablets. Revised Table 2.</td>
</tr>
</tbody>
</table>

**Rationale:** The twice daily dosing is no longer relevant for the tablet formulation.

| Synopsis Dose and Route of Administration; Section 5.3.4 Cycle Management; Section 5.3.5 Dose Modifications | Removed the twice daily dosing option. Removed wording on dose modification due to gastrointestinal discomfort. |

**Rationale:** Revised treatment compliance to account for capsules or tablets

| Section 5.5 Measures of treatment compliance; Schedule of Activities (Footnote 8) | Changed from “capsules” to “capsules or tablets.” Revised compliance to account for the difference in number of capsules versus tablets. |

**Rationale:** The Statistical Analysis Plan will include additional analyses for safety and for the primary endpoint by formulation subgroup.

| Section 13.2.1 Analysis of Primary Endpoint | Added the following sentence: Additional analyses by formulation subgroups will be performed for the MFS endpoint as described in the Statistical Analysis Plan. |
| Section 13.3.1 Analysis of Adverse Events | Added the following sentence: An additional analysis by formulation subgroups will be performed as outlined in the Statistical Analysis Plan. |

**Rationale:** The population PK analysis will include an additional analysis to explore the effect of the formulation switch.

<p>| Section 13.4.4 Population Pharmacokinetics (PopPK) Analysis | Added the following wording: “the effect of the formulations will also be explored in the covariate analysis.” |</p>
<table>
<thead>
<tr>
<th>Applicable Section(s)</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rationale:</strong> To clarify that patients who experience loco-regional tumor progression should continue on study drug until documentation of distant metastatic disease. Local therapies such as surgery or radiation are allowed with study treatment. This was not clearly stated in the protocol.</td>
<td></td>
</tr>
<tr>
<td>Section 6 Concurrent Medications</td>
<td>Added the following: Salvage radiation for locoregional pelvic disease and surgical procedures (eg, transurethral resection of the prostate [TURP], urethral and ureteral stent placement) to treat localized progression or symptoms are allowed. Patients receiving these therapies may continue on study drug.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> To incorporate a local restriction in Japan into the global protocol in order to avoid the need for a separate country-specific protocol. The Sponsor will not provide abiraterone acetate as subsequent therapy. The criteria outlined in Section 8.10 are not applicable to sites in Japan.</td>
<td></td>
</tr>
<tr>
<td>Section 8.10 Subsequent Therapy with Abiraterone Acetate; Schedule of Activities (Footnote 3)</td>
<td>Due to local restrictions in Japan, the Sponsor will not provide abiraterone acetate and the criteria outlined in this section do not apply.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> It is not necessary to administer study drug within 1 hour onsite after the trough PK sampling.</td>
<td></td>
</tr>
<tr>
<td>Section 7.3 Pharmacokinetic Measurements; Section 8.4 Day 1 of Cycles (±2 days); Schedule of Activities (Footnote 20)</td>
<td>Removed the requirement that the PK sample be taken up to 1 hour prior to administering the study drug in the clinic.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Patients who have a delay of study drug administration for ≥28 days due to toxicity will no longer automatically meet the criteria for discontinuation from the study.</td>
<td></td>
</tr>
<tr>
<td>Section 5.3.5 Dose Modifications; Section 10 End of Treatment</td>
<td>Revised to indicate that subjects may discontinue study treatment if delayed more than 28 days due to toxicity and must be discussed with the Sponsor.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Changes were made to improve clarity or correct errors</td>
<td>Minor changes were made to following eligibility criteria: Inclusion #3, 11, and 13; Exclusion #8 and #9. In Section 6.2, the bullet describing corticosteroid therapy was made consistent with other sections. Revised the wording in the last bullet of Section 8.2. Clarified in last bullet of Section 8.9 that disease progression refers to distant metastasis. Removed 1.7 nM for testosterone concentration. Corrected error of footnote for biomarkers in the Schedule of Events and revised Footnote 6 to match revision in Section 8.2.</td>
</tr>
</tbody>
</table>
Amendment INT-5 (1 July 2014)

This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union

The overall reason for the amendment: The overall reason for the amendment is to incorporate a time cutoff for the earliest prostate specific antigen (PSA) values used in the calculation of PSA doubling time (PSADT).

NOTE: Amendment INT-4 was never implemented and has been superseded by Amendment INT-5. The only change that affects study conduct between Amendments INT-5 and INT-4 is the addition of a 24 month collection time period during which PSA values used to calculate the PSADT can be obtained. This change was made shortly after finalization of the previous amendment. Please refer below to the table of changes for Amendment INT-4. All changes have been incorporated, as appropriate, into the protocol text.

<table>
<thead>
<tr>
<th>Applicable Section(s)</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rationale:</strong> The previous amendment did not include information on a timeframe for PSA values that should be used for the calculation of PSADT. A collection period during which PSA values used to calculate the PSADT can be obtained, is now specified. Therefore, this amendment will incorporate a cutoff that allows inclusion of PSA values collected within 24 months prior to the subject’s randomization.</td>
<td></td>
</tr>
<tr>
<td>4.1 Inclusion Criteria, Inclusion Criterion #1</td>
<td>Simplified Criterion #1 and referred to Section 5.1 for details on timing and calculation of PSADT. Revised the criterion to read: Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of metastases, defined as PSADT ≤ 10 months. PSADT is calculated using at least 3 PSA values obtained during continuous ADT (see Section 5.1).</td>
</tr>
<tr>
<td>5.1 Randomization</td>
<td>Added the requirement for PSA values to be within 24 months prior to randomization with the specification that at least 3 values be used. Clarified that the earliest PSA value and all subsequent PSA values be entered into the Interactive Voice Randomization System (IVRS).</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Minor revision for consistency with Janssen Research &amp; Development protocol template to numbering of eligibility criteria.</td>
<td></td>
</tr>
<tr>
<td>4.1 Inclusion Criteria, Inclusion Criteria #1; #5, and #6</td>
<td>Revised the numbering to incorporate the current template style.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Remove the inclusion of the number of sites as this information is not necessary in the protocol and is subject to change.</td>
<td></td>
</tr>
<tr>
<td>Synopsis, Number of Sites, 3.1 Study Overview and Rationale</td>
<td>Removed the information on the number of sites from the synopsis and study overview.</td>
</tr>
</tbody>
</table>
Amendment INT-4 (16 June 2014)

This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union.

The overall reason for the amendment: The overall reason for the amendment is to incorporate investigator feedback for Inclusion criteria #1 and 2 in order to clarify the definitions of prostate specific antigen doubling time (PSADT) and castration-resistance so that the intended homogenous and high-risk patient population is enrolled. Section 5.1 is also being revised to reflect the change to Inclusion Criterion #1. The addition of an optional prescreening period is being incorporated to allow investigators time to obtain the required number of prostate-specific antigen (PSA) values for meeting the study eligibility criteria.

<table>
<thead>
<tr>
<th>Applicable Section(s)</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rationale:</strong></td>
<td>The window of requiring prostate specific antigen (PSA) values collected within 6 months prior to randomization for calculation of the PSADT has the unintended consequence of excluding patients who are otherwise eligible, but who may have had one or more of the required PSAs collected outside the 6 month window. Currently, we are asking sites to continue to monitor and collect more recent PSAs from these patients; this delay increases the risk of screen fails as these patients are at high risk for metastasis. This requirement window has been removed from Inclusion Criterion #1 and a reference to Section 5.1 of the protocol, which details the calculation of PSADT for eligibility, has been added.</td>
</tr>
<tr>
<td>4.1 Inclusion Criteria, Inclusion Criterion #1</td>
<td>Revised the criterion to read: Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of metastases, defined as PSADT ≤ 10 months. PSADT is calculated using at least 3 PSA values obtained during continuous ADT. The first and last PSA values used in the calculation must be separated by at least 8 weeks (see Section 5.1).</td>
</tr>
<tr>
<td>5.1 Randomization</td>
<td>Removed the requirement for 3 PSA values to be within 6 months prior to randomization. For consistency with the eligibility criteria the description of PSADT calculation is based on “at least” 3 PSA values. Also added the sentence that the first and last PSA values used in the calculation must be separated by at least 8 weeks.</td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
<td>Inclusion Criterion #2 requires that castration resistant prostate cancer is defined as 3 consecutive rises of PSA. This is not consistent with the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria, and has the unintended consequence of excluding patients who are otherwise eligible, but who have had one or more PSA in a consecutive sequence not rise although there may be 3 rises in total. Currently, we are asking sites to continue to monitor and collect more PSAs until the three consecutive rises are met; this delay increases the risk of screen fails as these patients are at high-risk for metastasis. The requirement for two 50% increases of PSA above the nadir is also considered too stringent and is not consistent with the PCWG2 criteria.</td>
</tr>
<tr>
<td>4.1 Inclusion Criteria; Inclusion Criterion #2</td>
<td>Revised the criterion to read: Castration-resistant prostate cancer demonstrated during continuous ADT, defined as 3 PSA rises, at least 1 week apart, with the last PSA &gt; 2 ng/mL.</td>
</tr>
</tbody>
</table>
Applicable Section(s) | Description of Change(s)
--- | ---

**Rationale:** The washout period following anti-androgen may be longer than 4 weeks depending on the anti-androgen. Clarified that the washout period must be at least 4 weeks.

4.1 Inclusion Criteria; Inclusion Criterion #5
Revised the criterion to read:
Patients who received a first generation anti-androgen (e.g., bicalutamide, flutamide, nilutamide) must have at least a 4-week washout prior to randomization AND must show continuing disease (PSA) progression (an increase in PSA) after washout.

**Rationale:** Sampling for PSA may not be frequent enough at some sites. In order to ensure eligible patients are not “missed,” the patient may be asked to participate in the optional Prescreening Phase and sign a prescreening informed consent. The prescreening PSA evaluations will be performed by a local laboratory. As no study medication is being introduced at this point, only collection of serious adverse events related to the PSA blood draw will be collected.

3.1 Study Overview and Rationale; 7.2.1 PSA; 8.1 Prescreening; 9.2.1 SAE Reporting; 9.2.2 Non-Serious AE Reporting; Appendix 1: Schedule of Events; Footnote 1, new Footnote 10; new Footnote 18.
Added the prescreening details to appropriate sections of the protocol body and Appendix 1. For clarity, added a separate footnote for PSA evaluations to Appendix 1. Added a new section (8.1 Prescreening). Added Footnote 18 to clarify that only SAEs related to the PSA blood draw will be collected.
All other footnotes were renumbered accordingly.
Section 9.2.1 was modified to add the SAE reporting requirement during the Prescreening Period.
Section 9.2.2 was modified to clarify the reporting period and an error was corrected (strikethrough text removed):
Adverse events should be recorded on the AE CRF from the time the patient has signed the informed consent at screening (see Section 8.2) taken at least one dose of study drug until 28 days after the last dose of study drug.

**Rationale:** The description of androgen deprivation therapy as ADT/post-surgery castration is redundant, wording was revised, as applicable.

Throughout the protocol
ADT/post-surgical castration was revised to ADT

**Rationale:** The term radiographic progression-free survival or rPFS originated with the ZYTIGA COU-AA-302 study and has specific criteria for the determination of radiographic progression that is not applicable to the patient population in this study. To avoid confusion, the term radiographic PFS or rPFS is being revised to progression-free survival or PFS.

Throughout the protocol
Revised radiographic progression-free survival or radiographic PFS or rPFS terminology to progression-free survival or PFS.

**Rationale:** Aminoglutethimide was erroneously included under Inclusion Criterion # 6 and should be under Exclusion Criterion #4.

4.1 Inclusion Criteria, Inclusion Criterion# 6
4.2 Exclusion Criteria, Exclusion Criterion# 4.
Moved aminoglutethimide to the Exclusion Criterion # 4 after ketoconazole.
### Rationale: Update to pregnancy section for consistency with the Janssen Template wording

9.1.6 Exposure During Pregnancy

Updated with Janssen template wording

### Rationale: Clarified timing of submitting the FFPE archival tumor samples or slides.

Footnote 21

Updated the footnote to indicate that FFPE samples can be submitted anytime starting from Cycle 1 Day 1.

### Rationale: The number of sites is planned to increase.

Synopsis, Number of Sites; 3.1 Study Design Overview and Rationale

Increased number of sites from 330 to 400.

### Rationale: Fasting period requirement for the ventricular repolarization study is very long, subjects will be now be allowed to have an approved snack.

Appendix 8, Additional Inclusion Criteria

Added that the subject can have an approved snack:
Must agree to fast at least 3 hours prior to dose and continue fasting (except for approved snack) until completion of the 4 hour post dose assessments on Cycle 1 Day 1 and Cycle 3 Day 1.

### Rationale: Minor errors or clarifications were noted

Throughout the protocol

Minor grammatical, typographical or clarification changes were made.

---

**Amendment 3 (11 March 2014)**

This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and the Council of the European Union

**The overall reason for the amendment:** The overall reasons for the amendment are the following: to incorporate modifications to the statistical analysis plan for the secondary endpoints; incorporate provision of abiraterone acetate as subsequent therapy for eligible patients; addition of exploratory biomarkers; reduction of population pharmacokinetic sample collection and modification of the population PK analysis, and modification of the patient-reported outcomes analysis. Additional changes were also implemented based on Health Authority and Investigator feedback. Updated nonclinical and clinical data were also incorporated.
<table>
<thead>
<tr>
<th>Applicable Section(s)</th>
<th>Description of Change(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rationale:</strong> Statistical analysis of the secondary endpoints was modified and will incorporate multiple testing method in agreement with the FDA proposal.</td>
<td></td>
</tr>
<tr>
<td>Synopsis, Secondary Objectives and Endpoints, Other Objectives and Evaluations; 2.2 Secondary Objectives; 2.3 Other Objectives; 3.2.2 Secondary Endpoints; 3.2.3 Other Evaluations; Synopsis, Statistical Analysis Plan and Rationale for Number of Patients; 13.2.2 Analysis of Secondary Endpoints</td>
<td>Overall survival (OS) is no longer a separate key secondary objective or endpoint. Removed “key” and “other” secondary endpoints sections and regrouped into 2 groups of “Secondary Endpoints.” Group 1 includes: time to symptomatic progression, time to initiation of cytotoxic chemotherapy, radiographic progression-free survival (rPFS), and time to metastasis (TTM). Group 2 includes OS. Added “Other” objectives and evaluations (see additional rationale below). The statistical testing of the 2 groups of secondary endpoints will be performed by allocating 0.01 to Group 1 and 0.04 for the OS endpoint in Group 2 with an overall familywise type I error rate of 0.05. Details of the testing procedure will be provided in the statistical analysis plan.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Modification of the interim analysis of OS, 2 interim analyses and 1 final analysis are now planned.</td>
<td></td>
</tr>
<tr>
<td>Synopsis, Statistical Analysis Plan and Rationale for Number of Patients; 13.5 Interim Analysis; 13.6 Determination of Sample Size; Synopsis, Duration of Patient Participation and Duration of Study; 15.6 End of Trial Notification in All Participating Countries</td>
<td>Two interim analyses and 1 final analysis are planned for the OS endpoint. With the decrease in alpha from 5% to 4%, the number of death events is now 526 (final analysis). At the time of the first interim analysis, approximately 46% (243/526) of the death events will be observed with an alpha spend of 0.0012. The second interim analysis will be performed after observing approximately 70% (369/526) of the death events with a cumulative alpha spend of 0.0109. The actual alpha spent for the 2 interim analyses will be based on the number of death events observed at the time of the analyses.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Added “Other” Objectives and Evaluations</td>
<td></td>
</tr>
<tr>
<td>Synopsis, Other Objectives; Other Evaluations; 2.2 Other Objectives; 3.2.3 Other Evaluations</td>
<td>Also added PSA response and time to PSA progression, analyses are included in Section 13.4.1, but they were not listed as evaluations in the previous versions of the protocol. Added medical resource utilization and exploratory biomarkers Previous endpoints listed as “Other Secondary” Objectives and Evaluations were renamed “Other” Objectives and Evaluations.</td>
</tr>
<tr>
<td>Applicable Section(s)</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Provision of abiraterone acetate as subsequent therapy for those patients who meet the protocol-specified eligibility criteria.</td>
<td></td>
</tr>
<tr>
<td>8.9 Subsequent Therapy with abiraterone acetate; 9.2.1 Serious Adverse Event Reporting; 10 End-of-Treatment</td>
<td>Addition of a new section (8.9) incorporating the provision of abiraterone acetate by the Sponsor.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Population pharmacokinetic (PK) sampling and analysis were modified. The number of sparse samples for population PK analysis was decreased as steady state of ARN-509 and metabolite ARN000308 can be reached within approximately 3 months. Pharmacokinetic samples collected up to 24 months should be sufficient to characterize the kinetics of both compounds, and no relevant information would be obtained from later timepoints. Analysis of the metabolite ARN000066 is being removed as this is a minor metabolite in humans with minimal activity.</td>
<td></td>
</tr>
<tr>
<td>7.3 Pharmacokinetic Measurements; 8.2 Cycle 1 Day 1; 8.3 Day 1 of Cycles n.; Appendix 1; Footnote 17; 13.4.3 Population PK Analysis; Appendix 8</td>
<td>Removed analysis for the ARN000066 metabolite. Removed sample collection from Cycle 36 onwards. Sparse PK samples will not be taken from patients participating in the ventricular repolarization substudy (Appendix 8).</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Exploratory biomarker research was added to study the potential mechanisms of resistance to ARN-509. Based on limited published data, approximately 10% of patients with late stage disease may develop resistance over the course of treatment. There is not sufficient data to indicate whether resistance develops at a different frequency in patients with NM-CRPC. In the original plan proposed by FDA, a sample size of 300 patients was considered sufficient. Based on follow-up advice from the FDA and assuming lower frequencies of mutation emergence in the NM-CRPC, the number of samples was increased from 300 to 400 in order to have sufficient power for correlative analysis based on calculation on a sliding scale. To capture the F876L mutation status in patients progressing in the later course of treatment, the collection of samples was modified to include Day 1 of Cycle 36, the Day 1 of Cycle 6 assessment was removed.</td>
<td></td>
</tr>
<tr>
<td>7.5 Exploratory Biomarkers; 13.1 Analysis Populations; 13.4.4 Exploratory Biomarkers; References; 14.7 Patient Confidentiality</td>
<td>Section 7.5 was added to explain background and rationale for the exploratory biomarker research. A new analysis population was added. Long-term storage details for biomarker samples was incorporated into Section 14.7.</td>
</tr>
<tr>
<td>8.6 End-of-Treatment Visit; Appendix 1 and added Footnote 19.</td>
<td>Sample collection details for exploratory biomarkers were incorporated. Archival tumor formalin-fixed paraffin embedded (FFPE) tumor blocks or tumor slides will be retrieved from consenting patients on Cycle 1 Day 1, blood samples will be collected before dosing on Day 1 of Cycles 1, 12, 18, 24, 36, and end-of-treatment. Footnote 19 indicates blood volumes collected during each cycle.</td>
</tr>
<tr>
<td>Applicable Section(s)</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Rationale:</strong> The previous patient-reported outcomes analysis incorporated a 16-point improvement in the Functional Assessment of Cancer Therapy-Prostate (FACT-P) total score as the definition for a health-related quality of life improvement. Improvement of the total score is not applicable for this study population. The magnitude of a clinically meaningful change was redefined.</td>
<td></td>
</tr>
<tr>
<td>13.4.2 Health-Related Quality of Life and Prostate Cancer-Specific Symptoms Analysis</td>
<td>A 10-point change in the FACT-P total score is considered clinically meaningful. Therefore, any patient experiencing a 10-point decrement in FACT-P total scores from baseline will be considered to have experienced clinically meaningful deterioration in functional status.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> The completion of the PRO questionnaires was reduced after Cycle 13 to every other cycle to relieve the burden to the patient and for consistency with other Sponsor protocols.</td>
<td></td>
</tr>
<tr>
<td>7.4 Patient-Reported Outcomes; 8.3 Day 1 of Cycles n…; Appendix 1, Footnote 18</td>
<td>Reduced the collection of FACT-P and EQ-5D questionnaires after Cycle 13 to every other cycle.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Added second progression-free survival (PFS2) as an evaluation per agreement with health authorities.</td>
<td></td>
</tr>
<tr>
<td>Synopsis, Other Evaluations; 3.2.3 Other Evaluations; 8.8 Survival Follow-Up; 13.4.1 Second progression-free survival (PFS2); Appendix 1</td>
<td>This endpoint is defined as the time from randomization to second documentation (progression on first subsequent therapy) investigator-assessed disease progression (PSA, radiographic, symptomatic, or any combination) or death from any cause.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Inclusion criterion was modified for consistency with Section 5.1 of the protocol and based on Investigator feedback.</td>
<td></td>
</tr>
<tr>
<td>4.1 Inclusion Criteria, Criterion #1</td>
<td>Clarified determination of PSADT</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Inclusion of patients with documented Gilbert’s disease is allowed</td>
<td></td>
</tr>
<tr>
<td>4.1 Inclusion Criteria, Criterion #11</td>
<td>Added exception to elevated bilirubin in cases of documented Gilbert’s disease.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Bone sparing therapies indicated for the treatment of skeletal events due to bone metastases are not allowed as concurrent therapy.</td>
<td></td>
</tr>
<tr>
<td>4.1 Inclusion Criteria, Inclusion Criterion #4; 4.2 Exclusion Criteria, Exclusion Criterion 8</td>
<td>Clarified inclusion Criterion #4 to allow bone sparing therapies for the treatment of osteoporosis if on stable doses for at least 4 weeks prior to randomization. Modified Exclusion Criterion #8 to exclude bone sparing therapy (eg., denosumab [Xgeva®]) indicated for the treatment of skeletal events due to bone metastases.</td>
</tr>
<tr>
<td>Applicable Section(s)</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Exclusion criterion #1 was modified to clarify that a <em>history</em> of distant metastases is also exclusionary.</td>
<td></td>
</tr>
<tr>
<td>4.2 Exclusion Criteria, Exclusion Criterion #1</td>
<td>Presence of distant metastases confirmed by blinded independent central review (BICR), including CNS and vertebral or meningeal involvement, or history of distant metastases. Exception: pelvic lymph nodes &lt; 2 cm in short axis (N1) located below the iliac bifurcation are allowed.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Inclusion Criterion #5 was modified to clarify the criteria for eligibility following previous anti-androgen treatment to include the 4 week washout period prior to randomization and documented prostate specific antigen (PSA) progression.</td>
<td></td>
</tr>
<tr>
<td>4.1 Inclusion Criteria; Inclusion Criterion #5</td>
<td>Patients who received a first generation anti-androgen (e.g., bicalutamide, flutamide, nilutamide) must have a 4-week washout prior to randomization AND must show continuing disease (PSA) progression (an increase in PSA) once they are off the anti-androgen.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Inclusion Criteria #6 to clarify that prior estrogen treatment discontinuation is irrespective of dose used.</td>
<td></td>
</tr>
<tr>
<td>4.1 Inclusion Criteria, Inclusion Criterion #6</td>
<td>At least 4 weeks must have elapsed from the use of 5-α reductase inhibitors (e.g., dutasteride, finasteride, aminoglutethamide), estrogens (irrespective of dose used), and any other anti-cancer therapy prior to randomization, including chemotherapy given in the adjuvant/neoadjuvant setting (e.g., clinical trial).</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Clarified that patients with a history of uncontrolled blood pressure are eligible if controlled with anti-hypertensive treatment.</td>
<td></td>
</tr>
<tr>
<td>4.2 Exclusion Criteria, Exclusion Criterion #9</td>
<td>Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic BP ≥100 mHg). Patients with a history of uncontrolled hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Gonadotropin releasing hormone analogs (GnRHa) (or surgical castration) for patients is required as a concomitant therapy and should be continuous throughout treatment.</td>
<td></td>
</tr>
<tr>
<td>Inclusion Criterion #3; 3.1 Study Design Overview and Rationale; 6 Concurrent Medications</td>
<td>Revised Inclusion Criterion #3 and incorporated text in relevant sections throughout the protocol to reiterate the requirement for GnRHa treatment (or surgical castration) for all patients (both treatment groups).</td>
</tr>
<tr>
<td>Applicable Section(s)</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Per Sponsor policy adverse events (AEs) should be collected from the signing of the informed consent form.</td>
<td>Modified these sections to include collection of AEs from the signing of the informed consent form and not at the time of the first dose of study drug. General addition, where needed, for collection of AEs at all times from informed consent up to 28 days after the last dose of study drug.</td>
</tr>
<tr>
<td>8.1 Screening, 8.2 Cycle 1 Day 1; 8.3 Day 1 of Cycles n; 8.6 End-of-Treatment Visit; 8.7 Safety Follow-up; 9.1.1 Adverse Events; 9.2.2 Non-serious AE Reporting; Appendix 1</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> Analysis of vital signs and concomitant medications should be under safety evaluations and not under other evaluations.</td>
<td>Moved from the Other Evaluations section to Safety Evaluations Section.</td>
</tr>
<tr>
<td>13.3.3 Vital Signs Analysis; 13.3.4 Concomitant Medications</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> Clarification that patients are expected to be treated with local standard of care before enrollment. Rescreening information for screen failures was added.</td>
<td>It is expected that all patients will be treated according to local standard of care, including radiation therapy if needed for local disease, prior to enrolling. Patients considered screen failures may be subsequently rescreened. Rescreening must be discussed with and approved by the Sponsor on a case by case basis. Patients who are determined to be eligible for the study after rescreening must sign a new ICF and be assigned a new patient number.</td>
</tr>
<tr>
<td>4 Patient Selection</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> Timing of tumor assessments and collection of blood for thyroid stimulating hormone (TSH), testosterone, and fasting lipid panel was modified from every 16 weeks starting from the date of randomization to starting from Cycle 1 Day 1. Urinalysis was removed as a required laboratory assessment.</td>
<td>Change timing of the start of assessments from date of randomization to Cycle 1 Day 1. A separate column for these assessments was added to the Schedule of Events.</td>
</tr>
<tr>
<td>8.4 and 8.5 Every 16 weeks from Cycle 1 Day 1; Appendix 1</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> Incorporated the Danish Health Authority request for inclusion of detailed methods of contraception and required duration of contraceptive methods or donation of sperm after discontinuation of the study drug.</td>
<td>Added more detailed information for patients and partners of childbearing potential. Also added that effective contraception is required during the study and for 3 months after the last dose of study drug. Donation of sperm is not allowed during the study and for 3 months following the last dose of study drug.</td>
</tr>
<tr>
<td>6.3 Life Style Guidelines</td>
<td></td>
</tr>
<tr>
<td>Applicable Section(s)</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Updated nonclinical data</td>
<td></td>
</tr>
<tr>
<td>Synopsis; 1.1.2 Preclinical Development Overview</td>
<td>Revised and updated in vitro metabolism data. Summarized the final 13-week rat and dog GLP toxicity results, removed the dog 28-day toxicity summary. Updated the genotoxic, clastogenic, and phototoxicity data for ARN-509 and the metabolites (ARN000308 and ARN000066).</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Updated clinical information</td>
<td></td>
</tr>
<tr>
<td>1.13 Overview of Clinical Studies</td>
<td>Updated with general overview of ongoing clinical studies and data from Study ARN-509-001.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> The protocol had no information regarding product quality complaint handling. Added a Product Quality Complaint section to the protocol</td>
<td></td>
</tr>
<tr>
<td>9.2.4 Product Quality Complaint Handling</td>
<td>Added new section per Sponsor template.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Patient initials will not be used for any documents in this study.</td>
<td></td>
</tr>
<tr>
<td>14.1 Data Collection Instruments; 14.7 Patient Confidentiality; 15.1 Investigator Responsibilities</td>
<td>All reference to patient initials was removed.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Per request of Danish Health Authority, investigator responsibilities section was updated to include a Declaration of Helsinki statement. Wording consistent with the current Sponsor template was incorporated.</td>
<td></td>
</tr>
<tr>
<td>15.1 Investigator Responsibilities; 15.4 Informed Consent Form</td>
<td>Incorporated Sponsor template language, which meets the requirements of the HA request.</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Added instruction that subsequent ECG readings should be collected using same position as the baseline reading.</td>
<td></td>
</tr>
<tr>
<td>7.2.2 Electrocardiogram (ECG)</td>
<td>Subsequent ECG readings should be collected with the patient in the same position (e.g., fully supine or semi-recumbent).</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Protocol violation forms do not exist.</td>
<td></td>
</tr>
<tr>
<td>11 Protocol Violations</td>
<td>Removed paragraph explaining that protocol violation forms would be completed and archived. There are no such forms.</td>
</tr>
<tr>
<td>Applicable Section(s)</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
<td>At the time for the final analysis OS, a decision will be made regarding whether or not an amendment of the protocol may be needed.</td>
</tr>
<tr>
<td>Synopsis, Duration of Patient Participation and Duration of Study; 15.6 End of Trial in All Participating Countries</td>
<td>Removed wording indicating that the protocol may be amended to minimize the number of assessments.</td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
<td>Time from screening to randomization was increased from 28 days to 35 days because the required 28 day washout period for eligibility was not allowing enough time to complete screening assessments in some patients. The time from randomization to Cycle 1 Day 1 was also increased by 1 day from 3 days to 4 days to accommodate unforeseen delays due to holidays, weather, etc.</td>
</tr>
<tr>
<td>Appendix 1; 8.1 Screening Within 35 Days of Randomization; 8.3 Cycle 1 Day 1</td>
<td>Change timing from screening to randomization to 35 days, also revised the timing from randomization to Cycle 1 Day 1 from 3 days to 4 days</td>
</tr>
<tr>
<td><strong>Rationale:</strong></td>
<td>Laboratory assessments deemed nonessential for safety or efficacy were removed</td>
</tr>
<tr>
<td>Appendix 2</td>
<td>Removed phosphorus, total protein, chloride, uric acid, and lactate dehydrogenase.</td>
</tr>
<tr>
<td>Appendix 1; Appendix 2; 7.2 Clinical Laboratory Measurements; 8.1 Screening within 35 Days of Randomization; 8.4 Every 16 Weeks Starting From Cycle 1 Day 1 ...; 8.6 End-of-Treatment Visit</td>
<td>Removed collection of urine samples and urinalysis.</td>
</tr>
<tr>
<td>Applicable Section(s)</td>
<td>Description of Change(s)</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Rationale:</strong> Prostate-specific antigen (PSA) was listed under the wrong column in the Appendix 2 table</td>
<td>Moved PSA measurements to the every cycle column for consistency with the Schedule of Events.</td>
</tr>
<tr>
<td>Appendix 2</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> The approximate number of sites has increased from 250 to 330.</td>
<td>Revised from approximately 250 in the synopsis to 330 and added this information to Section 3.1.</td>
</tr>
<tr>
<td>Synopsis, Number of Sites; 3.1 Study Overview and Rationale</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> Additional eligibility criteria for participation in the QT substudy were incorporated. Holter monitoring assessment included at Screening. Informed consent requirement was previously not included in the Appendix 8 Schedule of Activities for Screening.</td>
<td>Screening assessment incorporated with the addition of the Holter monitoring and requirement for signing of informed consent. Added required fasting conditions for participation in the substudy, exclusion of patients if they required a dose reduction at any time from Cycle 1 Day 1 through Cycle 3 Day 1. Made a minor wording to the sample size determination: A sample size of at least 100 patients will ensure that at least 60 patients treated with ARN-509 will be enrolled on the substudy and 60 patients will provide at least 98.7% power to detect a true effect of 10 milliseconds (msec) change from baseline considering only the active group. Informed consent was added to Table 1 of Appendix 8.</td>
</tr>
<tr>
<td>Appendix 8</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> Inclusion of all criteria in the synopsis was unnecessary.</td>
<td>Replace the individual criteria with a summary.</td>
</tr>
<tr>
<td>Synopsis, Enrollment Criteria</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> Clarified that pomegranate is excluded (not just juice)</td>
<td>Removed the word “juice.”</td>
</tr>
<tr>
<td>Section 4.2 Exclusion Criteria, Criterion #8; Appendix 5</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> Added that a patient eligibility form must be completed and submitted to the medical monitor before randomization</td>
<td>Added a bullet to Section 8.1. Also added to the subsequent bullet that the medical monitor must confirm eligibility before randomization.</td>
</tr>
<tr>
<td>8.1 Screening Within 35 Days of Randomization</td>
<td></td>
</tr>
<tr>
<td><strong>Rationale:</strong> In order to avoid a protocol amendment in the case where contact information may change, the contact information was removed.</td>
<td>Removed contact information, which will be provided separately.</td>
</tr>
<tr>
<td>9.1.2 Serious Adverse Events</td>
<td></td>
</tr>
</tbody>
</table>
### Applicable Section(s) Description of Change(s)

<table>
<thead>
<tr>
<th>Rationale: The Schedule of Events was confusing to follow and not well organized</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appendix 1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rationale: Modified wording throughout the document for conciseness or clarity.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Throughout the protocol</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rationale: Minor errors were noted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Throughout the protocol</td>
</tr>
</tbody>
</table>
1. BACKGROUND

Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer death in males, accounting for 14% (903,500) of the total new cancer cases and 6% (258,400) of the total cancer deaths in males worldwide. Treatment aimed at eradicating the primary tumor, typically with surgery or radiation, is unsuccessful in ~30% of men, who develop recurrent disease that usually manifests first as a rise in plasma prostate-specific antigen (PSA) followed by metastasis to distant sites. Given that prostate cancer cells depend on androgen receptor (AR) for their proliferation and survival, the standard treatment for patients with recurrent disease is androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog (GnRHa) with or without an anti-androgen.

Treatment results with ADT are generally predictable: a decline in PSA followed by tumor regression, a period of stability in which the tumor does not proliferate and PSA remains stable, followed by rising PSA and regrowth as a castration-resistant disease. Nearly all men with progressive prostate cancer eventually develop castration-resistant disease. Prostate cancer progression despite castrate levels of testosterone represents a transition to a lethal disease stage.

Molecular profiling studies of castration-resistant prostate cancer (CRPC) commonly show increased AR gene expression. The increased AR levels are sufficient to confer resistance to anti-androgen therapy in mouse models, shorten tumor latency and confer agonist properties to first generation AR antagonists, such as bicalutamide or flutamide. The potential for agonist activity by these approved anti-androgens in the setting of increased AR expression is a potential liability, best illustrated by the observation of tumor regression and declines in PSA following discontinuation of either of these AR antagonists, the so-called anti-androgen withdrawal syndrome. Collectively, these findings implicate increased AR levels as one mechanism of drug resistance. They also suggest that drugs retaining antagonism and not displaying agonism in cells over-expressing AR levels might be useful therapeutically.

ARN-509 (JNJ-56021927; apalutamide, hereafter referred to as apalutamide) is a next generation AR antagonist that has been developed to overcome the potential therapeutic deficiencies of first-generation AR antagonists (e.g., bicalutamide).

1.1 APALUTAMIDE

Apalutamide is an orally available, potent and selective AR antagonist that acts by inhibiting the action of androgen, nuclear translocation of the AR and DNA binding to androgen response elements and unlike bicalutamide, it exhibits no significant agonist activity in AR-overexpressing prostate cancer cells.

Complete information for apalutamide (JNJ-56021927) can be found in the Investigator’s Brochure, the safety reference document for this study.
1.1.1 Molecular Formula and Chemical Class

Apalutamide drug substance is a white to off-white crystalline solid.

**Chemical Name:** (4-[7-(6-Cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide)

**Chemical Structure:**

![Chemical Structure](image)

**Molecular Formula:** $C_{21}H_{13}F_{4}N_{5}O_{2}S$

**Molecular Weight:** 477.44

1.1.2 Pre-Clinical Development Overview

The mechanism of action of apalutamide is through antagonism of androgen action and inhibition of AR nuclear translocation and DNA binding to androgen response elements, a mechanism that is distinct from the first generation anti-androgen, bicalutamide. Unlike bicalutamide, it shows no significant agonist properties in an in vitro model of CRPC (e.g., AR-over-expressing prostate cancer cells; LNCaP/AR cells). $^3$ Gene transcription of the androgen-driven genes, PSA and TMPRSS2, is inhibited by apalutamide and results in concentration-dependent reduction of these protein levels in vitro. Apalutamide was also shown to reduce proliferation of CRPC cells as well as increase apoptosis and necrosis in vivo. These effects are supported by the anti-tumor activity of apalutamide observed in murine tumor models of CRPC. In these models, apalutamide showed dose-dependent tumor growth inhibition and tumor regression that were superior to bicalutamide. $^3$ Figure 1 depicts the percent change in tumor volume and plasma concentrations (filled circles above waterfall plot) of bicalutamide and apalutamide on Day 28.
Apalutamide is a low clearance molecule with a moderate volume of distribution and high bioavailability (when dosed with a lipid-based formulation). Apalutamide was found to have a very low turnover when incubated for up to 120 minutes with rat, dog, and human liver S9 fraction and liver microsomes. The primary in vivo metabolites were formed by N-demethylation and amide hydrolysis in the rat and dog. In vitro, CYP3A4 may be partially involved in the metabolism of apalutamide.

Apalutamide and its primary metabolite ARN000308 (M3) are inducers of human CYP2B6 and CYP3A4 in hepatocytes at concentrations up to 30 µM. Apalutamide is a moderately potent inhibitor of human cytochrome P450 isoform CYP2C8 (IC_{50}=13.9 µM), but a weak inhibitor of the other major isoforms (IC_{50}>25 µM); M3 is also a weak inhibitor of CYP major isoforms (IC_{50}>25 µM).

Four metabolites have been identified with different proportions between species. All four were assessed for their on-target effects against the androgen receptor. Metabolite M1 was found to be essentially inactive as an AR antagonist, while metabolites M2 and M4 were approximately 30-fold less potent against AR than apalutamide. Metabolite M3 was the most potent AR antagonist, but was still 3-fold less potent than apalutamide. Metabolite M3 is considered the predominant metabolite, with a longer elimination half-life than apalutamide.

In vitro and in vivo studies to assess cardiovascular, CNS, and respiratory system effects of apalutamide did not reveal any concerns.

Single-dose and repeat-dose toxicology studies up to 13 weeks of dosing have been conducted in male Sprague Dawley (SD) rats and male Beagle dogs (repeat-dose studies only).
Acute administration of apalutamide at 1,000 mg/kg was well tolerated in SD rats, with no morbidity, mortality or significant effects on body weight or serum chemistry markers.

In repeat-dose toxicology studies, apalutamide was well tolerated at doses up to 100 mg/kg/day in the 13-weeks study in SD rats and 10 mg/kg/day in Beagle dogs. In male SD rats, lethality was observed at doses of 150 mg/kg/day and greater. The morbidity/mortality observed at these doses occurred within the first 5 days of dosing; however, animals that did survive at these higher doses, appeared to develop a tolerance for the test article with extended exposure. Clinical signs observed in the moribund animals were piloerection, hypothermia, breathing abnormalities, dehydration, and decreased activity. The cause of the morbidity/mortality in male rats could not be determined by pathologic examination. Key clinical pathology changes at doses of 150 mg/kg/day or greater included significant increases in cholesterol (greater than 200% from controls), decreases in erythrocytes, hemoglobin and hematocrit, and increases in reticulocytes, platelets, leukocytes, lymphocytes, basophils, and aPTT. The increase in cholesterol is attributed to the anti-androgen activity of apalutamide and is believed to be responsible for the stated hematologic changes. Examination of red blood cell morphology revealed changes that were consistent with excess cholesterol being transferred to the outer membrane of the erythrocytes, resulting in a mild hemolytic anemia. Pharmacologic effects were also observed in the male accessory sex organs (epididymides, prostate, seminal vesicles and to a lesser degree, the testes) at apalutamide doses as low as 50 mg/kg/day. Other target organs in the rat that were observed at apalutamide doses of 150 mg/kg/day or higher included adrenals (also at 50 mg/kg/day), liver, pituitary, thyroid, spleen, salivary glands, mammary gland, and stomach. With the exception of the salivary glands and stomach, the effects on those organs are also believed to be due to the anti-androgen effect of apalutamide and in many cases are specific to the physiology of the rat.

Once daily oral gavage dosing of apalutamide for 13 weeks was well tolerated in male rats up to 100 mg/kg/day, i.e. the highest dose tested. Pharmacologic changes characteristic of anti-androgen compounds were noted in the adrenal gland, pituitary gland, spleen, mammary gland, seminal vesicles, testes, prostate, and epididymides, while changes in the spleen and bone marrow correlated with a mild regenerative anemia. The 100 mg/kg/day dose level was considered to be the no observed adverse effect level (NOAEL) and was associated with steady-state (Day 91) plasma \( C_{\text{max}} \) and \( \text{AUC}_{0-24\text{h}} \) values of 30.1 µg/mL and 521 µg•h/mL, respectively, for the parent compound.

In male Beagle dogs, seizures necessitating humane euthanasia occurred at apalutamide doses of 25 mg/kg/day and greater, 7 to 14 days after dosing was initiated. Daily administration of 25 mg/kg/day of apalutamide resulted in tremors and seizures in 3 of 8 animals after 1 week of dosing. The average apalutamide concentration at the time of first observation of central nervous system (CNS) toxicity was determined to be 30.2 µg/mL, which was about 4-fold higher than the mean apalutamide steady-state \( C_{\text{max}} \) (7.55 µg/mL) at the Phase 3 dose of 240 mg/day measured during repeated dosing in subjects with CRPC. It is likely that the convulsive seizures observed in dogs at very high doses are the result of apalutamide’s functional antagonism of the GABA\(_A\) receptor. This is similar to what has been observed with other second generation AR antagonists. The 10 mg/kg/day dose was considered to be the NOAEL in the 28-day study, and was associated with an apalutamide
\(C_{\text{max}}\) of 13.2 µg/mL and an \(\text{AUC}_{0-24}\) of 290 µg•h/mL. Other clinical pathology and target organ changes were limited to increases in cholesterol (up to 50% compared to controls) and effects on the epididymides, prostate and testes at all doses tested and attributed to the anti-androgen effect of apalutamide.

Once daily oral capsule administration of apalutamide for 13 weeks was well tolerated in male dogs up to 10 mg/kg/day, i.e. the highest dose tested. Gross and microscopic pathology changes and organ weight changes characteristic of anti-androgen compounds were noted in the pituitary gland, prostate, testes, and epididymides; these changes were reversible and were attributable to the expected pharmacologic effect of apalutamide. Based upon the lower body weight performance in the group receiving 10 mg/kg/day, the 5 mg/kg/day dose was considered to be the NOAEL. Corresponding steady-state (Day 91) plasma \(C_{\text{max}}\) and \(\text{AUC}_{0-24h}\) values were 10.3 µg/mL and 202 µg•h/mL, respectively, for the parent compound.

Preclinical studies have demonstrated the absence of genotoxic, clastogenic, and phototoxic properties for apalutamide and its pharmacologically active metabolite ARN000308 (M3). ARN000066 (M4), an inactive metabolite of apalutamide, tested negative in an in vitro bacterial reverse mutation (Ames) assay, but was weakly positive in an in vitro chromosome aberration test in human peripheral blood lymphocytes. However, the totality of nonclinical data supports the lack of an in vivo genotoxic potential of ARN000066 (M4).

### 1.1.3 Overview of Clinical Studies

In addition to Study ARN-509-003, apalutamide is also being evaluated in Phase I studies in healthy men and Phase I/II, Phase II, and Phase III studies in patients with prostate cancer.

Study ARN-509-001 is an ongoing Phase I/II study in patients with progressive advanced CRPC. In the Phase I portion of the study, 30 patients with mCRPC received at least 1 dose of apalutamide at escalating dose levels: 3 patients each at 30, 60, 90, 120, 180, 240, 390, 480 mg/day, and 6 patients at 300 mg/day. \(^{19,20}\) Three subgroups are being evaluated in the Phase 2 portion (Group 1: NM-CRPC; Group 2: mCRPC without previous ketoconazole, abiraterone acetate, enzalutamide or chemotherapy [for mCRPC]; and Group 3: mCRPC post abiraterone acetate, no previous chemotherapy [for mCRPC]). All patients received apalutamide orally once daily, except those in the 300, 390, and 480 mg cohorts who received a twice-daily dosing regimen due to the higher pill burden at those levels. The results of the Phase 1 portion of the study from 30 patients with mCRPC demonstrated that treatment with apalutamide resulted in PSA declines at all dose levels tested. Eighteen subjects (60%) had a ≥50% or higher maximum decrease in PSA from baseline and 6 (20%) had ≥90% maximum decrease. Ten patients had measureable soft tissue disease at baseline; 5 (50%) subjects maintained stable disease response for more than 6 months, 1 (10%) subject experienced disease progression, and the remaining 4 subjects had indeterminate responses. Apalutamide was well tolerated, with only 1 dose-limiting toxicity (DLT) at the 300 mg dose level (Grade 3 treatment-related abdominal pain). The event lasted 6 days and resolved with dose interruption and subsequent dose reduction to 240 mg (120 mg twice daily). Three additional subjects were treated at the 300 mg dose level with no reported DLTs. No seizures were reported at any dose level. The maximum tolerated dose (MTD) was not determined. The PK profile is linear and dose-proportional.
Sixteen subjects participated in an evaluation of AR binding in vivo using 16β-[18F] fluor-α-dihydrotestosterone (FDHT) positron emission tomography (PET)/CT scan. Apalutamide treatment reduced FDHT uptake across all dose levels (30 to 390 mg dose levels). A plateau was reached at approximately 120 mg (with FDHT uptake near background) indicating saturation of AR binding. The mean plasma trough levels associated with this dose (2.5 µg/mL) were at the lower end of the range that produced tumor regression in the LNCaP/AR mouse model. Steady state plasma levels at the 240 mg dose level (3 to 6 µg/mL) were more in the range sufficient to elicit a tumor response in the mouse xenograft model. Therefore, the 240 mg daily regimen was chosen for Phase 2 and Phase 3 dosing.

Apalutamide was rapidly absorbed, with measurable plasma concentrations within 30 minutes after ingestion of a single oral dose of 1 to 16 soft gelatin capsules (total apalutamide dose, 30 to 480 mg). On average, peak plasma concentrations occurred 2 to 3 hours after administration in each dose group. The increases in plasma C_max values and in the area under the plasma concentration curve (AUC) were linear and dose proportional. Plasma apalutamide concentrations declined slowly, with a mean half-life value at steady-state of 4 days.

The percentage of patients with PSA reductions of ≥50% at 12 weeks were 91% for the Group 1, 88% for the Group 2, and 24% for Group 3. Similar data were observed after 24 weeks. The data available to date indicate that apalutamide shows durable PSA responses in NM-CRPC and early mCRPC (before treatment with abiraterone acetate or chemotherapy). Apalutamide also has activity in a subgroup of patients with mCRPC that have progressed on abiraterone acetate. For the NM-CRPC subgroup, the metastasis-free survival at 12 months was 87% and with a median follow-up of 15 months the time to PSA progression had not been reached.

In the NM-CRPC subgroup (n =51 ), the most frequent treatment-related adverse events reported in >10% as of 30 November 2013 are fatigue (43%), diarrhea (31%), nausea (20%), increased thyroid stimulating hormone (12%), dysgeusia (12%), and hot flush 12%. Eight (16%) patients have discontinued the study due to adverse events. Seven (14%) patients have discontinued due to disease progression. No deaths were reported in this subgroup as of the safety cutoff.

Refer to the Investigator’s Brochure for most up to date information.
2. STUDY OBJECTIVES

2.1 PRIMARY OBJECTIVE

- To demonstrate superiority in the metastasis-free survival (MFS) of men with high risk NM-CRPC treated with apalutamide versus placebo

2.2 SECONDARY OBJECTIVES

- To compare the overall survival (OS) of men with high risk NM-CRPC treated with apalutamide versus placebo
- To compare the time to symptomatic progression in men with high risk NM-CRPC treated with apalutamide versus placebo
- To compare the time to initiation of cytotoxic chemotherapy in men with high risk NM-CRPC treated with apalutamide versus placebo
- To compare the progression-free survival (PFS) of men with high risk NM-CRPC treated with apalutamide versus placebo
- To compare the time to metastasis (TTM) in men with high risk NM-CRPC treated with apalutamide versus placebo
- To evaluate the safety and tolerability of apalutamide

2.3 OTHER OBJECTIVES

- To compare patient reported outcomes (PROs) of health-related quality of life and prostate cancer-specific symptoms in men with high risk NM-CRPC treated with apalutamide versus placebo
- To evaluate the population pharmacokinetics (PK) of apalutamide
- To evaluate the effect of apalutamide on ventricular repolarization in a subset of patients from selected clinical sites
- To evaluate exploratory biomarkers predictive of response and resistance to apalutamide treatment

Aragon Pharmaceuticals, Inc - Confidential
3. STUDY DESIGN

3.1 STUDY OVERVIEW AND RATIONALE

This is a randomized (2:1), multicenter, double-blind, placebo-controlled, Phase III clinical trial evaluating the efficacy and safety of apalutamide versus placebo in men with high risk (M0) NM-CRPC, defined as PSA Doubling Time (PSADT) ≤ 10 months.

Short PSADT has been consistently associated with reduced time to first (bone) metastasis and death, thus the selected patient population represents one at high risk for development of (distant) metastasis and prostate cancer-specific death.\(^\text{7,25,26}\)

No approved treatments are available for the proposed patient population besides continuous administration of ADT (with or without a first generation anti-androgen) as part of the current de facto community standard practice, therefore randomization to either apalutamide or placebo is justified in this setting.\(^\text{14,16}\) Based on the Phase II preliminary results from Study ARN-509-001, apalutamide is associated with a highly favorable safety profile, and the encouraging anti-tumor activity observed to date in the subgroup of patients with high risk NM-CRPC indicates that apalutamide might have the potential to be efficacious in this earlier line of therapy. The placebo arm will allow an objective comparison of safety and efficacy between treatment with apalutamide and placebo.

Additional PSA evaluations may be necessary to determine eligibility. In order to ensure investigators can obtain these additional evaluations, there is an optional Prescreening Phase with a separate informed consent (see Section 8.1).

The study will consist of a Screening Phase; a Treatment Phase, and a Posttreatment Follow-up Phase. A double-blind study design was chosen to preserve study integrity and minimize bias in the assessment of all study endpoints. A 2:1 randomization scheme will increase the probability that eligible patients will be randomized to receive apalutamide, thereby improving study feasibility.

Randomization will be stratified by PSADT, the use of a bone-sparing agent and the presence of loco-regional disease. These stratification factors were chosen on the basis that they may be sufficiently prognostic such that an imbalance may bias the results.

Apalutamide or matched placebo will be administered orally on a continuous daily dosing schedule at a starting dose of 240 mg per day, the recommended Phase II dose selected based on preclinical projections of the optimal biological dose combined with safety and the PK/pharmacodynamic profiles observed during Phase I. Apalutamide or matched placebo will be given with continuous GnRHa (if patient has not been surgically castrated).

Patients will be followed for safety and efficacy as per the schedule of activities and will remain on study treatment until documented radiographic progression (development of distant metastases as assessed by blinded independent central review [BICR]) or the development of unacceptable toxicity. Treatment decisions will not be based on PSA as the clinical significance of PSA changes during treatment in the setting of NM-CRPC is unknown; therefore, PSA will be collected and analyzed by a central laboratory but
Investigators, patients, and the Sponsor will be blinded to the results until the time of the primary analysis.

Patients discontinuing treatment due to documented radiographic progression will enter the Long-term Follow-up Phase (See Section 8.9 and Appendix 1). Patients discontinuing treatment prior to documented radiographic progression will also enter the Long-term Follow-up Phase where they will continue to have scheduled disease assessments every 16 weeks until documented radiographic progression.

### 3.1.1 Crossover Option in the Event of Unblinding

At the time of study unblinding and in the event of a positive study result, all subjects currently receiving placebo will have the opportunity to receive active therapy with apalutamide (refer to Appendix 10).

### 3.1.2 Selection of the Primary Endpoint

Men with high risk NM-CRPC, characterized by rapidly rising PSA in the absence of detectable metastases despite castrate levels of testosterone, are at significant risk for development of metastases and prostate cancer-specific death. As verified in a recently completed Phase III trial of denosumab, men with NM-CRPC who are at high risk for development of bone metastasis have a median overall survival of 44.8 months and a median bone-metastasis-free survival of 25.2 months (placebo arm). To date there are no approved treatments or standard of care for men with high risk NM-CRPC and thus this patient population represents an area of unmet medical need.

In consideration of the relatively long median OS (~49 months) in this population and the opportunity to assess for the development of distant metastasis as a clinically important milestone, metastasis-free survival (MFS) was chosen as the primary objective of this study. Metastasis from prostate cancer, especially bone metastases, is the source of prostate cancer specific morbidity and mortality. In addition, it triggers the need for a change in therapy that can be associated with an increase in morbidity (e.g., toxicity associated with chemotherapy), and in some cases leading to a change in quality of life for that patient.

Delaying the emergence of radiographically detectable distant metastasis, or prolongation of MFS as proposed, is a clinically relevant outcome that can be robustly and reliably assessed for determination of the true impact of a treatment on the NM-CRPC disease. In a high risk cohort of patients with biochemical recurrence after radical prostatectomy and a PSADT < 15 months, metastatic prostate cancer was reported to account for an estimated 90% of all deaths it is therefore conceivable that delaying the development of metastases would likely translate to delaying prostate cancer-specific death. The proposed MFS definition incorporates not only time to (bone or soft tissue) distant metastasis but also time to death and thus MFS can be a reasonable correlate to overall survival. Of note, based on retrospective landmark analyses at 3 and 5 years from the Radiation Therapy and Oncology Group 92-02 randomized trial in patients with locally advanced prostate cancer who had been treated with ADT and external beam radiation therapy, distant metastasis has been shown to be consistent with all four of Prentice’s criteria for being a potential surrogate endpoint for prostate cancer-specific survival at 10 years.
3.2 STUDY OUTCOMES

3.2.1 Primary Endpoint

- Metastasis-Free Survival (MFS)

3.2.2 Secondary Endpoints

- OS
- Time to symptomatic progression
- Time to initiation of cytotoxic chemotherapy
- PFS
- TTM

3.2.3 Other Evaluations

- Health-related quality of life and prostate cancer-specific symptoms
- Type, incidence, severity, timing, seriousness, and relatedness of adverse events and laboratory abnormalities
- PSA response
- Time to PSA progression
- Population PK
- Exploratory biomarkers
- Assessment of ventricular repolarization
- Second progression-free survival (PFS2)
- Medical Resource Utilization (MRU)

4. PATIENT SELECTION

This study can only fulfill its objectives if appropriate patients are enrolled. The following eligibility criteria are designed to select patients for whom protocol treatment is considered appropriate. All relevant medical and non-medical conditions should be taken into consideration when deciding whether this protocol is suitable for a particular patient. It is expected that all patients will be treated according to local standard of care, including radiation therapy if needed for local disease, prior to enrolling.

No waivers will be granted for eligibility criteria deviations.

Patients considered screen failures may be subsequently rescreened. Rescreening must be discussed with and approved by the Sponsor on a case-by-case basis. Patients who are determined to be eligible for the study after rescreening must sign a new informed consent form (ICF) and be assigned a new patient number.
Treatment criteria for placebo subjects who crossover to active treatment with apalutamide (in the event of a positive study result and unblinding) are described in Appendix 10.

4.1 INCLUSION CRITERIA

1. Criterion modified per Amendment INT-3
   1.1 Criterion modified per Amendment INT-5
   1.2 Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features, with high risk for development of metastases, defined as PSADT ≤ 10 months. PSADT is calculated using at least 3 PSA values obtained during continuous ADT (see Section 5.1).

2. Criterion modified per Amendment INT-5
   2.1 Castration-resistant prostate cancer demonstrated during continuous ADT, defined as 3 PSA rises at least 1 week apart, with the last PSA >2 ng/mL

3. Criterion modified per Amendment INT-3
   3.1 Criterion modified per Amendment INT-6
   3.2 Surgically or medically castrated, with testosterone levels of <50 ng/dL. If the patient is medically castrated, continuous dosing with GnRHa must have been initiated at least 4 weeks prior to randomization and must be continued throughout the study to maintain castrate levels of testosterone.

4. Criterion modified per Amendment INT-3
   4.1 Patients receiving bone loss prevention treatment with bone-sparing agents indicated for the treatment of osteoporosis at doses and dosing schedule appropriate for the treatment of osteoporosis (e.g., denosumab [Prolia®], zoledronic acid [Reclast®]) must be on stable doses for at least 4 weeks prior to randomization.

5. Criterion modified per Amendment INT-3
   5.1 Criterion modified per Amendment INT-5
   5.2 Patients who received a first generation anti-androgen (e.g., bicalutamide, flutamide, nilutamide) must have at least a 4-week washout prior to randomization AND must show continuing disease (PSA) progression (an increase in PSA) after washout.

6. Criterion modified per Amendment INT-3
   6.1 Criterion modified per Amendment INT-5
   6.2 At least 4 weeks must have elapsed from the use of 5-α reductase inhibitors (e.g., dutasteride, finasteride), estrogens (irrespective of dose used), and any other anti-cancer
therapy prior to randomization, including chemotherapy given in the adjuvant/neoadjuvant setting (e.g., clinical trial)

7. At least 4 weeks must have elapsed from major surgery or radiation therapy prior to randomization

8. Age ≥ 18 years

9. Eastern Cooperative Oncology Group (ECOG) Performance Status grade 0 or 1

10. Resolution of all acute toxic effects of prior therapy or surgical procedure to Grade 1 or baseline prior to randomization

11. Criterion modified per Amendment INT-3

   11.1 Criterion modified per Amendment INT-6

   11.2 Adequate organ function as defined by the following criteria:

   ▪ Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x upper limit of normal (ULN)

   ▪ Total serum bilirubin ≤1.5 x ULN. Total serum bilirubin >1.5 x ULN is allowed if Gilbert’s disease is documented prior to end of screening procedures.

   ▪ Serum creatinine ≤ 2 x ULN

   ▪ Absolute neutrophil count (ANC) ≥ 1500/μL

   ▪ Platelets ≥ 100,000/μL

   ▪ Hemoglobin ≥ 9.0 g/dL

     o Administration of growth factors or blood transfusions will not be allowed within 4 weeks of the hematology labs required to confirm eligibility

12. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to randomization

13. Criterion modified per Amendment INT-6

   13.1 Criterion modified per Amendment 7

   13.2 Willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures, including ability to swallow study drug tablets, the completion of patient reported outcomes questionnaires and long-term follow-up
4.2 EXCLUSION CRITERIA

1. Criterion modified per Amendment INT-3
   1.1 Presence of distant metastases confirmed by blinded independent central review (BICR), including CNS and vertebral or meningeal involvement, or history of distant metastases. Exception: Pelvic lymph nodes <2 cm in short axis (N1) located below the iliac bifurcation are allowed

2. Symptomatic loco-regional disease requiring medical intervention, such as moderate or severe urinary obstruction or hydronephrosis, due to primary tumor (e.g., tumor obstruction of bladder trigone)

3. Prior treatment with second generation anti-androgens (e.g., enzalutamide)

4. Criterion modified per Amendment INT-5
   4.1 Prior treatment with CYP17 inhibitors (e.g., abiraterone acetate, orteronel, gableterone, ketoconazole, aminoglutethimide)

5. Prior treatment with radiopharmaceutical agents (e.g., Strontium-89), immunotherapy (e.g., sipuleucel-T), or any other investigational agent for NM-CRPC

6. Prior chemotherapy for prostate cancer, except if administered in the adjuvant/neoadjuvant setting

7. History of seizure or condition that may pre-dispose to seizure (e.g., prior stroke within 1 year prior to randomization, brain arteriovenous malformation, Schwannoma, menigioma, or other benign CNS or meningeal disease which may require treatment with surgery or radiation therapy)

8. Criterion modified per Amendment INT-3
   8.1 Criterion modified per Amendment INT-6
   8.2 Concurrent therapy with any of the following (all must have been discontinued or substituted for at least 4 weeks prior to randomization):
      - Medications known to lower the seizure threshold (for a complete list please see Appendix 5)
      - Herbal (e.g., saw palmetto) and non-herbal (e.g., pomegranate) products that may decrease PSA levels
      - Systemic (oral/IV/IM) corticosteroids. Short term use (≤ 4 weeks) of corticosteroids during the study is allowed if clinically indicated, but it should be tapered off as soon as possible
      - Any other experimental treatment on another clinical trial

Aragon Pharmaceuticals, Inc - Confidential
Agents indicated for the prevention of skeletal-related events in patients with solid tumors (e.g., denosumab [Xgeva®])

9. Criterion modified per Amendment INT-3

9.1 Criterion modified per Amendment INT-6

9.2 History or evidence of any of the following conditions:

- Any prior malignancy (other than adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other cancer in situ currently in complete remission) within 5 years prior to randomization

- Any of the following within 6 months prior to randomization: Severe/unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias

- Uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic BP ≥100 mmHg). Patients with a history of uncontrolled hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment.

- Gastrointestinal disorder affecting absorption

- Active infection, such as human immunodeficiency virus (HIV)

- Any other condition that, in the opinion of the Investigator, would impair the patient’s ability to comply with study procedures.
5. STUDY TREATMENTS

5.1 RANDOMIZATION CRITERIA

After patients have provided their written informed consent, completed all Screening assessments and received confirmation of eligibility, they will be randomized into the study using an Interactive Voice Randomization System (IVRS) and stratified based on:

- PSADT: > 6 months vs. ≤6 months
- Bone-sparing agent use: Yes vs. No
- Loco-regional disease: N0 vs. N1

In order to ensure accurate and consistent determination of PSADT across all sites, the IVRS will also provide PSADT calculations (using a linear regression model of the normal logarithm of PSA and time) based on at least 3 PSA values obtained during continuous ADT. All available consecutive PSA values obtained within 24 months prior to randomization beginning with the earliest value chosen for the PSADT calculation must be entered in the IVRS. The first and last PSA values used in the calculation must be separated by at least 8 weeks.

Those same PSA values should be used during Screening to determine whether the patient is eligible for the study (inclusion criterion #1.2). In order to pre-screen patients for possible enrollment into the study, PSADT can be calculated using the Memorial Sloan-Kettering Cancer Center (MSKCC) PSA Doubling Time prediction tool, available at the following website:

http://nomograms.mskcc.org/Prostate/PsaDoublingTime.aspx

5.2 BLINDING

Due to the objectives of the study, the identity of test and control treatments will not be known to investigators, research staff, or patients.

Only selected individuals not affiliated with the protocol will be unblinded to individual patient treatment assignment during the trial for the purposes of efficacy analyses and safety review. The randomization codes and all data sets will be stored in a secure area accessible only to these individuals, and only released on completion of the study and after the study database has been locked.

In emergency situations for reasons of patient safety (e.g., a serious unexpected/unlisted drug-related event; a medical emergency; a potentially life-threatening drug interaction), the blinding code may need to be broken. In those cases, whenever possible, a request for unblinding should be discussed with the Sponsor (or designee) prior to unblinding. Detailed instructions on the method for breaking the blind will be provided during site training and in the Investigator Site File.
5.3 FORMULATION

5.3.1 Apalutamide/Matched Placebo

The apalutamide tablet supplied for this study contains 60 mg of JNJ-56021927. It will be manufactured and provided under the responsibility of the Sponsor. Refer to the Investigator's Brochure for a list of excipients. Placebo will be provided as a tablet formulation and will be matched in size, color, and shape to active study drug in order to maintain the study blind.

5.3.2 Packaging, Storage, and Labeling

The apalutamide 60-mg tablets will packaged in 120-count, 160 cc high-density polyethylene (HDPE) bottles with . Bottles will include desiccant.

The study drug will be periodically tested and monitored for its acceptable shelf life for at least the duration of the study. Any study drug that fails to comply with the manufactured specifications will be promptly removed from the clinical study site and replaced with new supplies by the Sponsor (or designee).

Each bottle of study drug will be labeled with the required regulatory agency warning statement, the protocol number, the Sponsor’s name, and directions for patient use and storage. The Investigator will ensure that the study drug is stored in appropriate conditions in a secure location with controlled access. For clinical formulation-specific and batch-specific storage instructions, see the packaging label.

5.3.3 Drug Administration

Apalutamide/matched placebo tablets will be administered orally on a continuous daily dosing regimen at a dose of 240 mg per day (4 x 60-mg tablets) with or without food.

5.3.4 Cycle Management

For the purposes of the study, a treatment cycle will consist of 4 weeks (28 days).

It is anticipated that individual patients may occasionally forget to take a dose. In those cases, missed doses should only be replaced if the patient remembers within a 12-hour window. After that, patients should just take the next dose the following day, without compensating for the missed dose (including vomited doses). In the event of dose delays due to transient toxicity, tumor assessments should remain on schedule independent of cycle length.

5.3.5 Dose Modifications

Intrapatient dose interruptions and/or reductions will be permitted provided that study discontinuation criteria have not been met (please see Section 10).

- Patients experiencing treatment-related seizure of any grade will have study drug permanently discontinued.

Aragon Pharmaceuticals, Inc - Confidential
For patients experiencing Grades 1-2 treatment-related adverse events, short treatment breaks can be instituted as per the discretion of the Investigator until the severity of the toxicity decreases to Grade 1 or returns to baseline. If toxicity recurs, dose reductions to the next lower dose level will be allowed as per the discretion of the Investigator.

For patients experiencing Grade ≥ 3 treatment-related adverse events other than seizure, study drug should be held until the severity of the toxicity decreases to Grade 1 or returns to baseline. If toxicity recurs at Grade 3 or higher, the dose of apalutamid should be reduced to the next lower dose level. A maximum of 2 dose level reductions will be allowed (Table 1).

Any patient requiring > 28 days delay in treatment due to AEs may meet one of the criteria for study treatment discontinuation (see Section 10), which must be discussed with Sponsor.

<table>
<thead>
<tr>
<th>Dose Level</th>
<th>Total Daily Dose</th>
<th>Number of 60-mg Tablets (QD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>240 mg</td>
<td>4</td>
</tr>
<tr>
<td>-1</td>
<td>180 mg</td>
<td>3</td>
</tr>
<tr>
<td>-2</td>
<td>120 mg</td>
<td>2</td>
</tr>
</tbody>
</table>

Doses reduced for study treatment-related toxicities should generally not be re-escalated, however, re-escalation back to the previous dose level may be permitted in consultation with the Sponsor (or designee).

5.4 STUDY DRUG ACCOUNTABILITY

The Sponsor (or designee) will ship study drug to the investigational sites. The initial study drug shipment will be shipped after all required regulatory documentation has been received by the Sponsor and a Clinical Trial Agreement fully executed. Subsequent study drug shipments will be made according to an automated resupply algorithm managed by the IVRS.

The study drug will only be dispensed to patients who meet the eligibility criteria and are randomized to a treatment arm in the trial. An accurate and current accounting of the dispensing and return of study drug for each patient will be maintained on an ongoing basis by the Investigator or his/her designated personnel. The number of study drug dispensed and returned by the patient will be recorded on the Investigational Product Accountability Log. The study monitor will verify these documents throughout the course of the study.

At the end of the study, the Sponsor will provide instructions as to the disposition of any unused study drug. If destruction at the site is authorized, the Investigator must ensure that all investigational product is destroyed in compliance with the applicable environmental regulations, institutional policy, and any other special instructions provided by the Sponsor. Drug destruction must be adequately documented.

Aragon Pharmaceuticals, Inc - Confidential
5.5 MEASURES OF TREATMENT COMPLIANCE

At each clinic visit, patients will be asked to return any remaining study drug from the previous dosing cycle as well as all used and unused study drug containers.

The overall treatment compliance will be defined as the total dose in mg taken during the study divided by the expected total dose in mg. Patients completing their last cycle on capsules should continue with a maximum of 8 capsules per day and patients on tablets should have a maximum of 4 tablets per day.

Capsules or tablets that are not returned will be considered to have been taken, unless otherwise specified in the case report form (CRF).

6. CONCURRENT MEDICATIONS

All patients should be maintained on the same medications throughout the entire study period, as medically feasible, with minimum introduction of new chronic therapies. Every medication or treatment taken by the patient during the trial and the reason for its administration must be recorded on the CRF. Standard medical treatment as applicable is allowed except for treatments noted in the eligibility criteria and/or listed in the prohibited medications section below.

Continuous treatment with a GnRHa or surgical castration is mandatory for all patients in order to maintain castrate concentrations of testosterone (<50 ng/dL). The choice of GnRHa is at the discretion of the investigator. Dose and dose schedule (without interruption) will be consistent with the prescribing information and should only be adjusted if clinically indicated to maintain castrate concentrations of testosterone.

Salvage radiation for loco-regional pelvic disease and surgical procedures (eg, transurethral resection of the prostate [TURP], urethral and ureteral stent placement) to treat localized progression or symptoms are allowed. Patients receiving these therapies may continue on study drug.

6.1 PROHIBITED MEDICATIONS AND TREATMENTS

As a class effect, androgen receptor antagonists have been associated with seizures due to an off-target mechanism of action (GABA\(A\) inhibition).\(^6,16\) In preclinical studies, at very high doses, dogs treated with apalutamide had tremors and generalized seizures. Patients will be closely monitored for seizures, but as a precautionary measure, drugs known to decrease the seizure threshold and/or cause seizure will be prohibited while on study. A list of these medications can be found in Appendix 5.

6.2 RESTRICTED THERAPIES

Investigators should refer to the apalutamide Investigator’s Brochure (Sections 4.3.3.3 and 5.10) and associated addenda for complete details on the drug interaction potential of apalutamide. Highlights of drug interaction are summarized below.
- Strong CYP3A4 inducers: the potential for drug-drug interactions with apalutamide has not been tested clinically. Strong inducers of CYP3A4 (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, efavirenz, tipranavir, St. John's wort) should be avoided as much as possible. Additional information is provided in Appendix 5.
- Apalutamide may also induce CYP3A4; therefore, caution should be taken when administered in conjunction with CYP3A4 substrates that have a narrow therapeutic index
- Strong CYP2C8 inhibitors (e.g., gemfibrozil) should be used with caution with apalutamide

- The potential for drug-drug interaction between apalutamide and warfarin (e.g., Coumadin) is unknown at present. If a patient is taking warfarin, re-assess (prothrombin) PT/(international normalized ratio) INR as clinically indicated and adjust the dose of warfarin accordingly.
- Corticosteroids (Oral, IV, or IM): due to possible resistance mechanisms, which may be contributed by glucocorticoid receptor signaling, concurrent use of corticosteroids during the study is not recommended; short term use (≤ 4 weeks) will be allowed if clinically indicated, however, its use must be tapered off as soon as possible.

6.3 LIFE STYLE GUIDELINES

To avoid risk of drug exposure through the ejaculate (even men with vasectomies), patients must use a condom during sexual activity while on study drug and for 3 months following the last dose of study drug. Donation of sperm is not allowed during the study and for 3 months following the last dose of study drug.

There are no data on the use of apalutamide in pregnancy. Maternal use of an anti-androgen is expected to produce changes in hormone levels that may affect fetal development. It is not known if apalutamide or its metabolites are present in semen.

If the patient is engaged in sexual activity with a woman of childbearing potential, a condom is required along with another effective contraceptive method consistent with local regulations regarding the use of birth control methods for patients participating in clinical studies and their partners. Highly effective forms of contraception include:

- established use of oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device (IUD) or intrauterine (IUS) system;
- barrier methods: condom with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
- vasectomy;

Aragon Pharmaceuticals, Inc - Confidential
- true abstinence (an option when this is in line with the preferred and usual lifestyle of the patient).

Two highly effective forms of contraception are required during the study and for 3 months after the last dose of study drug.
7. STUDY PROCEDURES AND GUIDELINES

A Schedule of Activities representing the required testing procedures to be performed during the study is diagrammed in Appendix 1.

Prior to conducting any study-related activities, written informed consent and any other authorizations must be signed and dated by the patient or patient’s legal representative.

Every effort should be made to ensure that the protocol required tests and procedures are completed as described. However, it is anticipated that from time to time there may be circumstances outside of the control of the Investigator that may make it unfeasible to perform the test. In those cases, the Investigator should take all steps necessary to ensure the safety and wellbeing of the patient. When a protocol required test cannot be performed, the Investigator will document the reason for this and any corrective and preventive actions which he/she has taken to ensure that normal processes are adhered to as soon as possible. The study team should be informed of these incidents in a timely fashion.

7.1 CLINICAL ASSESSMENTS

7.1.1 Demographics

Demographic information (e.g., date of birth, gender, race) will be recorded at Screening, as allowed per local country privacy law regulations.

7.1.2 Medical History

Relevant medical history, including history of current disease, other pertinent clinical conditions, and information regarding underlying diseases will be recorded at Screening.

7.1.3 Physical Examination

A complete physical examination will be performed by either the Investigator or a sub-Investigator at Screening. Qualified staff (e.g., nurses or physician assistants) may complete either a full or abbreviated physical exam at all other visits. New abnormal physical exam findings must be documented and followed by a physician or other qualified staff at the next scheduled visit.

The complete physical examination should include, but not limited to, general appearance, skin, neck, eyes, ears, nose, throat, breast, lungs, heart, abdomen, back, lymph nodes, extremities, and nervous system, as well as examination of known and suspected sites of disease. Height will be recorded at Screening only. Body weight will be recorded at Screening and every scheduled visit during treatment and at the end of treatment.

7.1.4 Vital Signs

Body temperature, blood pressure, pulse and respiratory rate will be performed after resting for 5 minutes at Screening and every scheduled visit during treatment and at the end of treatment.
7.1.5 Performance Status
The Eastern Cooperative Oncology Group (ECOG) performance status scale will be used (Appendix 3) and will be assessed at Screening and every subsequent clinic visit.

7.1.6 Adverse Events
Assessment of adverse events will include type, incidence, severity (graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], Version 4.0), timing, seriousness, and relatedness (Appendix 4). Adverse events will be assessed at every clinic visit.

7.1.7 Concomitant Medications/Therapies
All concomitant medication and concurrent therapies will be documented from the first dose of study drug until 28 days after the last dose of study drug. Name, indication for administration, and dates of medication or therapy will be captured.

7.1.8 Tumor Assessments
Disease assessments are to be performed as scheduled according to the calendar, regardless of treatment delays resulting from toxicity. Care must be taken in scheduling disease assessments to prevent the introduction of bias based on treatment delays.

Disease assessments will be performed at baseline (Screening), at 16-week intervals from Cycle 1 Day 1, whenever disease progression is suspected, and at the end of treatment. Imaging studies will include a CT scan of the chest, abdomen, and pelvis, plus a bone scan. At Screening, there will be an additional CT of the brain to rule out the presence of CNS metastases.

Radiographic confirmation of disease progression (appearance of distant metastasis) will be based on RECIST 1.1 and assessed by blinded independent central review (see below). For new bone lesions detected on bone scans, a second imaging modality (e.g., CT or MRI) will be required to confirm progression.

The same method of assessment and the same technique should be used at Screening and during follow-up. Intravenous (IV) contrast is required when not medically contraindicated. Patients who have a contraindication to IV contrast may have MRI exams of the brain, abdomen and pelvis performed in lieu of CTs and a non-contrast CT of the chest. Tumor evaluation by positron emission tomography (PET) scan or by ultrasound may not substitute for CT or MRI scans, but the CT portion of a PET/CT may be submitted in lieu of a dedicated CT. Additional requirements are provided in the Imaging Site Manual.

7.1.8.1 Blinded Independent Central Review (BICR)
All scans will be submitted to a third-party core imaging laboratory for independent review of patient eligibility (within 3 days of receipt of imaging scans that pass quality assessment) and disease progression during the study according to an Independent Review Charter to be prepared by the core imaging laboratory in consultation with the Sponsor.
It is important to the integrity of the study that all imaging studies and pertinent clinical information (e.g., bone trauma, fracture, or infection) are forwarded to the core imaging laboratory throughout the study.

Further details regarding materials to be forwarded for central review can be found in the Imaging Manual and/or Investigator Site File.

7.2 CLINICAL LABORATORY MEASUREMENTS

Blood will be obtained at the time points described in the Schedule of Activities and sent to a central lab for hematology and blood chemistry profile. Appendix 2 lists all of the specific tests that will be performed. Complete details with regards to sample collection and shipment processes can be found in the Laboratory Manual and/or Investigator Site File.

Investigators may have additional blood tests performed for the purpose of planning treatment administration, dose modification, or following adverse events.

7.2.1 PSA

Optional prescreening PSA evaluations will be performed by local laboratories.

All other PSA evaluations will be performed at the central laboratory. Results during treatment (until the time of the primary analysis) will be kept blinded to the patients, the Investigators, and the Sponsor, in order to preserve the double-blind nature of this study.

7.2.2 Electrocardiogram (ECG)

A standard 12-lead ECG (with a 10-second rhythm strip) will be collected at Screening and as clinically indicated. ECGs should be collected after the patient has rested quietly and is awake in a fully supine (or semi-recumbent, if supine is not tolerated) position for 10 minutes, and prior to any blood draw collection. Subsequent ECG readings should be collected with the patient in the same position (e.g., fully supine or semi-recumbent). For patients participating in the ventricular repolarization substudy see Appendix 8 for specific instructions.

7.3 PHARMACOKINETIC MEASUREMENTS

Blood for determination of plasma concentrations of apalutamide and its metabolite, ARN000308, will be collected as described in the Laboratory Manual on Day 1 of Cycles 1, 2, 3, 6, 11, 17, and 25. All samples will be assayed using an analytical method validated for apalutamide and metabolite.

On Cycle 1 Day 1, the blood sample must be collected between 0.5 and 4 hours post the first dose of study drug. For all other PK blood collections, the blood sample must be collected prior to study drug administration. No sparse PK samples will be collected from patients participating in the ventricular repolarization study. All reasonable measures must be taken to ensure accurate recording of information on dosing, including the time of the doses of study drug administered on the 2 days preceding the PK sampling day and whether the doses were taken based on a once daily or twice daily schedule (see also Section 8).
7.4 PATIENT-REPORTED OUTCOMES

At each scheduled visit and during Long-term Follow-up (see Appendix 1), patients will be required to complete two self-administered quality of life instruments: the Functional Assessment of Cancer Therapy-Prostate (FACT-P) and the Euro-QoL Group EQ-5D.\textsuperscript{3,30}

The FACT-P will be used to assess health-related quality of life and prostate cancer-specific symptoms. The FACT-P consists of the 27-item FACT-General (FACT-G) and 12 items for the prostate cancer specific concerns. The 27 items in FACT-G are grouped into 4 domains: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB) and functional well-being (FWB). The 12 prostate cancer symptoms items focus on pain (3 items), urination problems (3 items), and sexual functions (2 items). In addition, it also contains items for weight loss, appetite, overall comfort, and bowel movement. The FACT-P can be completed in 15 minutes.

The EQ-5D is a validated and reliable self-administered instrument used to assess health status. It contains 6 items designed to assess health status in terms of a single index value or health utility score. The EQ-5D can be completed in less than 5 minutes.

7.5 EXPLORATORY BIOMARKERS

Results from a Phase 1 study in patients with metastatic CPRC provide evidence that acquired genetic anomalies in the AR may be associated with resistance to apahutamide treatment.\textsuperscript{10} In this study, 3 of the 29 patients who developed the F876L mutation were considered non-responders. Preclinical data show that changes in expression or development of mutations in genes in the AR-axis may lead to resistance to drug treatment.\textsuperscript{12,13} Therefore, blood samples will be collected at various treatment time points from approximately 400 patients to determine the number of patients who develop this mutation and who have resistance to drug treatment. Additional tests will be performed to detect gene expression changes and appearance of other mutations from a panel of preselected RNA and DNA biomarker candidates. Archival formalin-fixed paraffin-embedded (FFPE) tumor blocks or tumor slides will be collected from at least 400 patients in this study to investigate whether genomic classifiers can be used to identify a more homogeneous population of high-risk patients.
8. STUDY ASSESSMENTS BY VISIT (APPENDIX 1)

8.1 PRESCREENING
- For this optional Prescreening Phase, review the study with the patient (or patient’s legal representative) and obtain written informed consent. The optional prescreening PSA evaluations will be performed by the local laboratories. This Prescreening Phase will allow additional time to obtain the required number of PSA values for determining eligibility. The patient must then sign another informed consent before any additional study-related procedures are conducted (see Section 8.2).

8.2 SCREENING (WITHIN 35 DAYS OF RANDOMIZATION)
- Review the study with the patient (patient’s legal representative) and obtain written informed consent
- Calculate PSADT using IVRS to confirm patient eligibility
- Obtain CT of the brain, chest, abdomen, and pelvis, plus bone scan and submit for BICR to confirm patient eligibility (scans obtained prior to signing informed consent will be allowed provided the timing of the scans fall within the Screening window)
- Record demographics data
- Record medical history, including history of prostate cancer, diagnosis date, and prior treatments
- Record concomitant medications
- Perform a complete physical examination (adverse events must be recorded from the time of signed informed consent)
- Perform and record vital signs and ECOG performance status grade
- Perform and record standard 12-lead ECG
- Collect blood for clinical laboratory assessments
- Submit patient eligibility form to medical monitor
- If patient is confirmed eligible by the medical monitor, randomize patient and proceed to Cycle 1 Day 1 visit (can be same day or within 4 days of randomization)

8.3 CYCLE 1 DAY 1
- Administer FACT-P and EQ-5D questionnaires
- Record changes to concomitant medications
- If available, retrieve archival FFPE tumor blocks or tumor slides from consenting patients for exploratory biomarker analysis
- Record any adverse events
- Perform abbreviated physical examination
- Perform and record vital signs and ECOG performance status
- Collect blood for hematology, blood chemistry, TSH, fasting lipid profile, testosterone, and PSA (Screening evaluations can be used if done within 4 days of Cycle 1 Day 1)
- Collect blood for exploratory biomarker analysis from consenting patients prior to study drug administration
- **Administer study drug in clinic**
  - Collect blood for PK sample between 0.5 and 4 hours post-dose and record actual time of collection relative to dosing (not required for patients participating in the ventricular repolarization substudy; see Appendix 8).

### 8.4 DAY 1 OF CYCLES 1-6, THEN DAY 1 OF EVERY 2 CYCLES STARTING FROM CYCLE 7 UP TO C13 THEN DAY 1 OF EVERY 4 CYCLES (±2 DAYS)

- Administer FACT-P and EQ-5D questionnaires
- Record any adverse events
- Record changes to concomitant medications
- Assess study drug compliance
- Perform abbreviated physical examination
- Perform and record vital signs and ECOG performance status
- Collect blood for hematology, blood chemistry, and PSA
- For Cycles 2, 3, 6, 11, 17, and 25 collect blood for PK sample **prior to study drug administration** (record time of administration of study drug on the 2 days preceding the day of the PK sampling and the dosing regimen [once daily or twice daily]). Not required for subjects participating in the ventricular repolarization study (see Appendix 8).
- Collect blood for exploratory biomarker analysis from consenting patients (Cycles 11, 17, 25, and 37) prior to study drug administration

### 8.5 EVERY 16 WEEKS STARTING FROM CYCLE 1 DAY 1 (±2 DAYS)

- Collect blood for TSH, fasting lipid panel, and testosterone
- If TSH is abnormal; total T3, free T4 (direct), and total T4 are required

### 8.6 EVERY 16 WEEKS STARTING FROM CYCLE 1 DAY 1 (±7 DAYS)

- Obtain CT of the chest, abdomen, and pelvis, plus bone scan and submit for BICR to evaluate for disease progression (ie, distant metastasis)

### 8.7 END-OF-TREATMENT VISIT

- Administer FACT-P and EQ-5D questionnaires (**optional if performed within 2 weeks of the last dose of study drug**)
- Assess study drug compliance
- Obtain CT of the chest, abdomen, and pelvis, plus bone scan and submit for BICR to evaluate for disease progression (optional if performed with 8 weeks of the last dose of study drug)
- Record any adverse events
- Record changes to concomitant medications

The following are optional if the End-of-Treatment Visit is performed within 1 week of the last dose of study drug:
- Perform abbreviated physical examination
- Perform and record vital signs and ECOG performance status
- Collect blood for clinical laboratory assessments
- Collect blood for exploratory biomarker analysis from consenting patients

8.8 SAFETY FOLLOW-UP (28 DAYS FOLLOWING THE LAST DOSE OF STUDY DRUG)
- Record any adverse events
- Record changes to concomitant medications

8.9 LONG-TERM FOLLOW-UP
- Obtain survival status, recording of development of symptomatic progression, initiation of any new systemic anti-cancer therapies, progression on first subsequent therapy (PFS2), and MRU every 4 months via clinic visit, telephone contact, or an alternative contact method per institution policy/practice. The FACT-P and EQ-5D questionnaires will be collected up to 12 months post-progression.
- In addition, if patients discontinue study treatment prior to documented disease progression (ie, distant metastasis, see Section 7.1.8), obtain CT of the chest, abdomen, and pelvis, plus bone scan and submit for BICR to evaluate for disease progression (every 16 weeks, until documentation of disease progression)

8.10 SUBSEQUENT THERAPY WITH ABIRATERONE ACETATE
Due to local restrictions in Japan, the Sponsor will not provide abiraterone acetate and the criteria outlined in this section do not apply.

The Sponsor will provide abiraterone acetate to all other patients who meet the following criteria:
- Patient signs informed consent to receive treatment with abiraterone acetate
- Documented disease progression (ie, meet criteria for the primary endpoint [distant metastasis], see Section 13.2.1). If the study is unblinded, the requirement for meeting disease progression by BICR in Section 13.2.2 will not be required.
the patient resides in a country in which abiraterone acetate and prednisone (or prednisolone) are indicated for the treatment of metastatic CRPC before chemotherapy

- the investigator caring for the patient decides that abiraterone acetate is the appropriate first subsequent treatment after discontinuation of study drug; and

- no other subsequent treatment has been prescribed after the progression event and before abiraterone acetate is prescribed.

Abiraterone acetate should be used according to the product label-prescribing information in the country of residence.

Prednisone (or prednisolone) should be used according to the product label-prescribing information in the country of residence. Prednisone (or prednisolone) will not be provided by the Sponsor, but should be prescribed as part of the regimen.

In countries where abiraterone acetate in combination with prednisone (or prednisolone) is not approved for the treatment of asymptomatic or mildly symptomatic mCRPC before chemotherapy, patients should be treated according to the local standard of care. Provision of abiraterone acetate will continue until the patient or investigator decides not to continue further treatment for any reason, unacceptable toxicity or the study is terminated by the Sponsor.

Serious adverse events will be collected during subsequent therapy with abiraterone acetate.
9. ADVERSE EVENT REPORTING REQUIREMENTS

9.1 DEFINITIONS

9.1.1 Adverse Events (AE)

An AE is any untoward medical occurrence in a clinical study patient administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. (Definition per International Conference on Harmonisation [ICH])

This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition, or abnormal results of diagnostic procedures, including laboratory test abnormalities.

Note: The Sponsor collects AEs starting with the signing of the ICF (refer to Section 9.2, for time of last AE recording).

Examples of AEs include but are not limited to:

- Abnormal test findings
- Clinically significant signs and symptoms
- Changes in physical examination findings
- Worsening of signs and symptoms of the malignancy under study. Disease progression assessed by measurement of malignant lesions on radiographs or other methods should not be reported as an adverse event, unless the outcome is fatal during the study or within the safety reporting period – see definition of serious adverse event below.
- Signs or symptoms resulting from dose overdose, dependency, withdrawal, abuse, and/or misuse
- Drug interactions
- Exposure in utero (pregnancy)

For laboratory abnormalities, the criteria for determining whether an abnormal test finding should be reported as an adverse event are as follows:

- Test result is associated with accompanying symptoms, and/or
- Test result requires additional diagnostic testing or medical/surgical intervention, and/or
- Test result leads to a change in study dosing outside of protocol-stipulated dose adjustments or discontinuation from the study, significant additional concomitant drug treatment, or other therapy, and/or
- Test result is considered to be an adverse event by the Investigator

### 9.1.2 Serious Adverse Events (SAE)

A serious adverse event (SAE) based on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for Human Use is any untoward medical occurrence that at any dose:

- **Results in death.** *If the malignancy under study has a fatal outcome during the study or within the safety reporting period, the event leading to death should be reported as a Grade 5 SAE; death is an outcome and not the adverse event in itself.*

- **Is life-threatening** (i.e., immediate risk of death from the reaction as it occurred). *It does not include a reaction which hypothetically might have caused death had it occurred in a more severe form.*

- Requires or prolongs inpatient hospitalization (i.e., the event required at least a 24-hour hospitalization or prolonged a hospitalization beyond the expected length of stay). Hospitalization admissions and/or surgical operations scheduled to occur during the study period, but planned prior to study entry are not considered SAEs if the illness or disease existed before the person was enrolled in the trial, provided that it did not deteriorate in an unexpected manner during the trial (e.g., surgery performed earlier than planned)

- **Results in persistent or significant disability/incapacity.** Disability is defined as a substantial disruption of a person’s ability to conduct normal life functions

- **Results in a congenital anomaly or birth defect**

- **Is a suspected transmission of any infectious agent via a medicinal product**

- **Is an important medical event when, based upon appropriate medical judgment, it may jeopardize the participant and require medical or surgical intervention to prevent one of the outcomes listed above.** Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home; blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse

Events **not** considered to be SAEs are hospitalizations for:

- Routine treatment or monitoring of the studied indication, not associated with any deterioration in condition

- Elective or pre-planned treatment for a pre-existing condition that did not worsen

- Emergency outpatient treatment for an event not fulfilling the serious criteria outlined above and not resulting in inpatient admission

- Respite care or social admissions

### 9.1.3 Expectedness

An adverse event or suspected adverse reaction is considered “unexpected” if it is not listed in the Investigator’s Brochure or is not listed at the specificity or severity that has been observed.

Aragon Pharmaceuticals, Inc - Confidential
Unexpected, as used in this definition, also refers to adverse events or suspected adverse reactions that are mentioned in the Investigator’s Brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation. Such events would be considered unexpected until they have been observed with the drug under investigation.

9.1.4 Attribution

A suspected adverse reaction means any adverse event for which there is reasonable possibility that the study drug caused the adverse event. For the purposes of IND safety reporting, “reasonable possibility” means there is evidence to suggest a causal relationship between the drug and the adverse event.

The Investigator will assign attribution of the possible association of the event with the study drug using the following definitions:

- **Unrelated to study drug**: The adverse event is *clearly not related* or is *doubtfully related* to the study drug
- **Related to study drug**: The adverse event *may be related*, *is likely related*, or is *clearly related* to the study drug

9.1.5 Severity

Signs or symptoms should be graded and recorded by the Investigator according to the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (*Appendix 4*). When specific adverse events are not listed in the CTCAE, they are to be graded as mild, moderate, severe, or life-threatening according to the following grades and definitions:

**Table 2  AE Severity Grading**

<table>
<thead>
<tr>
<th>Severity (Toxicity Grade)</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grade 1</td>
<td>Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated</td>
</tr>
<tr>
<td>Grade 2</td>
<td>Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL)</td>
</tr>
<tr>
<td>Grade 3</td>
<td>Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL</td>
</tr>
<tr>
<td>Grade 4</td>
<td>Life-threatening consequences; urgent intervention indicated</td>
</tr>
<tr>
<td>Grade 5</td>
<td>Death related to AE</td>
</tr>
</tbody>
</table>

Aragon Pharmaceuticals, Inc - Confidential
9.1.6 Pregnancy
Because the effect of the blinded study drug on sperm is unknown, pregnancies in partners of male subjects included in the study will be reported by the investigational staff within 24 hours of their knowledge of the event using the appropriate pregnancy notification form.

Follow-up information regarding the outcome of the pregnancy and any postnatal sequelae in the infant will be required.

9.2 REPORTING REQUIREMENTS
All AEs and SAEs whether reported by the patient, discovered during questioning, directly observed, or detected by physical examination, laboratory test or other means, will be recorded in the patient’s medical record and on the appropriate study-specific CRFs. Anticipated events will be recorded and reported as described in Appendix 9 (see also Section 9.2.3).

9.2.1 SAE Reporting
During the Prescreening Phase only, the SAE reporting would be limited to SAEs related to the PSA blood draw. At screening, the reporting period for SAEs begins from the time the patient provides informed consent and prior to the patient’s participation in the study, i.e., prior to undergoing any study-related procedure through and including 28 days after the last dose of study drug. Serious adverse events will also be collected during subsequent therapy with abiraterone acetate (see Section 8.10).

All SAEs occurring during the study must be reported to the appropriate Sponsor contact person by study-site personnel within 24 hours of their knowledge of the event.

Information regarding SAEs will be transmitted to the Sponsor using the Serious Adverse Event Form, which must be completed and signed by a physician from the study site, and transmitted to the Sponsor within 24 hours. The initial and follow-up reports of an SAE should be made by facsimile (fax) or email. The names (and corresponding telephone numbers) of the individuals who should be contacted regarding safety issues or questions regarding the study will be provided as a separate document.

The Investigator is also responsible for notifying the Institutional Review Board/Independent Ethics Committee (IRB/IEC) in accordance with local regulations.

All events should be followed to their resolution, until the Investigator assesses them as stable, irreversible, or until the patient is lost to follow-up, whichever comes first. Any SAEs occurring any time after the reporting period must be promptly reported if a causal relationship to apalutamide is suspected.

Reporting Deaths: Regardless of relationship to study drug, all deaths on study should be reported through and including 28 days after the last dose of study. Deaths occurring after the safety follow-up period do not have to be reported as SAEs unless considered related to study drug.
For all SAEs, the Investigator is obligated to pursue and provide information to the Sponsor in accordance with the timeframes for reporting specified above. In addition, an Investigator may be requested to obtain specific additional follow-up information in an expedited fashion. This information may be more detailed than that captured on the AE CRF. In general, this will include a description of the adverse event in sufficient detail to allow for a complete medical assessment of the case and independent determination of possible causality. Information on other possible causes of the event, such as concomitant medications and illnesses must be provided. In the case of a patient death, a summary of available autopsy findings must be submitted as soon as possible to the Sponsor or its designated representative.

9.2.2 Non-Serious AE Reporting

Adverse events should be recorded on the AE CRF from the time the patient has signed the informed consent at screening (see Section 8.2) until 28 days after the last dose of study drug. All events should be followed to their resolution, until the Investigator assesses them as stable, irreversible, or until the patient is lost to follow-up, whichever comes first. If a patient begins a new systemic anti-cancer therapy, the AE reporting period for non-SAEs ends at the time the new treatment is started.

9.2.3 Sponsor Reporting Requirements to Regulatory Authorities

Adverse events reporting, including suspected serious unexpected adverse reactions, will be carried out in accordance with applicable local regulations. The Sponsor or its designee will be responsible for determining whether or not the suspected adverse reaction meets the criteria for expedited reporting.

- For anticipated events reported as individual serious adverse events the Sponsor will make a determination of relatedness in addition to and independent of the investigator’s assessment. The Sponsor will periodically evaluate the accumulating data and, when there is sufficient evidence and the sponsor has determined there is a reasonable possibility that the drug caused a serious anticipated event, they will submit a safety report in narrative format to the investigators (and the head of the institute).

- The Sponsor or its designee will be responsible for reporting relevant SAEs to the Competent Authority, other applicable regulatory authorities, and participating investigators, in accordance with ICH guidelines, FDA regulations, European Clinical Trials Directive (Directive 2001/20/EC), and/or local regulatory requirements.

- The Sponsor or its designee will be responsible for reporting unexpected fatal or life-threatening events associated with the use of the study drug to the regulatory authorities by telephone or fax within 7 calendar days after being notified of the event.

- The Sponsor or its designee will report other relevant SAEs associated with the use of the study drug to the appropriate regulatory authorities (according to local guidelines) and Investigators by a written safety report within 15 calendar days of notification.
9.2.4 Product Quality Complaint Handling

A product quality complaint (PQC) is defined as any suspicion of a product defect related to manufacturing, labeling, or packaging, i.e., any dissatisfaction relative to the identity, quality, durability, or reliability of a product, including its labeling or package integrity. A PQC may have an impact on the safety and efficacy of the product. Timely, accurate, and complete reporting and analysis of PQC information from studies are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by regulatory agencies worldwide. The sponsor has established procedures in conformity with regulatory requirements worldwide to ensure appropriate reporting of PQC information; all studies conducted by the sponsor or its affiliates will be conducted in accordance with those procedures.

9.2.4.1 Procedures

All initial PQCs must be reported to the sponsor by the study-site personnel within 24 hours after being made aware of the event.

If the defect is combined with a SAE, the study-site personnel must report the PQC to the sponsor according to the SAE reporting timelines (refer to Section 9.2.1). A sample of the suspected product should be maintained for further investigation if requested by the sponsor.

9.2.4.2 Contacting Sponsor Regarding Product Quality

The names (and corresponding telephone numbers) of the individuals who should be contacted regarding product quality issues are listed on the Contact Information page(s), which will be provided as a separate document.

10. END OF TREATMENT

A patient may be discontinued from study treatment at any time if the patient, the Investigator, or the Sponsor feels that it is not in the patient’s best interest to continue on study. If a patient’s study treatment must be discontinued, this will not result in automatic withdrawal of the patient from the study.

The following is a list of possible reasons for early discontinuation of study treatment:

- Disease progression (patients should be highly encouraged to stay on study treatment until there is BICR-confirmed radiographic progression; treatment decisions should not be based on PSA alone)
- Any episode of seizure
- Any other adverse event that cannot be adequately managed with dose modifications, including dose interruption for ≥ 28 days may require study drug discontinuation, which must be discussed with the Sponsor.
- Protocol violation requiring discontinuation of study treatment
- Patient is not compliant with study procedures
- Lost to follow-up
- Patient withdrawal of consent

Aragon Pharmaceuticals, Inc - Confidential
Sponsor request for early termination of study

All patients discontinuing study treatment will enter the Long-term Follow-up Phase and will be followed for the development of symptomatic progression and initiation of subsequent anti-cancer therapies every 4 months until death, loss of follow-up, or withdrawal of consent, whichever comes first.

If a patient is lost to follow-up, every reasonable effort must be made by the study site personnel to contact the patient and determine the reason for discontinuation/withdrawal. The measures taken to follow up must be documented.

When a subject withdraws before completing the study, the reason for withdrawal is to be documented in the CRF and in the source document. Study drug assigned to the withdrawn subject may not be assigned to another subject. Subjects who withdraw will not be replaced.

Data to be collected for the end of treatment visit are described in Section 8.7. Patients will be followed for at least 28 days after the last dose of study drug. If a patient is withdrawn from treatment due to an adverse event, the patient will be followed until the adverse event has resolved or stabilized as per Section 9.2.

For information on subsequent therapy with abiraterone acetate see Section 8.10

11. PROTOCOL VIOLATIONS

A protocol violation occurs when the patient or Investigator fails to adhere to significant protocol requirements affecting the inclusion, exclusion, patient safety and primary endpoint criteria. Protocol violations for this study include, but are not limited to, the following:

- Failure to meet inclusion/exclusion criteria [no waivers will be granted to meet the eligibility criteria]
- Use of a prohibited concomitant medication
- Dose modifications that are not within the protocol specifications
- Any other deviation that presents significant risk or safety concerns to the patient

Failure to comply with Good Clinical Practice (GCP) guidelines will also result in a protocol violation. The Sponsor, in consultation with the Investigator, will determine if a protocol violation should result in withdrawal of a patient.
12. DATA MONITORING COMMITTEE

An Independent Data Monitoring Committee (IDMC) will be established to monitor data on an ongoing basis to ensure the safety of the subjects enrolled in this study. The committee will meet periodically to review interim safety data. After the review, the IDMC will make recommendations regarding the conduct of the study. The IDMC will serve as the primary reviewers of the efficacy analysis. Further details will be provided in a separate IDMC charter.

The IDMC will consist of at least 2 medical experts in the relevant therapeutic area and at least 1 statistician. The IDMC responsibilities, authorities, and procedures will be documented in the IDMC charter.

13. STATISTICAL METHODS AND CONSIDERATIONS

A detailed methodology for summary and statistical analyses of the data collected in this study will be documented in a Statistical Analysis Plan (SAP) that will be dated, version-controlled and maintained by the Sponsor.

13.1 ANALYSIS POPULATIONS

**Full Analysis (Intent-to-Treat) Population [ITT]:** All eligible patients who are randomized into the study, with study drug assignments designated according to initial randomization, regardless of whether patients receive study drug or receive a different drug from that to which they were randomized to will be included in the analyses of all efficacy and clinical benefit endpoints and patient characteristics.

**Safety Analysis Population [SAFETY]:** All patients who receive at least one dose of study drug, with treatment assignments designated according to actual study treatment received will be the primary population for evaluating safety and treatment compliance and administration.

- **Patient Report Outcomes Population [PRO]:** Subset of the safety analysis population that has completed at least the baseline assessment (Cycle 1 Day 1) of either FACT-P or EQ-5D questionnaires.
- **Population Pharmacokinetics Populations [PK]:** Subset of the safety analysis population that was randomized to the apalutamide treatment arm and that has at least one PK sample collected.
- **Biomarker Population:** Subset of the safety analysis populations that has at least 1 biomarker sample collected.

13.2 EFFICACY ANALYSES

Efficacy analyses will be performed on the ITT population, incorporating the randomization stratification factors as documented on the CRF, unless otherwise specified.

Analyses of efficacy endpoints which are based on radiographic tumor assessments (MFS, PFS, and TTM) will be based on the results of the BICR. Investigator assessments may be used for sensitivity analyses, as described in the Statistical Analysis Plan.

Aragon Pharmaceuticals, Inc - Confidential
13.2.1 Analysis of Primary Endpoint

The primary endpoint for the study is metastasis-free survival (MFS) which is defined as the time from randomization to first evidence of BICR-confirmed radiographically detectable bone or soft tissue distant metastasis (simply referred to as “metastasis” from this point forward) or death due to any cause (whichever occurs earlier) + 1 day.

The MFS data for patients without metastasis or death will be censored on the date of the last tumor assessment (or, if no tumor assessment was performed after the baseline visit, at the date of randomization + 1 day). Additional censoring rules will vary according to whether the analysis is performed for US or ex-US regulatory purposes, as shown below; both results will be provided in the clinical study report.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>US regulatory guidance</th>
<th>ex-US regulatory guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data from patients who are lost to follow-up or whose disease progression (development of metastasis) or death occurs after 2 or more consecutively missing or unevaluable tumor assessments</td>
<td>Censored on the date of the last tumor assessment that the patient was known to be metastasis-free</td>
<td>Time of progression will be determined using the first date when there is documented evidence of progression or death (whichever occurs earlier) regardless of missed or unevaluable tumor assessments</td>
</tr>
<tr>
<td>Patients that receive new systemic anti-cancer therapy prior to documented disease progression (development of metastasis) or death</td>
<td>Censored on the date of the last tumor assessment prior to the start of the new systemic anti-cancer therapy</td>
<td>Time of progression will be determined using the first date when there is documented evidence of progression or death (whichever occurs earlier) regardless of change of therapy</td>
</tr>
</tbody>
</table>

The primary efficacy analysis will be completed when approximately 372 MFS events have occurred. The primary analysis will compare the MFS distributions in the two treatment arms using a two-sided log-rank test, stratified by PSADT (> 6 months vs. ≤ 6 months), the use of a bone-sparing agent (Yes vs. No), and the presence of loco-regional disease (N0 vs. N1) at the 0.05 significance level. The unstratified log-rank test will be provided as a sensitivity analysis. A complete list of sensitivity analyses is provided in the Statistical Analysis Plan.

Kaplan-Meier methods will be used to estimate median MFS for each treatment arm. Cox proportional-hazard models, including the same factors as above, will be used to estimate the hazard ratio and its 95% confidence interval (CI). Additional analyses by formulation

Aragon Pharmaceuticals, Inc - Confidential
subgroups will be performed for the MFS endpoint as described in the Statistical Analysis Plan.

### 13.2.2 Analyses of Secondary Endpoints

For the secondary endpoints, a hierarchical testing will be performed in the following order:

- TTM
- PFS
- Time to symptomatic progression
- OS
- Time to initiation of cytotoxic chemotherapy

Each secondary endpoint will have a final analysis but there will be no interim analysis for TTM and PFS. There will be 1 interim analysis for time to symptomatic progression, and up to 2 interim analyses for OS and time to initiation of cytotoxic chemotherapy. The testing of time to symptomatic progression, OS and time to initiation of cytotoxic chemotherapy endpoints will utilize an adaptive group sequential method, according to the pre-specified O’Brien-Fleming-type alpha spending function with possible re-estimation of the required number of events necessary for the next analysis to maintain the desired conditional power. If time to symptomatic progression is significant at the IA, then there will be only 1 interim analysis for OS and time to initiation of cytotoxic chemotherapy; otherwise there will be 2 interim analyses for OS and time to initiation of cytotoxic chemotherapy.

The final analysis of TTM and PFS, interim analysis of time to symptomatic progression, and the first interim analysis of OS and time to initiation of cytotoxic chemotherapy will all be performed at the same time as the primary analysis of MFS (approximately 372 events).

Full details about the adaptive group sequential testing procedure will be provided in the statistical analysis plan.

Time-to-event-based secondary endpoint analyses (TTM, PFS, time to symptomatic progression, OS, and time to initiation of cytotoxic chemotherapy) will be performed using a two-sided log-rank test, stratified by PSADT (> 6 months vs. ≤ 6 months), the use of a bone-sparing agent (Yes vs. No), and the presence of loco-regional disease (N0 vs. N1). Unstratified log-rank tests will also be provided as sensitivity analyses.

Kaplan-Meier methods will be used to estimate medians for each treatment arm. Cox proportional-hazard models, including the same factors as above, will be used to estimate the hazard ratio and its 95% confidence interval (CI). One year, 2-year, 3-year, and 5-year survival rates will be estimated using the Kaplan-Meier method.
13.2.2.1 OS

Overall survival will be defined as the time from randomization to the date of death due to any cause + 1 day. Patients who are alive at the time of the analysis will be censored on the last known date that they were alive. In addition, the following censoring rules will apply:

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Date of Censoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with no post-baseline information</td>
<td>Censored on the date of randomization + 1 day</td>
</tr>
<tr>
<td>Patients who are lost to follow-up or who withdraw consent for further follow-up</td>
<td>Censored on the last known date that they were alive</td>
</tr>
<tr>
<td>Sensitivity Analysis: Patients that receive new systemic anti-cancer therapy</td>
<td>Censored on the day before the start date of the new systemic anti-cancer therapy</td>
</tr>
</tbody>
</table>

13.2.2.2 Time to Symptomatic Progression

Time to symptomatic progression will be defined as the time from randomization to documentation in the CRF of any of the following (whichever occurs earlier) + 1 day:

- Development of a skeletal-related event (SRE): pathologic fracture, spinal cord compression, or need for surgical intervention or radiation therapy to the bone.
- Pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anti-cancer therapy.
- Development of clinically significant symptoms due to loco-regional tumor progression requiring surgical intervention or radiation therapy.

Adverse event, concomitant medication, concomitant treatment, or survival follow-up CRFs will be the source of these findings.

Time to symptomatic progression for patients who do not experience any of the events described above will be censored on the date on which they were last known to be event-free.

13.2.2.3 Time to Initiation of Cytotoxic Chemotherapy

Time to initiation of cytotoxic chemotherapy will be defined as the time from randomization to documentation in the CRF of a new cytotoxic chemotherapy being administered to the patient (e.g., survival follow-up CRF) + 1 day.

Time to initiation of cytotoxic chemotherapy for patients who do not start cytotoxic chemotherapy will be censored on the date of last contact.
13.2.2.4 Progression-Free Survival

In order to capture loco-regional disease progression, a secondary endpoint of progression-free survival (PFS) will be assessed and defined as the time from randomization to first documentation of BICR-confirmed radiographic progressive disease or death due to any cause (whichever occurs first) + 1 day.

Progressive disease will be determined based on RECIST v1.1, and further defined as follows:

- For patients with at least one measurable lesion, disease progression will be defined as at least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Furthermore, the appearance of one or more new lesions is also considered progression.

- For patients with only non-measurable disease observed on CT or MRI scans, unequivocal progression (representative of overall disease status change) or the appearance of one or more new lesions will be considered progression. For new bone lesions detected on bone scans, a second imaging modality (e.g., CT or MRI) will be required to confirm progression.

Progression-free survival data for patients without loco-regional disease will be censored on the date of the last tumor assessment (or, if no tumor assessment was performed after the baseline visit, at the date of randomization + 1 day). Additional censoring rules will vary according to whether the analysis is performed for US or ex-US regulatory purposes, as shown below; both results will be provided in the clinical study report.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>US regulatory guidance</th>
<th>ex-US regulatory guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data from patients who are lost to follow-up or whose disease progression or death occurs after 2 or more consecutively missing or unevaluable tumor assessments</td>
<td>Censored on the date of the last tumor assessment that the patient was known to be progression-free</td>
<td>Time of progression will be determined using the first date when there is documented evidence of progression or death (whichever occurs earlier) regardless of missed or unevaluable tumor assessments</td>
</tr>
<tr>
<td>Patients that receive new systemic anti-cancer therapy prior to documented disease progression or death</td>
<td>Censored on the date of the last tumor assessment prior to the start of the new systemic anti-cancer therapy</td>
<td>Time of progression will be determined using the first date when there is documented evidence of progression or death (whichever occurs earlier)</td>
</tr>
</tbody>
</table>
13.2.2.5 Time to Metastasis

Time to metastasis will be defined as the time from randomization to first evidence of BICR-confirmed radiographically detectable bone or soft tissue distant metastasis (simply referred to as “metastasis” from this point forward) + 1 day.

Time to metastasis data for patients without metastasis will be censored on the date of the last tumor assessment (or, if no tumor assessment was performed after the baseline visit, at the date of randomization + 1 day). Additional censoring rules will vary according to whether the analysis is performed for US or ex-US regulatory purposes, as shown below; both results will be provided in the clinical study report.

<table>
<thead>
<tr>
<th>Scenario</th>
<th>US regulatory guidance</th>
<th>ex-US regulatory guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data from patients who are lost to follow-up or whose disease progression (development of metastasis) occurs after 2 or more consecutively missing or unevaluable tumor assessments</td>
<td>Censored on the date of the last tumor assessment that the patient was known to be metastasis-free</td>
<td>Time of progression will be determined using the first date when there is documented evidence of progression regardless of missed or unevaluable tumor assessments</td>
</tr>
<tr>
<td>Patients that receive new systemic anti-cancer therapy prior to documented disease progression (development of metastasis)</td>
<td>Censored on the date of the last tumor assessment prior to the start of the new systemic anti-cancer therapy</td>
<td>Time of progression will be determined using the first date when there is documented evidence of progression regardless of change of therapy</td>
</tr>
</tbody>
</table>

13.3 SAFETY EVALUATIONS

The SAFETY population will be the primary population for evaluating safety.

13.3.1 Analysis of Adverse Events

Adverse events (AEs) will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 and coded to preferred term and system organ class (SOC) using the most recent version of MedDRA.

All AEs reported from the first dose of study drug until 28 days after the last dose of study drug will be considered as treatment-emergent AEs and will be summarized by treatment arm.
For each treatment arm, adverse event incidence rates will be summarized with frequency and percentage by MedDRA SOC and preferred term, with all patients treated in that treatment arm as the denominator, unless otherwise specified. In addition, AE incidence rates will also be summarized by severity and relationship to study drug. Treatment-related AEs are those judged by the Investigator to be at least possibly related to the blinded study drug. Adverse events with missing severity or relationship to study drug will be classified as severe and treatment-related, respectively. Patients with multiple occurrences of events will only be counted once at the maximum severity to study drug for each preferred team, SOC, and overall. Deaths that occur within 28 days after the last dose of study drug are defined as on-study deaths.

Summary tables and individual patient listings will be prepared as per the Statistical Analysis Plan. An additional analysis by formulation subgroups will be performed as outlined in the Statistical Analysis Plan.

13.3.2 Analysis of Clinical Laboratory Results

Only data collected by the central laboratory will be summarized. Local laboratory data collected for the purposes of planning treatment administration, dose modification, or monitoring adverse events, will not be summarized.

Normal ranges will be used to identify values that are outside the normal ranges and abnormal laboratory results will be graded according to the NCI CTCAE Version 4.0. Descriptive statistics will be provided for each test result and for the change from baseline by visit.

A shift summary of baseline grade by maximum post-baseline CTCAE grade will be presented, as appropriate. For each laboratory parameter, the baseline laboratory value will be defined as the last laboratory value collected on or prior to the first dose of study drug.

Patients who develop toxicities of Grade ≥ 3 will be summarized. Laboratory test results not having CTCAE grade will also be summarized. Parameters that have criteria available for both low and high values (e.g., hypercalcaemia vs. hypocalcaemia) will be summarized for both criteria. Patients will only be counted once for each criterion.

13.3.3 Analysis of Vital Signs

Each vital sign (temperature, blood pressure (systolic and diastolic), respiration rate, and heart rate) and respective change from baseline will be summarized and presented by treatment arm and study visit. Patients with clinically significant abnormalities in vital signs as compared to baseline will be listed.

13.3.4 Concomitant Medications/Treatments

All medications and/or treatments received during the protocol Treatment Phase will be considered as concomitant medications and/or concomitant treatments and will be coded by WHO medical dictionary; patients who received concomitant medications and/or treatments will be listed.
13.4 OTHER EVALUATIONS

13.4.1 Second Progression-free Survival (PFS2)

This endpoint is defined as the time from randomization to second documentation of investigator-assessed disease progression (PSA, radiographic, symptomatic, or any combination) or death from any cause.

13.4.2 PSA

PSA kinetics (e.g., 12-week PSA response and time to PSA progression) will be assessed according to the Prostate Cancer Clinical Trials Working Group (PCWG2) recommendations.

Summary tables and waterfall plots describing change in PSA relative to baseline will be reported at 12 weeks (or earlier for those who discontinue study treatment prior to 12 weeks), and separately, the maximum change at any time on study will also be reported for each patient using summary tables and waterfall plots.

The time to PSA progression will be calculated as the time from randomization to the time when the criteria for PSA progression according to PCWG2 are met + 1 day. Kaplan-Meier methods will be used to estimate the median time to PSA progression and 95% confidence intervals for each treatment arm.

13.4.3 Health-Related Quality of Life and Prostate Cancer-Specific Symptoms Analysis

The FACT-P and EQ-5D data will be scored and handled as recommended in their respective User’s manuals, including handling of missing data both within the subscales and overall. All the analysis for FACT-P and EQ-5D data will be performed in the PRO population.

A 10-point change in the FACT-P total score is considered clinically meaningful. Therefore, any patient experiencing a 10-point decrement in FACT-P total scores from baseline will be considered to have experienced clinically meaningful deterioration in functional status. The proportion of patients with at least a 10-point decrement in FACT-P total score will be summarized by treatment arm. The decrement in the FACT-P total score between treatment arms will be compared using a Mantel-Haenszel test, stratified by PSADT (>6 months vs. \(\leq 6\) months), the use of a bone-sparing agent (Yes vs. No), and the presence of loco-regional disease (N0 vs. N1) at a two-sided 0.05 significance level.

The EQ-5D data will be summarized descriptively by treatment group and study visit.

13.4.4 Population Pharmacokinetics (Pop PK) Analysis

Population PK analysis will utilize patient covariates to identify sub-populations where possible; the effect of the formulations will also be explored in the covariate analysis. The relationship of exposure to apalutamide and active metabolite (ARN000308) to measures of efficacy and adverse events will also be modeled to the extent possible. The PK population will be the primary population used for population PK analysis, while placebo data will also be included for PK-efficacy or PK-adverse events analyses.
Population analysis methods will be utilized as applicable. Population PK analysis of plasma concentration-time data of apalutamide will be performed using nonlinear mixed-effects modeling. The population PK analysis results will be presented in a separate report.

13.4.5 Exploratory Biomarkers Analysis

Blood and plasma samples will be collected at multiple time points and archived FFPE tumor blocks or tumor slides may be analyzed for development of the F876L mutation (plasma) and for high risk features (FFPE tumor blocks or tumor slides) and associations may be made with clinical endpoints as follows.

- F876L mutation and other DNA mutations from cfDNA in plasma collected at Day 1 of Cycles 1, 11, 17, 25, 37, and End-of-Treatment Visit.
- AR splice variants or other RNA anomalies in cfRNA in blood collected at Day 1 of Cycles 1 and 11, and End-of-Treatment Visit.
- Global mRNA expression levels in FFPE tumor blocks or tumor slides to identify expression levels of ‘high-risk’ classifier genes.

High-risk genomic classifiers may be evaluated if it can be used to identify a more homogeneous population of high-risk patients using appropriate categorical or regression methods.

The association of the rest of the biomarkers with clinical response or relevant survival endpoints may be assessed using appropriate statistical methods (e.g. analysis of variance [ANOVA], categorical or survival models), depending on the endpoints. Analyses may be performed within and between each treatment group. Other clinical covariates (such as baseline tumor characteristics and patient demographics) may also be included in the model. Correlation of baseline biomarker expression levels with clinical response or relevant time-to-event endpoints may be performed to identify responsive (or resistant) subgroups. Association of biomarkers with clinical response or relevant time-to-event endpoints will also be explored in the overall population to identify “high-risk” biomarker profiles that are correlated with poor outcome. Appropriate details of these exploratory analyses will be included in the statistical analysis plan. Results of these exploratory analyses will be presented in separate technical reports.

13.4.6 Assessment of Ventricular Repolarization

The assessment of ventricular repolarization will be a substudy conducted in a subset of patients from selected clinical sites and analyzed by an independent cardiac safety laboratory (Appendix 8).

13.4.7 Medical Resource Utilization Analysis

Protocol-mandated procedures, tests, and encounters are excluded. The MRU data may be used to conduct economic analyses.
13.5 INTERIM ANALYSIS
There will be 1 interim analysis for time to symptomatic progression, and up to 2 interim analyses for OS and time to initiation of cytotoxic chemotherapy; see Section 13.2.2 for an outline of analysis methods.

13.6 DETERMINATION OF SAMPLE SIZE
The primary efficacy analysis will be event-driven and will take place when approximately 372 MFS events have occurred. The study provides 90% power to detect a 30% reduction in the risk of developing metastases (HR = 0.70) for patients receiving apalutamide, with a 2-sided α of 0.05. Based on an assumed median MFS of 25 months in the placebo arm, this treatment effect represents an increase in the median MFS of approximately 11 months (from 25 months to 36 months). Assuming an accrual period of 24 months (with 75% of the patients accrued in the second year), approximately 1,200 patients will need to be enrolled.

The study was also sized to provide 85% power to detect a 25% reduction (HR = 0.75) in the risk of death for patients receiving apalutamide, based on an assumed median OS of 49 months in the placebo arm. This treatment effect represents an increase in the median OS of approximately 16 months (from 49 to 65 months).

14. DATA COLLECTION, RETENTION AND MONITORING

14.1 DATA COLLECTION INSTRUMENTS
The Investigator will prepare and maintain adequate and accurate source documents designed to record all observations and other pertinent data for each patient treated with the study drug.

Study personnel at each site will enter data from source documents corresponding to a patient’s visit into the protocol-specific electronic case report form (eCRF) when the information corresponding to that visit is available. Patients will not be identified by name in the study database or on any study documents to be collected by the Sponsor (or designee), but will be identified by a site number, patient number.

If a correction is required for an eCRF, the time and date stamps track the person entering or updating eCRF data and creates an electronic audit trail.

The Investigator is responsible for reviewing all information collected on patients enrolled in this study for completeness and accuracy. A copy of the eCRF will remain at the Investigator’s site at the completion of the study.

14.2 DATA MANAGEMENT PROCEDURES
The data will be entered into a validated database. The Sponsor-designated data management group will be responsible for data processing, in accordance with procedural documentation. Database lock will occur once quality assurance procedures have been completed.

All procedures for the handling and analysis of data will be conducted using good computing practices meeting FDA guidelines for the handling and analysis of data for clinical trials.
14.3 DATA QUALITY CONTROL AND REPORTING

After data have been entered into the study database, a system of computerized data validation checks will be implemented and applied to the database on a regular basis. Queries are entered, tracked, and resolved through the electronic data capture (EDC) system directly. The study database will be updated in accordance with the resolved queries. All changes to the study database will be documented.

14.4 ARCHIVAL OF DATA

The database is safeguarded against unauthorized access by established security procedures; appropriate backup copies of the database and related software files will be maintained. Databases are backed up by the database administrator in conjunction with any updates or changes to the database.

At critical junctures of the protocol (e.g., production of interim and final reports), data for analysis is locked and cleaned per established procedures.

14.5 AVAILABILITY AND RETENTION OF INVESTIGATIONAL RECORDS

To enable evaluations and/or audits from regulatory authorities or the Sponsor, the Investigator agrees to keep records, including the identity of all participating subjects (sufficient information to link records, e.g., CRFs and hospital records), all original signed informed consent forms, copies of all CRFs, safety reporting forms, source documents, and detailed records of treatment disposition, and adequate documentation of relevant correspondence (e.g., letters, meeting minutes, telephone calls reports). The records should be retained by the Investigator according to ICH, local regulations, or as specified in the Clinical Trial Agreement, whichever is longer, but at a minimum, all study documentation must be retained for 2 years after the last marketing application approval in an ICH region or after at least 2 years have elapsed since formal discontinuation of clinical development of apalutamide.

If the Investigator becomes unable for any reason to continue to retain study records for the required period (e.g., retirement, relocation), the Sponsor should be prospectively notified. The study records must be transferred to a designee acceptable to the Sponsor, such as another investigator, another institution, or to the Sponsor itself. The Investigator must obtain the Sponsor’s written permission before disposing of any records, even if retention requirements have been met.

14.6 MONITORING

Monitoring visits will be conducted by representatives of the Sponsor according to the US CFR Title 21 Parts 50, 56, and 312 and ICH Guidelines for GCP (E6). By signing this protocol, the Investigator grants permission to the Sponsor (or designee), and appropriate regulatory authorities to conduct on-site monitoring and/or auditing of all appropriate study documentation.
14.7 PATIENT CONFIDENTIALITY

In order to maintain patient confidentiality, only a site number and patient number will identify all study patients on CRFs and other documentation submitted to the Sponsor. Additional patient confidentiality issues (if applicable) are covered in the Clinical Trial Agreement.

Blood samples from approximately 400 patients and archived tumor samples (FFPE tumor blocks or tumor slides) from approximately 400 patients may be collected from consenting patients for scientific research where local regulations permit.

**Long-term Storage of Samples for Future Research**

Samples collected for biomarker assessments are planned to be stored until testing and for up to 15 years after the end of the study based on local regulations.

15. ADMINISTRATIVE, ETHICAL, REGULATORY CONSIDERATIONS

15.1 INVESTIGATOR RESPONSIBILITIES

The investigator is responsible for ensuring that the study is performed in accordance with current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory and country-specific requirements.

Good clinical practice is an international ethical and scientific quality standard for designing, conducting, recording, and reporting studies that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of the study subjects are protected, consistent with the principles that originated in the Declaration of Helsinki, and that the study data are credible.

To maintain confidentiality, all laboratory specimens, evaluation forms, reports and other records will be identified by a coded number. All study records will be kept in a locked file cabinet and code sheets linking a patient’s name to a patient identification number will be stored separately in another locked file cabinet. Clinical information will not be released without written permission of the patient, except as necessary for monitoring by the FDA. The Investigator must also comply with all applicable privacy regulations (e.g., Health Insurance Portability and Accountability Act of 1996, EU Data Protection Directive 95/46/EC).

15.2 PROTOCOL AMENDMENTS

Any amendment to the protocol will be written by the Sponsor. Protocol amendments cannot be implemented without prior written IRB/IEC approval except as necessary to eliminate immediate safety hazards to patients. A protocol amendment intended to eliminate an apparent immediate hazard to patients may be implemented immediately, provided the IRB/IECs are notified within five working days.
15.3 INSTITUTIONAL REVIEW BOARDS AND INDEPENDENT ETHICS COMMITTEES

The protocol, Investigator’s Brochure, the consent forms, any information to be given to the patient (including patient recruitment materials) and relevant supporting information must be submitted to the IRB/IEC by the Investigator for review and approval before the study is initiated. Any member of the IRB/IEC who is directly affiliated with this study as an Investigator or as site personnel must abstain from the IRB/IEC vote on the approval of the protocol. The IRB/IECs unconditional approval statement will be transmitted by the Investigator to the Sponsor (or designee) prior to the shipment of study supplies to the site. This approval must refer to the study by exact protocol title and number and should identify the documents reviewed and the date of review.

Protocol and/or informed consent modifications or changes may not be initiated without prior written IRB/IEC approval except when necessary to eliminate immediate hazards to the patients or when the change(s) involves only logistical or administrative aspects of the study. Such modifications will be submitted to the IRB/IEC and written verification that the modification was submitted and subsequently approved should be obtained.

Investigators are required to promptly report to their respective IRB/IEC all unanticipated problems involving risk to human patients. Some IRBs/IECs may want prompt notification of all SAEs, whereas others require notification only about events that are serious, assessed to be related to study treatment, and are unexpected. Investigators may receive written IND safety reports or other safety-related communications from the Sponsor. Investigators are responsible for ensuring that such reports are reviewed and processed in accordance with regulatory requirements and with the policies and procedures established by their IRB/IEC and archived in the site’s study file.

Finally, the Investigator will keep the IRB/IEC informed as to the progress of the study, revisions to documents originally submitted for review, annual updates and/or request for re-approvals, and when the study has been completed.

15.4 INFORMED CONSENT FORM

Informed consent will be obtained in accordance with principles that originated in the Declaration of Helsinki, current ICH and GCP guidelines, applicable regulatory requirements, and Sponsor policy.

The Sponsor’s master ICF will be provided to each site. Sponsor or its designee must review and approve any proposed deviations from the master ICF or any alternate consent forms proposed by the site before IRB/IEC submission. Patients must be re-consented to the most current version of the consent forms during their participation in the study. The final IRB/IEC-approved consent forms must be provided to Sponsor for regulatory purposes.

The ICFs must be signed by the patient or the patient’s legal representative before his participation in the study. The case history for each patient shall document the informed consent process and that written informed consent was obtained prior to participation in the study. A copy of each signed ICF must be provided to the patient or the patient’s legal...
representative. If applicable, it will be provided in a certified translation of the local language.

All signed and dated consent forms must remain in each patient’s study file and must be available for verification by study monitors at any time.

The ICF should be revised whenever there are changes to procedures outlined in the informed consent or when new information becomes available that may affect the willingness of the patient to participate.

For any updated or revised consent forms, the case history for each patient shall document the informed consent process and that written informed consent was obtained for the updated/revised consent form for continued participation in the study. The final revised IRB/IEC-approved Informed Consent Form must be provided to Sponsor for regulatory purposes.

15.5 REPORTING OF SAFETY ISSUES AND SERIOUS BREACHES OF THE PROTOCOL OR ICH GCP

In the event of any prohibition or restriction imposed (i.e., clinical hold) by an applicable Competent Authority in any area of the World, or if the Investigator is aware of any new information which might influence the evaluation of the benefits and risks of the investigational product, the Sponsor should be informed immediately.

In addition, the Investigator will inform the Sponsor immediately of any urgent safety measures taken by the Investigator to protect the study subjects against any immediate hazard, and of any serious breaches of this protocol or of ICH GCP that the Investigator becomes aware of.

15.6 END OF TRIAL IN ALL PARTICIPATING COUNTRIES

Patients will remain on study treatment until BICR-confirmed disease progression, development of unacceptable toxicity, or withdrawal of consent. Patients discontinuing study treatment will enter the Long-term Follow-up Phase and remain on study until death, loss of follow-up, or withdrawal of consent, whichever comes first.

With an estimated accrual duration of 24 months, it is assumed that patients are expected to be followed for a minimum of approximately 9 months beyond Last Patient In (LPI) for the primary endpoint of MFS, to approximately 41 months beyond LPI for the key secondary endpoint of OS. This corresponds to total projected study duration of approximately 65 months.

If the study is not terminated beforehand per the recommendation of the IDMC, the end of trial in all participating countries will be defined as the time at which the secondary endpoint of OS has been met.

15.7 SPONSOR DISCONTINUATION CRITERIA

Premature termination of this study may occur because of a regulatory authority decision, change in opinion of the IRB/IEC, drug safety problems, or at the discretion of the Sponsor.
In addition, the Sponsor retains the right to discontinue development of apalutamide at any time.

If a study is prematurely terminated or discontinued, the Sponsor will promptly notify the Investigator. After notification, the Investigator must notify the respective IRB/IEC, and contact all participating subjects and the hospital pharmacy (if applicable) within a 4-week time period. As directed by the Sponsor, all study materials must be collected and all CRFs completed to the greatest extent possible.

15.8 PUBLICATIONS

Publication of study results is discussed in the Clinical Trial Agreement. Details regarding production of manuscripts and conference presentations will adhere to the International Committee of Medical Journal Editors (ICMJE) requirements for authorship and contributorship.

http://www.icmje.org/ethical_1author.html

16. REFERENCES

1. Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man: Methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials. European Medicines Agency 2011; Doc. Ref. EMA/CHMP/27994/2008.


Aragon Pharmaceuticals, Inc - Confidential


17. APPENDICES

Appendix 1  Schedule of Activities
Appendix 2  Required Laboratory Tests
Appendix 3  ECOG Performance Status
Appendix 4  National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)
Appendix 5  Prohibited or Restricted Medications or Supplements While On Study
Appendix 6  FACT-P Questionnaire
Appendix 7  EQ-5D
Appendix 8  Ventricular Repolarization Substudy at Selected Sites
Appendix 9  Anticipated Events
Appendix 10 Crossover to Open Label Apalutamide After Study Unblinding
## APPENDIX 1: SCHEDULE OF ACTIVITIES

<table>
<thead>
<tr>
<th>Activities and Forms to be Completed</th>
<th>Prescreening [1]</th>
<th>Screening ≤35 Days Prior to Randomization</th>
<th>Treatment Phase Cycle 1 Day 1 D1 C1-C6, D1 of every 2 cycles starting at C7 to C13, then D1 of every 4 cycles unless otherwise specified</th>
<th>Posttreatment Every 16 weeks (Starting on C1D1)</th>
<th>End-of-Treatment [2]</th>
<th>Safety Follow-up [3]</th>
<th>Long-term Follow-up [4]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Screening</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical/Oncological History [5]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization [6]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Study Drug Administration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apalutamido/Matched Placebo</td>
<td></td>
<td>X</td>
<td>→</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Administration [7]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Drug Compliance [8]</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Laboratory Studies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology [9]</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood Chemistry [9]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PSA [10]</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT brain [12]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT chest, abdomen, and pelvis [4,13]</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone scan [4, 13]</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Aragon Pharmaceuticals, Inc - Confidential
<table>
<thead>
<tr>
<th>Activities and Forms to be Completed</th>
<th>Prescreening [1]</th>
<th>Screening</th>
<th>Treatment Phase</th>
<th>Posttreatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical Resource Utilization</td>
<td></td>
<td>≤35 Days Prior to Randomization</td>
<td>Cycle 1 Day 1</td>
<td>D1 C1-C6, D1 of every 2 cycles starting at C7 to C13, then D1 of every 4 cycles unless otherwise specified</td>
</tr>
<tr>
<td>Progression on first subsequent therapy [14]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival [4]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Examination [15]</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Vital Signs [16]</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>12-lead ECG [17]</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Adverse Events</td>
<td>X [18]</td>
<td></td>
<td></td>
<td>Continuous from informed consent until 28 days after the last dose of study drugs</td>
</tr>
<tr>
<td>Concomitant Medications [19]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Population Pharmacokinetics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PK plasma sample [20]</td>
<td></td>
<td></td>
<td>Between 0.5 and 4 hours post-dose</td>
<td>D1 of C2, C3, C6, C11, C17, and C25</td>
</tr>
<tr>
<td>Patient Reported Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FACT-P and EQ-5D [21]</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Exploratory Biomarkers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Archival FFPE blocks/slides [22]</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Biomarker blood sample [22]</td>
<td></td>
<td></td>
<td>X</td>
<td>D1 of C11, C17, C25, and C37</td>
</tr>
</tbody>
</table>

C1D1 = Cycle 1 Day 1; BICR = blinded independent central review; CT = computed tomography; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology Group; EQ-5D = Euro QoL; FACT-P = functional assessment of cancer therapy-prostate; FFPE = formalin-fixed paraffin-embedded; PSA = prostate specific antigen.

Aragon Pharmaceuticals, Inc - Confidential
### Footnotes

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. <strong>Prescreening:</strong> Prior to study entry, additional PSA evaluations may be necessary to determine eligibility. This Prescreening Phase is optional; please also refer to prescreen informed consent.</td>
<td></td>
</tr>
<tr>
<td>2. <strong>End-of-Treatment:</strong> These assessments do not need to be completed if they have been performed within 1 week of the last dose of study drug (Exception: within the last 8 weeks for tumor assessments and 2 weeks for PROs, respectively).</td>
<td></td>
</tr>
<tr>
<td>3. <strong>Safety Follow-Up:</strong> Patients should be evaluated for safety up to 28 days after the last dose of study drug. All AEs should be followed to their resolution, until the Investigator assesses them as stable, irreversible, or until the patient is lost to follow-up, whichever comes first. If a patient begins a new systemic anti-cancer therapy, the AE reporting period for non-SAEs ends at the time the new treatment is started. Serious adverse events will be collected during treatment with abiraterone acetate (as first subsequent therapy). Note: See Section 8.10 for additional details. Treatment with abiraterone acetate does not apply in Japan.</td>
<td></td>
</tr>
<tr>
<td>4. <strong>Long-term Follow-up:</strong> Obtain survival status, collect information of development of symptomatic progression, initiation of any new systemic anti-cancer therapies, and progression on first subsequent therapy (every 4 months via clinic visit, telephone contact or an alternative contact method per institution policy/practice). The FACT-P and EQ-5D questionnaires will be collected up to 12 months post-progression (see also Footnote 21). In addition, if patients discontinued study treatment prior to documented disease progression, obtain CT of the chest, abdomen, and pelvis, plus bone scan and submit for BICR to evaluate for disease progression (every 16 weeks ±7 days), until documentation of disease progression.</td>
<td></td>
</tr>
<tr>
<td>5. <strong>Medical/Oncological History:</strong> Includes oncologic history, demographics, history of other disease processes (active or resolved) and concomitant illnesses.</td>
<td></td>
</tr>
<tr>
<td>6. <strong>Study Randomization:</strong> The Cycle 1 Day 1 visit can occur on the same day or within 4 days of randomization. Patient number and treatment assignment will be obtained via centralized randomization through the IVRS. PSADT will be calculated by the IVRS to ensure correct patient stratification.</td>
<td></td>
</tr>
<tr>
<td>7. <strong>Apalutamide/Matched Placebo:</strong> Patients will receive oral daily apalutamide or matched placebo continuously, starting on Cycle 1 Day 1. One cycle consists of 28 days.</td>
<td></td>
</tr>
<tr>
<td>8. <strong>Study Drug Compliance:</strong> Apalutamide and placebo bottle(s) including any unused tablets/capsules will be returned at the beginning of every cycle starting at Cycle 2 Day 1 and at end of treatment for drug accountability.</td>
<td></td>
</tr>
<tr>
<td>9. <strong>Samples for Hematology, Blood Chemistry:</strong> All laboratory assessments will be performed by a central laboratory. PSA results will be kept blinded until the analysis of the primary endpoint. On Cycle 1 Day 1 only, clinical laboratory tests do not need to be repeated if the Screening tests were done within 4 days of Cycle 1 Day 1. Sites may perform additional local hematology and/or blood chemistry assays for the purposes of planning treatment administration, dose modification, or monitoring adverse events.</td>
<td></td>
</tr>
<tr>
<td>10. <strong>Samples for PSA:</strong> Optional prescreening PSA evaluations will be performed by local laboratories. All other PSA valuations will be collected by the central laboratory; patients and investigators will be kept blinded until the analysis of the primary endpoint. On Cycle 1 Day 1 only, the PSA evaluation does not need to be repeated if the Screening tests were done within 4 days of Cycle 1 Day 1. For all subjects, at the time of unblinding and crossover, PSA data submitted to the central laboratory will no longer be blinded.</td>
<td></td>
</tr>
<tr>
<td>11. <strong>Samples for TSH, fasting lipid panel, and testosterone:</strong> All laboratory assessments will be performed by a central laboratory every 16 weeks (±2 days) from Cycle 1 Day 1. On Cycle 1 Day 1 only, clinical laboratory tests do not need to be repeated if the Screening tests were done within 4 days of Cycle 1 Day 1. Sites may perform additional local assays for the purposes of planning treatment administration, dose modification, or monitoring adverse events. See Appendix 2 for details on additional testing if TSH is abnormal.</td>
<td></td>
</tr>
<tr>
<td>12. <strong>Brain Imaging:</strong> CT (or MRI, if use of contrast agent is contraindicated) scan of the brain will be performed at Screening and submitted for BICR to confirm patient eligibility (absence of brain metastasis).</td>
<td></td>
</tr>
</tbody>
</table>
13. **Tumor Imaging:** CT scans of chest, abdomen, and pelvis plus bone scan will be performed at Screening (scans obtained prior to signing informed consent will be allowed provided the timing of the scans fall within the Screening window). Scans must be submitted for BICR to confirm patient eligibility. During treatment, CT scans of chest, abdomen and pelvis plus bone scan will be performed to assess disease status every 16 weeks (±7 days) from Cycle 1 Day 1, or whenever disease progression is suspected, and at the end of treatment. Note that tumor imaging should continue on this calendar schedule regardless of any delays in dosing. Patients who have a contraindication to IV contrast may have MRI exams of the brain, abdomen, and pelvis performed in lieu of CTs and a non-contrast CT of the chest. All scans will be submitted for blinded independent central review to confirm patient eligibility and assess for disease progression on study. Subjects who discontinue treatment before documented disease progression should continue with disease assessments during Long-term Follow-up every 16 weeks (±7 days) until disease progression (see also Footnote 4). For all subjects, at the time of unblinding and crossover, radiographic scans will no longer be to be submitted for blinded central independent review. Subjects will be followed for progression per Investigator decision including symptoms, radiographic scans or PSA.

14. **Progression on First Subsequent Therapy:** The date of progression on first subsequent therapy as assessed by the investigator and method of assessment of disease progression (radiographic, PSA, or both) will be collected.

15. **Physical Examination:** At Screening, a complete physical examination of major body systems, including known and suspected sites of disease, should be performed. During subsequent visits, either a full or abbreviated physical exam will be performed. New abnormal physical exam findings must be documented and followed by a physician or other qualified staff at the next scheduled visit. Height will be recorded at Screening only. Body weight will be recorded at Screening and at every scheduled visit during treatment and at the end of treatment.

16. **Vital Signs:** Body temperature, blood pressure, pulse and respiratory rate will be performed after resting for 5 minutes at Screening and every scheduled visit during treatment and at the end of treatment.

17. **ECG:** A standard 12-lead ECG will be collected at Screening and as clinically indicated. For patients on QTcF substudy, please refer to Appendix 8 for instructions on obtaining a screening ECG.

18. **Adverse Events:** During this Prescreening Phase, the SAE reporting would be limited to SAEs related to the PSA blood draws.

19. **Concomitant Medications/Treatments:** Concomitant medications and/or treatments will be recorded during the 28-day Screening Phase (prior to the start of study treatment), during the study, and up to 28 days post the last dose of study treatment.

20. **PK Samples for Population PK Analyses:** The Day 1 Cycle 1 sample will be collected between 0.5 and 4 hours postdose. All samples on Day 1 of the other cycles will be collected prior to study drug administration, see Section 8.4). Record the time for the doses administered on the 2 days preceding the PK sample day and whether the dose was administered on a once daily or twice daily schedule. No sparse PK samples will be collected from patients participating in the ventricular repolarization study (see Appendix 8). For all subjects, at the time of unblinding and crossover, PK samples will no longer need to be collected at the time of unblinding.

21. **FACT-P and EQ-5D questionnaires:** Patients will complete the FACT-P and EQ-5D at the clinic during the Treatment Phase PRIOR to any other clinical activity. During Long-term Follow-up every 4 months via clinic visit or an alternative contact method per institution policy/practice up to 12 months post-progression.

22. **Biomarker samples:** Archived FFPE tumor samples or tumor slides will be requested from a subset of approximately 400 patients and can be submitted at any time after Cycle 1 Day 1. Blood samples, 12.5 mL (on Day 1 of Cycles 1, 11 and end of treatment) and 10 mL (on Day 1 of Cycles 17, 25, and 37) will be collected prior to study drug administration from a subset of approximately 400 patients. Samples should be frozen and sent to the central laboratory.

Aragon Pharmaceuticals, Inc - Confidential
## APPENDIX 2: REQUIRED LABORATORY TESTS

<table>
<thead>
<tr>
<th>Hematology (See Appendix 1 for timing)</th>
<th>Chemistry and PSA (See Appendix 1 for timing)</th>
<th>Other (every 16 weeks from C1D1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>Total bilirubin (Note: if &gt; 1.5 x ULN, include analysis of direct and indirect bilirubin)</td>
<td>Testosterone</td>
</tr>
<tr>
<td>Platelet count</td>
<td>Alanine transaminase (ALT)</td>
<td>Thyroid stimulating hormone (TSH); if TSH is abnormal; total T3, free T4 (direct), and total T4 are required.</td>
</tr>
<tr>
<td>Red blood cell count</td>
<td>Aspartate transaminase (AST)</td>
<td>Fasting lipid panel</td>
</tr>
<tr>
<td>White blood cell count</td>
<td>Alkaline phosphatase</td>
<td></td>
</tr>
<tr>
<td>White blood cell differential</td>
<td>Albumin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sodium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Potassium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Calcium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Magnesium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Blood urea nitrogen (BUN) or urea</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Creatinine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glucose</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prostate specific antigen (PSA)</td>
<td></td>
</tr>
</tbody>
</table>

Aragon Pharmaceuticals, Inc - Confidential
APPENDIX 3: ECOG PERFORMANCE STATUS GRADES

0  Fully active, able to carry on all pre-disease activities without restriction
1  Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work or office work
2  Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours
3  Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours
4  Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair
5  Dead
APPENDIX 4: NATIONAL CANCER INSTITUTE (NCI) COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE)

The NCI CTCAE (Version 4.0) may be reviewed on-line at the following NCI website:

http://ctep.cancer.gov/reporting/ctc.html
APPENDIX 5: PROHIBITED OR RESTRICTED MEDICATIONS OR SUPPLEMENTS WHILE ON STUDY

Medications that are PROHIBITED while on study:
- Aminophylline/theophylline
- Atypical antipsychotics (e.g., clozapine, olanzapine, risperidone, ziprasidone)
- Bupropion
- Lithium
- Meperidine and pethidine
- Phenothiazine antipsychotics (e.g., chlorpromazine, mesoridazine, thioridazine)
- Tricyclic and tetracyclic antidepressants (e.g., amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine)

Supplements that are RESTRICTED while on study:
- Pomegranate

Medications that are RESTRICTED while on study:

Investigators should refer to the apalutamide Investigator’s Brochure (Sections 4.3.3.3 and 5.10) and associated addenda for complete details on the drug interaction potential of apalutamide. Highlights of drug interaction are summarized below.

- Strong CYP3A4 inducers: the potential for drug-drug interactions with apalutamide has not been tested clinically. Strong inducers of CYP3A4 (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, efavirenz, tipranavir, St. John's wort) should be avoided as much as possible.
- Apalutamide may also induce CYP3A4; therefore, caution should be taken when administered in conjunction with CYP3A4 substrates that have a narrow therapeutic index
- Strong CYP2C8 inhibitors (e.g., gemfibrozil) should be used with caution with apalutamide
- The potential for drug-drug interaction between apalutamide and warfarin (e.g., Coumadin) is unknown at present. If a patient is taking warfarin, re-assess (prothrombin) PT/(international normalized ratio) INR as clinically indicated and adjust the dose of warfarin accordingly.
- Corticosteroids (Oral, IV, or IM): due to possible resistance mechanisms, which may be contributed by glucocorticoid receptor signaling, concurrent use of corticosteroids during the study is not recommended; short term use (≤ 4 weeks) will be allowed if clinically indicated, however, its use must be tapered off as soon as possible.

Additional Information on CYP450 Drug Interactions
http://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteractionslabeling/ucm093664.htm

http://medicine.iupui.edu/clinpharm/ddis/table.aspx
APPENDIX 6: FACT-P QUESTIONNAIRE


COPYRIGHT MATERIAL
APPENDIX 8: VENTRICULAR REPOLARIZATION SUBSTUDY AT SELECTED SITES

Study Objectives

To evaluate the effect of apalutamide on ventricular repolarization in a subset of patients from selected clinical sites:

- The primary objective of this substudy is to evaluate whether apalutamide has a threshold pharmacologic effect on cardiac repolarization, as detected by changes in electrocardiogram (ECG) QT intervals corrected for heart rate by Fridericia’s correction method (QTcF)

- The secondary objectives of this study substudy are as follows:
  - To investigate the effect of apalutamide on the following ECG parameters: PR, RR, QRS, QT, QTcB (Bazett’s correction method), and T-Wave morphology
  - To determine the relationship between the plasma concentrations of apalutamide and metabolite ARN000308, and QT/QTc changes

Safety will be assessed as part of the main study. At the time of the analysis of this substudy, all safety data from the main study will be provided along with data specific to this subset of patients. In particular, any cardiac-related adverse events will be summarized in both main study and substudy populations.

Study Design and Patient Population

The effect of apalutamide on ventricular repolarization will be centrally analyzed by a third-party cardiac safety laboratory in a subset of 100 patients enrolled at selected sites that will be participating in the main protocol. Both apalutamide and placebo patients will be enrolled in a blinded manner as per the main protocol randomization criteria.

The subset of 100 patients will undergo the same screening procedures as the main protocol in order to be randomized into the study, following the same Inclusion/Exclusion criteria as per Section 4 of the protocol, with the following additional enrollment criteria:
### Additional Inclusion Criteria
- Enrollment in the main study
- Obtain separate informed consent for participation in the substudy
- Must agree to fast at least 3 hours prior to dose and continue fasting (except for approved snack) until completion of the 4 hour post dose assessments on Cycle 1 Day 1 and Cycle 3 Day 1.

### Additional Exclusion Criteria
- Heart rate outside of 50 to 100 beats/minute
- QTcF > 480 msec, determined by central assessment
- Diagnosed or suspected congenital long QT syndrome, or family history of congenital long QT syndrome or sudden death
- History of Mobitz II second degree or third degree heart block
- Implantable pacemaker or automatic implantable cardioverter defibrillator
- Complete Bundle Branch Block or ventricular conduction delay (QRS > 119 msec)
- Chronic or persistent atrial arrhythmia, including atrial fibrillation and atrial flutter.
- Concurrent therapy with medications known to prolong the QT interval and/or associated with TdP (Torsade de Pointes) arrhythmia [please refer to www.qtdrugs.org for the list of drugs to avoid]
- Smokers and planned nicotine replacement therapy users

**Note:** Sites will receive a notification report for any ECGs received above QTcF > 480msec. If patients do not qualify for the ventricular repolarization substudy, they can still participate in the main study provided they meet all other inclusion/exclusion criteria as per Section 4 of the protocol.

**Patient Withdrawal:** A patient may withdraw his consent to participate in the substudy at any time. If a patient withdraws such consent, the Investigator should inform the Sponsor (or designee) in writing and document in the Investigator Site File. The patient may continue participating in the main protocol.

**Rationale for the Study Design**

This substudy has been designed to evaluate the potential of apalutamide to prolong the QTc interval in a subset of patients with high-risk, NM-CRPC participating in the main protocol, Study ARN-509-003.

In accordance with ICH E14 guideline, QT evaluation is now expected to be routine in oncology drug development, and a Thorough QT (TQT) study should be conducted, if possible. In the case of apalutamide, in view of previous FDA advice and the observations to date that nonclinical (hERG and CV safety study) and clinical data (ECG collections in the Phase I/II Study ARN-509-001) suggest no apparent relationship between apalutamide and QT prolongation, an alternative design to the TQT study has been chosen. In this substudy, changes in QT interval following drug administration will be evaluated relative to the baseline measurement.
Rationale for the ECG Collection Time Points and PK Sampling Schedule

ECG time points have been selected to match the expected PK profile of apalutamide and metabolite (ARN000308). The ECG time points have also been selected to explore a potential shift between exposure and effect on QT/QTc.

In order to assess the QT interval prior to exposure to apalutamide, baseline triplicate ECG assessments will be performed twice prior to first study drug administration on Cycle 1 Day 1 (at hour -1 and hour 0 pre-dose). A baseline PK sample will also be collected at the hour 0, immediately after the ECGs have been collected and just prior to the first dose of apalutamide or placebo.

Subsequently, the purpose of all other ECGs is to assess for potential prolongation of the QT interval and other ECG changes as a result of apalutamide administration, with ECG collection coinciding with PK measurements to establish correlations between ECG changes and drug exposure. Triplicate ECGs, followed by blood samples for PK assessment, will be collected at 2 and 4 hours postdose on Cycle 1 Day 1 and Cycle 3 Day 1 (once steady-state can be assured). The 2- and 4-hour time points were selected because the oral plasma T_{max} of apalutamide is generally between 2 and 4 hours post-dose. Although the primary metabolite of apalutamide (ARN000308) typically has a later C_{max} than that of apalutamide (i.e., 6 to 12 hours), the peak to trough fluctuation ratio of this metabolite in patient plasma was shown to be minimal (less than 120% for ARN000308). Therefore, the potential for significant effects from this metabolite at later time points not assessed by ECG is deemed very small.

Methods

Digital 12-lead ECG equipment will be provided to each clinical site participating in this substudy by the central laboratory for the duration of the substudy.

ECGs should be collected after the patient has rested quietly and is awake in a fully supine (or semi-recumbent, if supine is not tolerated) position for 10 minutes, and prior to any blood collection. For each patient the same position (e.g., supine or semi-recumbent) should be used for all ECGs collected. Starting on Cycle 1, Day 1, time point matched blood samples for PK analyses will be collected immediately following the collection of ECGs and before the collection of blood for all other clinical evaluations. ECGs will be read by independent cardiologists from the central laboratory in a blinded manner and via single reader paradigm.

A detailed list of the required assessments is provided below. All other assessments at the other time points will follow the main protocol as per the Schedule of Activities in Appendix 1.
Schedule of Activities Specific to the Ventricular Repolarization Substudy:

- **Screening**
  - Signed informed consent for participation in this substudy
  - Collect a set of triplicate 12-lead ECGs, 2 minutes apart (Holter Monitoring using a 12-lead ambulatory device)

- **Cycle 1, Day 1**
  - One hour prior to administering the first dose of study drug, collect a set of triplicate 12-lead ECGs, 2 minutes apart
  - At time 0, just prior to administering the first dose of study drug, collect a second set of triplicate 12-lead ECGs, 2 minutes apart, and one blood sample for PK analysis
  - Administer study drug in clinic
  - At 2 and 4 hours postdose, collect a set of triplicate ECGs, 2 minutes apart, and 1 blood sample for PK analysis for each time point, respectively.

- **Cycle 3, Day 1 (Administer Study Drug in Clinic)**
  - At time 0, just prior to administering the dose of study drug, collect a set of triplicate 12-lead ECGs, 2 minutes apart, and one blood sample for trough PK analysis
  - Administer study drug in clinic
  - At 2 and 4 hours postdose, collect a set of triplicate ECGs, 2 minutes apart, and one blood sample for PK analysis for each time point, respectively.

<table>
<thead>
<tr>
<th>Table 1: Schedule of Events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Activities and Forms to be Completed Specific to the Substudy Only:</strong></td>
</tr>
<tr>
<td>Informed consent</td>
</tr>
<tr>
<td>Triplicate 12-lead ECG</td>
</tr>
<tr>
<td>PK samples*</td>
</tr>
</tbody>
</table>

*PK samples are to be collected immediately after each ECG. Sparse PK samples for the population PK analysis will not be collected for patients participating in this substudy.

**Statistical Methods**

A detailed Statistical Analysis Plan will be prepared prior to the planned analyses.

Two analyses will be performed: a primary analysis using the active treatment arm only, and a secondary analysis comparing the active and placebo arms, both accompanied by a pharmacokinetic/pharmacodynamics analysis.

Standard ECG parameters will be determined for each ECG recording. Corrected QTc intervals will be determined using Fridericia’s formula (QTcF) and Bazett’s formula (QTcB).
Changes in ECG intervals from baseline will be calculated. Baseline will be defined as the mean of the values for the triplicate ECG measurements taken pre-dose on Cycle 1 Day 1 (Hour -1 and Hour 0). In addition, QTcFs will be categorized based on ICH E14 guidelines. Tables will present the number and percentage of patients meeting or exceeding the following categories:

- **QTc interval prolongation:**
  - Absolute values > 450 to ≤ 480 msec
  - Absolute values > 480 to ≤ 500 msec
  - Absolute values > 500 msec

- **QTc interval change from baseline:**
  - Increase from baseline > 30 to ≤ 60 msec
  - Increase from baseline > 60 msec

Pharmacokinetic/Pharmacodynamic analyses will be performed using data from all subjects who have ECG data from at least one time point following the first dose. A linear modeling approach will be used to quantify the relationship (if any) between the plasma concentration of drug (apalutamide) and its principal metabolite (ARN000308), and the changes from baseline in the QTcF interval.

**Sample Size Determination**

A sample size of at least 100 patients will ensure that at least 60 patients treated with apalutamide will be enrolled on the substudy and 60 patients will provide at least 98.7% power to detect a true effect of 10 milliseconds (msec) change from baseline considering only the active group. Details for the power calculation and statistical assumptions are provided below.

**Criteria for a “negative” result**

It is assumed that the FDA criterion for regarding the outcome as negative (i.e., no QT prolongation concerns) will be that the mean QTcF increase observed in the active group should be significantly lower than a threshold of 20 msec at all on-study time points. “Significantly lower” means that the upper one-sided 95% confidence limit should be below the threshold.

For the primary analysis, the quantity of interest is the mean change from baseline (ΔQTcF). For the secondary analysis, the quantity of interest is the difference between the mean changes from baseline in the active and placebo groups (ΔΔQTcF), which should remove any fluctuations due to diurnal variation and/or changes due to time-on-study (e.g., disease progression).

**Statistical Assumptions**

The standard deviation of the change from baseline at each time point is assumed to be 20 msec. The magnitude of the true QTcF prolongation in the secondary analysis (i.e., the expected value of ΔΔQTcF) is taken as 5 msec. For the primary analysis, an allowance should also be made for possible diurnal variation etc., so results are presented assuming the true value of ΔQTcF is 8 msec and 10 msec.
The power calculations have been performed by looking at various possible sample sizes and deriving the resulting power for the analysis at a single time point. However, in order for the study to be declared negative, the upper confidence limit has to be below the threshold at all on-study time points. If the results at each on-study time point were uncorrelated, a power of about 98% at each individual on-study time point would be required to give an overall power (i.e., to achieve the desired result at all on-study time points) of 80%. Similarly, a 99% power at each individual on-study time point would give an overall power of about 90%. However, some correlation between the time points is expected to be present, therefore, the goal is to aim for a power (for an individual time point) well in excess of 95% in order to achieve a reasonable overall power.

**Power for the primary analysis:**

Results for sample sizes of 30 to 60 subjects are shown in Table 1.

**Table 2:** Power (%) for a change from baseline in the active group (at a single time point)

<table>
<thead>
<tr>
<th>Sample size</th>
<th>True effect 8 msec</th>
<th>True effect 10 msec</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>95.0</td>
<td>86.3</td>
</tr>
<tr>
<td>40</td>
<td>98.4</td>
<td>93.5</td>
</tr>
<tr>
<td>50</td>
<td>99.5</td>
<td>97.1</td>
</tr>
<tr>
<td>60</td>
<td>99.9</td>
<td>98.7</td>
</tr>
</tbody>
</table>

**Power for the secondary analysis (assuming a true effect of 5 msec):**

Results for sample sizes (placebo plus active) from 75 to 150 are shown in Table 2.

**Table 3:** Power (%) for comparing a change from baseline between two groups (at a single time point)

<table>
<thead>
<tr>
<th>Sample size</th>
<th>Power (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Active</strong></td>
<td><strong>Placebo</strong></td>
</tr>
<tr>
<td>50</td>
<td>25</td>
</tr>
<tr>
<td>60</td>
<td>30</td>
</tr>
<tr>
<td>80</td>
<td>40</td>
</tr>
<tr>
<td>100</td>
<td>50</td>
</tr>
</tbody>
</table>
APPENDIX 9: ANTICIPATED EVENTS

An anticipated event is an adverse event (serious or non-serious) that commonly occurs as a consequence of the underlying disease or condition under investigation (disease-related) or background regimen. For the purposes of this study, the following events will be considered anticipated events:

**Disease-specific Events**

- Cauda equina syndrome
- Erectile dysfunction
- Haematospermia
- Haematuria
- Incontinence
- Nocturia
- Painful ejaculation
- Pathologic fracture
- Pollakiuria
- Spinal cord compression
- Ureteral obstruction
- Urethral obstruction
- Urinary flow decreased
- Urinary retention
- Urinary tract obstruction
- Urinary hesitation
- Lymphoedema
- PSA Increased

**ADT-Related Events**

- Depression
- Gynaecomastia
- Hot flush
- Libido decreased
- Osteoporosis
- Sexual dysfunction
- Testicular atrophy

**Reporting of Anticipated Events**

All adverse events will be recorded in the CRF regardless of whether they are considered to be anticipated events and will be reported to the sponsor as described in Section 9.2. Any anticipated event that meets serious adverse event criteria will be reported to the sponsor within the appropriate timeline as described in Section 9.2.3. These anticipated events are exempt from expedited reporting as individual single cases to Health Authorities. (Note: Japan will not identify anticipated events for the Health Authorities). However if based on an aggregate review, it is determined that an anticipated event is possibly related to study drug, the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)

An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-specified anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to the study drug.

Statistical Analysis

Details of statistical analysis of anticipated events, including the frequency of review and threshold to trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events Safety Monitoring Plan (ASMP).
APPENDIX 10: CROSSOVER TO OPEN LABEL APALUTAMIDE AFTER STUDY UNBLINDING

At the time the decision is made to unblind the study, investigators will be notified by the sponsor. Subjects randomized to placebo who are currently on study treatment will be offered treatment with open-label apalutamide at 240 mg/day.

Subjects previously randomized to apalutamide will continue on protocol and follow the current schedule of activities (Appendix 1, with modifications below) and will be given open-label apalutamide.

For subjects who crossover from placebo to apalutamide, radiographic scans will no longer be required for the study and submitted for blinded central independent review. Subjects will be followed for progression per Investigator decision including symptoms, radiographic scans or PSA. PSA data submitted to the central laboratory will no longer be blinded. In addition, for all subjects, PK samples will no longer need to be collected at the time of unblinding.

Eligibility Criteria for Placebo Subjects to Crossover to Open Label Apalutamide

Subjects randomized to placebo must meet the criteria below to be eligible to crossover to open label apalutamide. The blood work for organ function criteria can be taken from the last study cycle evaluation prior to unblinding as long as not more than 2 months have elapsed between the last cycle evaluation and Cycle 1 Day 1 of the crossover phase.

1a. Subject is willing and able to provide written informed consent to crossover to open-label apalutamide

2a. Subject has adequate organ function as defined by the following criteria:

- Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase [SGOT]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase [SGPT]) ≤ 2.5 x upper limit of normal (ULN)
- Total serum bilirubin ≤1.5 x ULN. Total serum bilirubin >1.5 x ULN is allowed if Gilbert’s disease has been previously documented
- Serum creatinine ≤ 2 x ULN
- Absolute neutrophil count (ANC) ≥ 1500/µL
- Platelets ≥ 100,000/µL
- Hemoglobin ≥ 9.0 g/dL

3a. Subject has not received any other systemic therapy for non-metastastic castrate resistant prostate cancer other than blinded study drug and androgen deprivation therapy.
4a. Subjects who have previously had an end of treatment visit and evidence of distant metastasis from the blinded independent central reviewer will not be eligible for open label apalutamide.

5a. Subjects who had study treatment withheld for ≥28 consecutive days at the time of unblinding will need approval from the medical monitor to be eligible for crossover.

**Study Procedures for Subjects Previously on Placebo Who Crossover**

Subjects will start open-label apalutamide with Cycle 1 and will be evaluated every cycle for 6 cycles, every other cycle for the next 6 cycles and then every 4 cycles thereafter. Refer to the Time and Events Schedule for placebo subjects who crossover to open-label apalutamide (Table 3). See Section 7 for the description of study assessments in Table 3.

**Discontinuation Criteria for Subjects Who Crossover**

Subjects who discontinue open label apalutamide will continue in Long-Term Follow-up per Section 8.9.

If a subject meets criteria as defined in Section 10 of the protocol, apalutamide must be discontinued.
Table 3  Time and Events Schedule for Subjects on Placebo Crossing Over to Open Label Apalutamide

<table>
<thead>
<tr>
<th>Activities and Forms to be Completed</th>
<th>Screening</th>
<th>Crossover Phase</th>
<th>Posttreatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility Criteria</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Drug Administration</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Drug Compliance [5]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory Studies</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECOG</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Medical Resource Utilization</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progression on first subsequent therapy [8]</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survival [3]</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient Reported Outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Safety</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physical Examination [9]</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Vital Signs [10]</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Adverse Events</td>
<td></td>
<td></td>
<td>Continuous until 26 days after the last dose of apalutamide</td>
</tr>
<tr>
<td>Concomitant Medications</td>
<td></td>
<td></td>
<td>Continuous until 28 days after the last dose of apalutamide</td>
</tr>
</tbody>
</table>

CT=computed tomography, ECOG=Eastern Cooperative Oncology Group, PSA=prostate specific antigen

Aragon Pharmaceuticals, Inc - Confidential
Footnotes

1. **End-of-Treatment:** These assessments do not need to be completed if they have been performed within 4 weeks of the last dose of study drug.

2. **Safety Follow-Up:** Patients should be evaluated for safety up to 28 days after the last dose of study drug. All AEs should be followed to their resolution, until the investigator assesses them as stable, irreversible, or until the patient is lost to follow-up, whichever comes first. If a patient begins a new systemic anti-cancer therapy, the AE reporting period for non-SAEs ends at the time the new treatment is started.

3. **Long-term Follow-up:** Obtain survival status, collect information of development of symptomatic progression, initiation of any new systemic anti-cancer therapies, and progression on first subsequent therapy (every 4 months via clinic visit, telephone contact or an alternative contact method per institution policy/practice).

4. **Apalutamide:** Patients will receive open-label daily apalutamide continuously; a cycle consists of 28 days.

5. **Study Drug Compliance:** Apalutamide bottle(s) including any unused tablets/capsules will be returned at the beginning of every cycle starting at Cycle 2 Day 1 and at end of treatment for drug accountability.

6. **Samples for Hematology, Blood Chemistry:** All laboratory assessments will be performed by a central laboratory. On Cycle 1 Day 1 only, clinical laboratory tests do not need to be repeated if the Screening tests were done within 28 days of Cycle 1 Day 1. Sites may perform additional local hematology and/or blood chemistry assays for the purposes of planning treatment administration, dose modification, or monitoring adverse events.

7. **Samples for PSA, TSH, fasting lipid panel, and testosterone:** These laboratory assessments will be performed by a central laboratory every 16 weeks. On Cycle 1 Day 1 only, clinical laboratory tests do not need to be repeated if the Screening tests were done within 28 days of Cycle 1 Day 1. Sites may perform additional local assays for the purposes of planning treatment administration, dose modification, or monitoring adverse events. See Appendix 2 for details on additional testing if TSH is abnormal.

8. **Progression on First Subsequent Therapy:** The date of progression on first subsequent therapy as assessed by the investigator and method of assessment of disease progression (radiographic, PSA, or both) will be collected.

9. **Physical Examination:** At Screening, a complete physical examination of major body systems. During subsequent visits, either a full or abbreviated physical exam will be performed. New abnormal physical exam findings must be documented and followed by a physician or other qualified staff at the next scheduled visit. Body weight will be recorded at Screening and at every scheduled visit during treatment and at the end of treatment.

10. **Vital Signs:** Body temperature, blood pressure, pulse and respiratory rate will be performed after resting for 5 minutes at every scheduled visit during treatment and at the end of treatment.

11. **FACT-P and EQ-5D questionnaires:** Patients will complete the FACT-P and EQ-5D at the clinic PRIOR to any other clinical activity on Cycle 1 Day 1, then Day 1 of every Cycle up to Cycle 13, then Day 1 of every other cycle, and at the End-of-Treatment Visit. During survival follow-up contact every 4 months via clinic visit or telephone up to 12 months post-progression.